atorvastatin has been researched along with Elevated Cholesterol in 839 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 47 (5.60) | 18.2507 |
| 2000's | 462 (55.07) | 29.6817 |
| 2010's | 294 (35.04) | 24.3611 |
| 2020's | 36 (4.29) | 2.80 |
| Authors | Studies |
|---|---|
| Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M | 1 |
| Askew, V; Auerbach, B; Bainbridge, G; Caspers, N; Choi, C; Dillon, L; Hanselman, JC; Harris, MS; Hutchings, R; Kowala, M; Larsen, SD; Lin, Z; Lu, GH; Park, W; Pavlovsky, A; Pfefferkorn, JA; Robertson, A; Sekerke, C; Tait, BD | 1 |
| Imreh, É; Karádi, I; Karvaly, GB; Neely, MN; Prohászka, Z; Trojnár, E; Vásárhelyi, B; Vincze, I; Zsáry, A | 1 |
| Duarte, K; Fauler, G; Fellström, B; Girerd, N; Jardine, AG; März, W; Massy, ZA; Rossignol, P; Sadiku, S; Scharnagl, H; Schmieder, RE; Silbernagel, G; Zannad, F | 1 |
| Leal, K; Paez, I; Prado, Y; Rojas, G; Saavedra, K; Saavedra, N; Salazar, LA; Ubilla, CG | 1 |
| Borghi, C; Cicero, AFG; D'Addato, S; Fogacci, F; Giovannini, M; Rizzoli, E | 1 |
| Abolbashari, S; Eid, AH; Karimian, MS; Modaghegh, MHS; Saberianpour, S; Sahebkar, A; Sathyapalan, T | 1 |
| Chen, J; Ding, C; Ge, J; Li, Z; Liu, Y; Qian, J; Ren, X; Shi, M; Yang, P; Zhang, X | 1 |
| Al-Ashwal, FY; Halboup, A; Kubas, MA; Sheikh Ghadzi, SM; Sulaiman, SAS | 1 |
| Çenesiz, M; Çenesiz, S; Çiftci, A; Çiftci, G; Onuk, B; Savaşan, S | 1 |
| Cai, SY; Gu, X; Jiang, JJ; Jiang, YN; Li, RS; Liu, PJ; Wang, JA; Yao, W; Yin, YH; Yu, B; Yuan, ZY; Zhao, SP | 1 |
| Kowalcze, K; Krysiak, R; Okopień, B | 3 |
| Farooq Ur Rehman, RM; Khokhar, SA; Masood, S | 1 |
| Fu, Y; Liu, S; Wang, H; Zhou, C | 1 |
| Cho, JM; Choi, JY; Chun, SW; Chung, JW; Hong, SJ; Hong, YJ; Kim, BJ; Kim, CS; Kim, DH; Kim, HS; Kim, KS; Kim, SH; Kim, TN; Lee, CW; Lee, SA; Lee, SH; Lee, SR; Park, HC; Sung, JH; Yoon, SB | 1 |
| Chen, N; Chen, Y; Geng, D; Li, P; Liang, L; Liu, L; Liu, X; Wang, Z; Xu, J; Yang, H; Zhang, X; Zhao, K | 1 |
| Guo, JB; He, J; Li, LZ; Peng, SQ; Yu, L; Yuan, XY; Zhang, L; Zhang, TF; Zhao, J; Zhao, ZM | 1 |
| He, X; Liang, L; Liu, S; Peng, C; Xiao, C; Zhang, G; Zhao, S | 1 |
| Alaaeddine, R; El-Sabban, ME; El-Yazbi, AF; Elkhatib, MAW; Fouad, H; Mroueh, A; Plane, F; Saad, EI | 1 |
| Blot, WJ; Gonzales, H; Miller, R; Muñoz, D; Munro, H; Pappalardo, S; Reynolds, C; Song, W; Tousey, P; Uzoije, P; Walkley, D; Wang, TJ; White, C | 1 |
| Li, Y; Matsuoka, N; Suzuki, A; Teramoto, T; Yokote, K | 1 |
| Copkiran, Ö; Özdemir, IH; Tıkız, C; Tıkız, H | 1 |
| Akao, H; Fukizawa, S; Ieiri, I; Iwadare, M; Kajinami, K; Kusuhara, H; Lee, N; Maeda, K; Masauji, T; Niwa, O; Sugiyama, Y; Takeda, K; Tomaru, A; Yamane, N | 1 |
| Chakrapani, LN; Kalaiselvi, P; Singh, A; Srinivasan, AK | 1 |
| Kawashiri, MA; Nomura, A; Okada, H; Tada, H; Takamura, M | 1 |
| Chiba, T; Fujioka, T; Hara, F; Iwasaki, Y; Moroi, M; Nagayama, D; Nishizawa, K; Saiki, A; Sato, N; Shiba, T; Shimizu, K; Shirai, K; Sugi, K; Sugimoto, H; Takahashi, M; Tatsuno, I; Usui, S; Yamamura, S; Yamasaki, J | 1 |
| Fujisawa, S; Fukatsu, Y; Sugimoto, Y | 1 |
| Beaufrère, H; Douglas, JM; Graham, JL; Guzman, DS; Havel, PJ; Knych, H; Paul-Murphy, JR; Robertson, JA; Stanhope, KL; Tully, TN | 1 |
| Ahangari, G; Arshad, M; Babaheidarian, P; Emruzi, Z; Stockinger, H | 1 |
| El-Gallil, HA; El-Ghaweet, HA; El-Sayyad, HIH | 1 |
| Bélanger, M; Bouchard, DR; Doiron, MD; Eltonsy, S; Jose, C; LeBlanc, R; Sénéchal, M; Simard, P | 1 |
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Chen, MF; Chien, KL; Hsu, HC; Lee, YT; Lin, HJ; Lu, TP; Su, TC; Yu, SL | 1 |
| Burnett, JR; Dayasiri, K; Hooper, AJ; Majitha, SI; Thadchanamoorthy, V | 1 |
| Aslan, G; İlhan, N; Sahin, K; Sahna, E; Sezgin, D; Tuzcu, M | 1 |
| Urquhart, L | 1 |
| Hüttl, M; Kazdová, L; Malínská, H; Marková, I; Miklánková, D; Oliyarnyk, O; Poruba, M; Rácová, Z; Večeřa, R | 1 |
| Ahn, SG; Cho, YH; Doh, JH; Kim, JB; Kim, JW; Kim, SJ; Park, JS; Park, YH; Song, WH; Youn, TJ | 1 |
| Banach, M; Penson, PE | 1 |
| Hanselman, JC; MacDougall, DE; Nicholls, SJ; Rubino, J; Sterling, LR | 1 |
| Cha, KS; Chae, SC; Choi, BG; Choi, CU; Choi, JY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JW; Kim, W; Na, JO; Oh, SK; Park, CG; Park, Y; Rha, SW; Seo, HS; Seong, IW; Yoon, CH | 1 |
| Bortolin, RH; Cerda, A; Fajardo, CM; Hirata, MH; Hirata, RDC; Manriquez, V; Salazar, L; Zambrano, T | 1 |
| Abd El-Aal, RA; Abdel-Latif, HA; Abdelkader, NF; Abdulwahab, DK; Ibrahim, WW | 1 |
| Baralic, I; Ciric, MZ; Djordjevic, BI; Kotur-Stevuljevic, J; Markovic, S; Ostojic, M; Stankovic, I; Zivkovic, S | 1 |
| Bian, Z; Chen, X; Ding, Y; Liu, N; Lu, F; Wu, H; Yang, D; Zheng, P | 1 |
| Ahmadi, F; Ahmadi, M; Davoudi, A; Hassantabar, R; Kasgari, HA; Najafi, N; Rabiee, M; Sharifi, A; Tayebi, A | 1 |
| Baruch, A; Budha, NR; Chiu, CPC; Cowan, KJ; Davis, JC; Kahn, RS; Kirchhofer, D; Leabman, M; Luca, D; Peterson, A; Tingley, WG; Wu, Y | 1 |
| Bergeron, J; Catapano, AL; Krempf, M; Lee, LV; Louie, MJ; Thompson, D | 1 |
| Filipiak, KJ; Kapłon-Cieślicka, A; Kołtowski, Ł; Michalak, M | 1 |
| Collier, T; Collins, R; Dahlof, B; Gupta, A; Poulter, N; Sever, P; Thompson, D; Whitehouse, A | 1 |
| Hsieh, HC; Hsu, JC; Lu, CY | 1 |
| Chaudhuri, S; Imai, K; Kanada, S; Matsuoka, N; Matsuoka, O; Sekino, H; Tabira, J; Teramoto, T; Yokote, K | 1 |
| Baccara-Dinet, MT; Harada-Shiba, M; Ishigaki, Y; Kawabata, Y; Kiyosue, A; Kondo, A; Ozaki, A; Sata, M; Teramoto, T; Tobita, K | 1 |
| Abidin, IZ; Bewersdorf, JP; Ismail, D; Kofink, D; Loch, A; Veriah, RS | 1 |
| Cannon, CP; Khan, I; Klimchak, AC; Reynolds, MR; Sanchez, RJ; Sasiela, WJ | 1 |
| Prado, Y; Salazar, LA; Zambrano, T | 1 |
| Peng, D; Zhao, S | 1 |
| Carmichael, AJ; Ghadiri, SJ; Gunputh, P; Poyner, EFM | 1 |
| Al-Muzafar, HM; Amin, KA | 1 |
| Baum, CM; Billotte, S; Forgues, P; Garzone, PD; Gumbiner, B; Joh, T; Levisetti, M; Liang, H; Pons, J; Shelton, DL; Vana, AM; Wan, H | 1 |
| Lv, YZ; Wang, HM; Wang, ZZ; Xiao, W; Zhou, JM | 1 |
| Berbée, JFP; Boon, MR; Gart, E; Groen, AK; Hoeke, G; Klop, HG; Mol, IM; Pieterman, EH; Princen, HMG; Rensen, PCN; van Dam, AD; van den Berg, SM; Wang, Y | 1 |
| Arencibia, A; Prado, Y; Salazar, LA; Zambrano, T | 1 |
| Anzalone, DA; Evans, KA; Johnston, S; Lewis, SJ; Malangone-Monaco, E; Olufade, T | 1 |
| Ahmed, YM; Baothman, OAS; Khan, I; Khan, TJ; Mehanna, MG; Mohamed, SA; Yasir, M; Zamzami, MA | 1 |
| Kong, W; Li, Y; Ling, Z; Liu, L; Liu, X; Shu, N; Sun, B; Wang, F; Wu, T; Xu, F; Xu, J; Zhang, M; Zhong, Z; Zhu, L | 1 |
| Anil, C; Bozkus, Y; Demir, C; Kut, A; Mousa, U; Nar, A; Tutuncu, NB | 1 |
| Ahmed, YM; Baothman, OAS; Kaleemuddin, M; Khan, I; Khan, TJ; Kuerban, A; Mehanna, MG; Siddiqui, AM; Yasir, M; Zamzami, MA | 1 |
| Book, G; Dager, AD; Meda, S; Panza, GA; Pearlson, GD; Polk, DM; Stevens, MC; Tartar, S; Taylor, BA; Thompson, PD; White, CM; Zaleski, AL | 1 |
| Ballantyne, CM; Baum, SJ; Davidson, MH; Koren, A; Langslet, G; Mandel, J; McCullough, PA; Sanganalmath, SK; Shah, PK | 1 |
| Alvares, J; Bennie, M; de Acurcio, FA; do Nascimento, RCRM; Godman, B; Gomes, IC; Guerra, AA; Kurdi, AB | 1 |
| Chen, X; Li, Y; Lin, L; Wang, S; Zhang, H | 1 |
| Volpe, M | 1 |
| Abbasi, A; Bahrami, M; Farhad, N; Froushani, SMA; Zarei, L | 1 |
| Krysiak, R; Okopień, B; Szkróbka, W | 1 |
| Collier, T; Godec, T; Gupta, A; Mackay, J; Pocock, S; Poulter, N; Sever, P; Whitehouse, A | 1 |
| Drosdzol-Cop, A; Krysiak, R; Okopień, B; Skrzypulec-Plinta, V | 1 |
| Adam, S; Durrington, PN; Soran, H | 1 |
| Alía-Ramos, P; Baena-Díez, N; Caixàs-Pedragós, A; Calmarza, P; Candás-Estébanez, B; Güell-Miró, R; Jusmet-Miguel, X; Navarro-Badal, R; Padró-Miquel, A; Pintó-Sala, X; Puzo-Foncilla, JL; Ruiz-Iruela, C | 1 |
| Ai, C; He, Q; Shi, J; Zhang, S | 1 |
| Chan, P; Liu, ZM; Shao, L; Tomlinson, B; Zhang, Y | 1 |
| Ge, J; Jiang, H; Yu, Y; Zhang, L; Zhang, S | 1 |
| Bai, Y; Chen, K; Clements, TP; Cooke, JP; Diaz, MF; Fang, L; Gu, Q; Kim, JD; Li, W; Lv, J; Meng, S; Miller, YI; Tandon, B; Traver, D; Wagner, DS; Wang, R; Wenzel, PL; Xia, B; Xiong, F; Yang, X; Zhang, J; Zon, LI | 1 |
| Maghsoomi, Z; Moghadasi, M | 1 |
| Blé-Castillo, JL; Díaz-Zagoya, JC; Juárez-Rojop, IE; Marín-Medina, A; Ruíz-Hidalgo, G; Zamora, RM; Zetina-Esquivel, AM | 1 |
| Ihm, SH; Kim, CH; Park, CG; Shin, J | 1 |
| Chan, P; Liu, Z; Ma, YB; Tomlinson, B; Zhang, Y | 1 |
| Bednarska-Czerwińska, A; Kowalcze, K; Krysiak, R; Okopień, B | 1 |
| Hovland, A; Kjellmo, CA; Lappegård, KT; Pop, G | 1 |
| Cai, Y; Chen, C; Hu, Z; Li, C; Liu, X; Liu, Y; Luo, H; Wang, DZ; Wu, G; Xia, X; Xu, Z; Yang, Y; Yu, J; Zeng, C; Zhang, W; Zhang, X | 1 |
| Dézsi, CA; Simon, A | 1 |
| Georgianos, PI; Kanaki, AI; Kanavos, K; Lasaridis, AN; Sarafidis, PA; Tziolas, IM; Zebekakis, PE | 1 |
| Akin, F; Akin, MN; Ayça, B; Canbek, TD; Güngör, O; Köse, N; Sahin, I | 1 |
| Hirayama, A; Hiro, T; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Arazi, SS; Baudhuin, LM; Bernik, MM; Bertolami, MC; Bryant, SC; Cerda, A; Dorea, EL; Faludi, A; Genvigir, FD; Hirata, MH; Hirata, RD; Largura, A; Rodrigues, AC; Willrich, MA | 1 |
| Dormuth, CR; Ernst, P; Garg, AX; Hemmelgarn, BR; James, MT; Lafrance, JP; Levy, A; Paterson, JM; Raymond, CB; Teare, GF | 1 |
| Filipiak, KJ; Mamcarz, A; Naruszewicz, M; Siebert, J; Sliż, D | 1 |
| Gierman, LM; Huizinga, TW; Kloppenburg, M; Koudijs, A; Kühnast, S; Pieterman, EJ; Princen, HM; Stojanovic-Susulic, V; van Osch, GJ; Zuurmond, AM | 1 |
| Inazu, T; Kawahara, C; Kawahara, T; Nishikawa, M; Sakai, K; Suzuki, G | 1 |
| Biwa, T; Kurogi, K; Matsui, K; Nakamura, S; Ogawa, H; Sakamoto, K; Sugiyama, S; Tayama, S | 1 |
| Bakhoum, SW; Issac, MS; Mishriki, AA; Shabana, MF | 1 |
| Ozaydin, M; Varol, E | 1 |
| Choi, YH; DeGorter, MK; Dresser, GK; Hegele, RA; Iwuchukwu, O; Kim, RB; Myers, K; Schwarz, UI; Suskin, N; Tirona, RG; Wei, WQ; Wilke, RA; Zou, G | 1 |
| Chen, CH; Chu, CS; Dixon, RA; Huang, RY; Lai, WT; Lu, J; Lu, LS; Sawamura, T; Walton, B; Wang, YC; Yilmaz, HR | 1 |
| Delibas, N; Gocmen, AY; Gumuslu, S; Ocak, GA; Ozbilim, G | 1 |
| Bertolami, MC; Cavalli, SA; Cerda, A; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Issa, MH; Rohde, CB | 1 |
| Dabrowski, M; Wiliński, J | 1 |
| Averna, M; Bays, HE; Brudi, P; De Pellegrin, A; Farnier, M; Giezek, H; Lee, R; Lowe, RS; Majul, C; Muller-Wieland, D; Triscari, J | 1 |
| Catapano, AL; Corrao, G; Ibrahim, B; Mancia, G; Merlino, L; Nicotra, F; Pasini, TS; Zambon, A | 1 |
| Chen, JW; Chen, JY; Chien, KL; Hsia, CH; Hung, YR; Lin, HJ; Lin, LY; Liu, PY; Wu, TC; Yeh, HI | 1 |
| Calabria, P; Limbruno, U; Micheli, A; Picchi, A | 1 |
| Bozbeyoğlu, E; Çanga, Y; Kaya, C; Kul, Ş; Nurkalem, Z; Özcan, KS; Satılmış, S; Yildirimtürk, Ö | 1 |
| Banach, M; Celecova, Z; Gaspar, L; Hirnerova, E; Huckova, N; Kucera, M; Oravec, S | 1 |
| Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T | 1 |
| Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E | 1 |
| Becker, ML; de Keyser, CE; Hofman, A; Klungel, OH; Maitland-van der Zee, AH; Peters, BJ; Stricker, BH; Uitterlinden, AG; Verstuyft, C; Visser, LE | 1 |
| Ben-Yehuda, O; Constance, C; Hanson, ME; Lin, J; Lowe, RS; Tershakovec, AM; Wenger, NK; Zieve, F | 1 |
| Elens, L; Elisaf, M; Kolovou, G; Kolovou, V; Manolopoulos, VG; Ragia, G; Tavridou, A; Tselepis, AD; Van Schaik, RH | 2 |
| Bermúdez-Ocaña, DY; Díaz-Zagoya, JC; Espinosa-García, MT; Jiménez-Santos, MA; Juárez-Oropeza, MA; Juárez-Rojop, IE; Ramón-Frías, T; Tovilla-Zárate, CA | 1 |
| Fotiadis, G; Kadoglou, NP; Kapelouzou, A; Liapis, CD; Sailer, N | 1 |
| Chattopadhyay, S; Dey, S; Mazumder, B | 1 |
| Lagos, J; Rosales, A; Salazar, LA; Zambrano, T | 2 |
| Chang, WT; Huang, SK; Liau, I; Yang, YC | 1 |
| Elisaf, M; Giannakopoulou, E; Kolovou, G; Kolovou, V; Manolopoulos, VG; Ragia, G; Tavridou, A; Tselepis, AD | 1 |
| Hegele, RA; Joy, TR; Mahon, JL; McDonald, CG; Monjed, A; Zou, GY | 1 |
| Du, S; Han, YG; Li, L; Luo, P; Wang, GG; Wang, LX; Wu, SL; Zhu, HH | 1 |
| Belcaro, G; Cornelli, U; Finco, A | 1 |
| Simonyi, G | 1 |
| Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R | 1 |
| Lozzi, A | 1 |
| Mokhtari-Dizaji, M; Rahmani-Cherati, T; Rostami, A; Vajhi, A | 1 |
| Chang, TT; Chen, JS; Chen, JW; Huang, CC; Huang, PH; Leu, HB; Lin, LY; Lin, SJ; Wu, TC | 1 |
| Ceng, C; Han, W; Huang, C; Liu, Y; Zhan, H; Zheng, D | 1 |
| Budoff, M; Folse, HJ; Goswami, D; Kahn, R; Rengarajan, B | 1 |
| Hirayama, A; Nagao, K; Takahashi, A; Tani, S | 1 |
| Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Wang, Y; Zhao, S; Zhu, N | 1 |
| Almeida, S; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Lima, LO; Pires, RC; Smiderle, L; Van der Sand, CR; Van der Sand, LC | 1 |
| Jinnouchi, H; Masuda, I; Matsui, K; Mori, H; Ogawa, H; Saito, Y; Sugawara, M; Sugiyama, S; Waki, M; Watada, H; Yoshiyama, M | 1 |
| Chang, YP; Mitchell, BD; Montasser, ME; O'Hare, EA; Wang, X; Zaghloul, NA | 1 |
| Bays, HE; Colhoun, HM; Donahue, S; Du, Y; Hanotin, C; Jones, PH; Robinson, JG | 1 |
| Li, WS; Li, YX; Lin, CQ; Shi, DY; Zeng, SY | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| Cohen Tervaert, JW; de Jong, HJ; Helle, MJ; Klungel, OH; Meyboom, RH; Niskanen, L | 1 |
| Krysiak, R; Okopien, B | 1 |
| Ebisawa, S; Ikeda, U; Izawa, A; Kagoshima, M; Kashima, Y; Kitabayashi, H; Koyama, J; Miura, T; Miyashita, Y; Sakurai, S; Tomita, T; Yamamoto, H | 1 |
| Canas, JA; Caulfield, MP; Damaso, LC; Gidding, SS; Hossain, J; Mauras, N; Ross, JL; Sikes, KM; Taboada, MV | 1 |
| Bays, HE; Chen, E; McPeters, G; Polis, AB; Tomassini, JE; Triscari, J | 1 |
| Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A | 1 |
| Chan, LW; Gu, XY; Li, J; Liu, L; Luo, XP; Ni, HC; Qiao, J; Shi, HM; Wen, ZC | 1 |
| Dohi, T | 1 |
| Ahmed, A; Hameed, MK; Najam, A; Sheikh, ZA | 1 |
| Dubrovins'ka, TV; Skrypnyk, IM | 1 |
| Einecke, D | 3 |
| Ambegaonkar, BM; Cao, X; Ejzykowicz, F; Mavros, P; Ramey, DR; Sajjan, S; Tunceli, K | 1 |
| Gilowski, W; Krysiak, R; Okopien, B | 1 |
| Bacova, BS; Benova, T; Knezl, V; Radosinska, J; Tribulova, N; Viczenczova, C | 1 |
| de Entrambasaguas, M; Peñaranda, N; Ponz, A; Sánchez-Monzó, P | 1 |
| Alves, C; Cerda, A; Dorea, EL; Fajardo, CM; Genvigir, FD; Gusukuma, MC; Hirata, MH; Hirata, RD; Pinto, GA; Rodrigues, AC | 1 |
| Baer, AL; deGoma, EM; Donovan, DS; Dunbar, RL; Ginsberg, HN; Gutstein, DE; Holleran, S; Johnson-Levonas, AO; Jumes, P; Karmally, W; Lassman, ME; Liu, Y; Millar, JS; Obunike, J; Pollan, L; Rader, DJ; Rafeek, H; Ramakrishnan, R; Reyes-Soffer, G; Tohyama, J; Wagner, JA | 1 |
| AlBacha, Jd; Azar, A; Fajloun, Z; Haddad, K; Hamoui, S; Khoury, M; Makdissy, N; Mouawad, C | 1 |
| Deng, L; Gong, L; Li, D; Li, Y; Qi, C; Wu, W; Zhang, C; Zhang, Q; Zhang, T; Zhang, Y | 1 |
| Aguilar-Salinas, C; Arzola-Paniagua, A; Carreón-Torres, E; Flores-Castillo, C; Fragoso, JM; Franco, M; López-Olmos, V; Luna-Luna, M; Pérez-Méndez, Ó; Rodríguez-Pérez, JM; Vargas-Alarcón, G; Zamora-Pérez, JÁ | 1 |
| Brudi, P; Farnier, M; Giezek, H; Krempf, M; Lee, R; Ramey, DR; Simpson, RJ; Tomassini, JE | 1 |
| Rajamannan, NM | 1 |
| Brinkmann, SJ; Buijs, N; Couderc, R; Cynober, L; Richir, M; van Leeuwen, PA; Wörner, EA | 1 |
| Bai, L; Cheng, D; Cheng, G; Chu, Y; Gao, S; Liu, E; Sun, W; Wang, X; Wang, Y; Zhao, S | 1 |
| Dippel, DW; Scheele, M; van den Meiracker, AH; Versmissen, J | 1 |
| Akalin Çiftçi, G; Akalin, A; Alataş, İÖ; Ertorun, İ; Musmul, A | 1 |
| Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Nakagomi, A; Shibui, T; Shimizu, W | 1 |
| Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W | 1 |
| Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N | 1 |
| Al-Badriyeh, D; Al-Khal, A; Alabbadi, I; Fahey, M; Zaidan, M | 1 |
| Almeida, S; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Pires, RC; Smiderle, L; Van Der Sand, CR; Van Der Sand, LC | 1 |
| Lagos, J; Prado, Y; Rosales, A; Saavedra, N; Salazar, LA; Zambrano, T | 1 |
| Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM | 1 |
| Cuevas, A; Fernández, C; Ferrada, L; Rosales, A; Saavedra, N; Salazar, LA; Zambrano, T | 1 |
| Sozer, V | 1 |
| Bertacco, E; Buso, R; Di Virgilio, R; Fadini, GP; Faggin, E; Palmosi, T; Pauletto, P; Plebani, M; Puato, M; Rattazzi, M; Zaninotto, M | 1 |
| Anzalone, DA; Cain, VA; Friday, KE; Lewis, SJ; Welty, FK | 1 |
| Banerjee, P; Hamon, S; Hanotin, C; Kereiakes, D; Koren, MJ; McKenney, JM; Pourfarzib, R; Winegar, D | 1 |
| Bando, Y; Hisada, A; Kanehara, H; Okafuji, K; Tanaka, N; Toya, D; Toyama, H | 1 |
| Chiang, CE; Ferrières, J; Gotcheva, NN; Henriksson, KM; Hermans, MP; Raal, FJ; Shehab, A; Sung, J | 1 |
| De Meyer, GR; Martinet, W; Rombouts, M; Roth, L; Schrijvers, DM | 1 |
| Amuzie, C; Denham, S; Mais, DE; Rogers, CS; Swart, JR; Vihtelic, T | 1 |
| Ashavaid, TF; Kadam, P; Ponde, CK; Rajani, RM | 1 |
| Ferenci, T; Simonyi, G | 1 |
| Scheen, AJ | 4 |
| Ballantyne, CM; Brennan, DM; Bruckert, E; Ceška, R; Dent-Acosta, RE; Elliott, M; Gouni-Berthold, I; Lehman, SJ; Lepor, N; Nissen, SE; Preiss, D; Rosenson, RS; Sattar, N; Scott, R; Somaratne, R; Stein, EA; Stroes, E; Wasserman, SM | 1 |
| Crevar-Sakac, M; Ivanisević, J; Jelić-Ivanović, Z; Kotur-Stevuljević, J; Markelić, M; Milenković, M; Vujcić, Z; Vujić, Z | 1 |
| Sungkanuparph, S; Wangpatharawanit, P | 1 |
| Wang, M; Zeng, R; Zhang, L | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK; Wiklund, O | 1 |
| Amento, EP; Bigos, M; Madasamy, S; Shivasubramani, U; Villanueva, J; Wu, AH | 1 |
| Baccara-Dinet, MT; Bergeron, J; Langslet, G; Manvelian, G; Moriarty, PM; Rader, DJ; Roth, EM; Zhao, J | 1 |
| Cai, G; Crawford, R; Du, Z; Farnaghi, S; Friis, T; Mao, X; Prasadam, I; Xiao, Y | 1 |
| Chae, SC; Cho, DG; Chung, MH; Ha, JW; Han, GR; Hyon, MS; Jo, SH; Kim, CH; Kim, DW; Kim, KS; Kim, SH; Kim, YD; Lee, HL; Lee, NH; Lee, SC; Lee, SY; Oh, BH; Park, CG; Ryu, GH; Seung, KB; Yoon, MH | 1 |
| Al Mamun, A; Hashimoto, M; Hossain, S; Katakura, M; Shido, O; Tanabe, Y; Tsuchikura, S | 1 |
| Acevedo, M; Contreras, S; González, C; Hidalgo, P; Mezzano, D; Panes, O; Pereira, J; Rigotti, A; Sánchez, X; Valderas, JP | 1 |
| Ann, SJ; Cheon, DH; Cheon, EJ; Choi, D; Choi, S; Kang, SM; Kim, KY; Lee, CJ; Lee, JE; Lee, SH; Noh, HM; Park, S | 1 |
| Gromnaky, NI; Mikhin, VP; Zhilyaeva, YA | 1 |
| Duda, M; Maczewska, J; Maczewski, M | 1 |
| Baxter, LC; Connor, DJ; Haut, MW; Johnson, SC; Lemieux, SK; Lopez, JE; Sabbagh, MH; Sampath, H; Sparks, DL; Sparks, LM | 1 |
| Kevelaitiene, S; Slapikas, R | 1 |
| Hirano, T; Ito, Y; Michishita, I; Nozue, T | 1 |
| Gokkaya, SC; Guzel, O; Hakan Koyuncu, H; Levent Ozdal, O; Memis, A; Ozden, C | 1 |
| Ageta, M; Biro, S; Ikeda, Y; Kajiwara, K; Kobori, S; Kono, S; Kuribayashi, T; Otonari, T; Saikawa, T; Sasaki, J; Yamamoto, K | 1 |
| Ikeda, S; Koga, S; Kohno, S; Miyahara, Y; Oka, H | 1 |
| Bucci, A; Di Giacomo, S; Fraone, N; Mazza, F; Mazzarella, B; Stefanutti, C; Vivenzio, A | 1 |
| Beamer, B; Costa-Scharplatz, M; Frial, T; Gandhi, S; Ramanathan, K | 1 |
| Elsais, A; Kerty, E; Lund, C | 1 |
| Arazi, SS; Bernik, MM; Bertolami, MC; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Rebecchi, IM; Rodrigues, AC; Willrich, MA | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Benjanuwatra, T; Boonbaichaiyapruck, S; Buakhamsri, A; Cheepudomwit, S; Moleelerkpoom, W; Panjavenin, P; Sukanandachai, B; Suthichaiyakul, T | 1 |
| Daubresse, JC; Herregods, MC; Lamotte, M; Michel, G; Vandenhoven, G; Vissers, E | 1 |
| Agarwal, S; Baruch, L; Eng, C; Gupta, B; Lieberman-Blum, SS | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Sillesen, H; Welch, KM; Zivin, J | 1 |
| Coimbra, SR; Crisostomo, LM; Favarato, D; Luz, PL; Mendes, CM; Souza, CA | 1 |
| Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D | 1 |
| Korber, KE | 1 |
| Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Rubino, J; Tershakovec, AM; Tomassini, JE | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Rubino, J; Tershakovec, AM; Tomassini, JE | 1 |
| Kurabayashi, M; Yamazaki, T | 1 |
| Smith, M; Sullivan, D; Wlodarczyk, J | 1 |
| Argyropoulou, MI; Elisaf, M; Kiortsis, DN; Tselepis, AD; Tsouli, SG; Xydis, V | 1 |
| Fujii, T; Kunita, E; Maeda, K; Sekiguchi, Y; Tasaki, N; Tsujiyama, S; Urabe, Y | 1 |
| Jiang, GH; Qu, HY; Wang, ZY; Xiao, YW; Zhang, M; Zhang, Y | 1 |
| Simon, HB | 1 |
| Habon, T; Horvath, B; Szapary, L; Toth, K | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Cable, EE; Chi, B; Erion, MD; Fujitaki, JM; Ito, BR; Linemeyer, DL; MacKenna, DA; Song, X; van Poelje, PD; Wilker, CE; Zhang, BH | 1 |
| Abramsky, O; Boimel, M; Grigoriadis, N; Lourbopoulos, A; Rosenmann, D; Rosenmann, H; Touloumi, O | 1 |
| Amarenco, P; Benavente, O; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, MG; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA | 1 |
| Ayaori, M; Fayad, ZA; Kihara, T; Kusuhara, M; Momiyama, Y; Nagata, M; Nakamura, H; Nakaya, K; Ogura, M; Ohmori, R; Ohsuzu, F; Tamai, S; Tanaka, N; Taniguchi, H; Yonemura, A | 1 |
| Akbay, E; Corapcioglu, D; Emral, R; Gen, R; Sezer, K | 1 |
| Ikewaki, K; Inoue, Y; Nakada, Y; Ozasa, H; Terao, Y; Tohyama, J; Yoshimura, M | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Alcudia, JF; Badimon, L; Guadall, A; Martínez-González, J; Raposo, B; Rodríguez, C; Sánchez-Gómez, S | 1 |
| Altug, T; Aydin, S; Sozer, V; Uzun, H | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; O'Neill, BJ; Sillesen, H; Welch, KM; Zivin, JA | 1 |
| Jeon, TI; Osborne, TF; Seo, YK; Zhu, B | 1 |
| Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE | 1 |
| Bláha, M; Bláha, V; Nováková, L; Sadílek, P; Satínský, D; Solich, P; Solichová, D; Vlcková, H | 1 |
| Saito, Y; Yokote, K | 1 |
| Bregar, U; Jug, B; Poredos, P; Sabovic, M; Sebestjen, M | 1 |
| Abramczyk, P; Bidiuk, J; Ciarka, A; Dobosiewicz, A; Gaciong, Z; Lewandowski, J; Siński, M | 1 |
| Chen, P; Gan, Y; Li, G; Wu, S; Xing, X; Zhang, J; Zhang, Y; Zhao, S | 1 |
| Claudel, T; Fauler, G; März, W; Putz-Bankuti, C; Scharnagl, H; Sourij, H; Stauber, RE; Stojakovic, T; Trauner, M; Wagner, M; Wascher, TC; Winkler, K | 1 |
| Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K | 1 |
| Kuriyama, G; Mori, Y; Tajima, N; Tanaka, T | 1 |
| Raczak, G | 1 |
| Bailey, KM; Balmforth, AJ; Hall, AS; Romaine, SP | 1 |
| Mamotte, CD; Pocathikorn, A; Taylor, RR | 1 |
| Basili, S; Cangemi, R; Carnevale, R; Loffredo, L; Pignatelli, P; Sanguigni, V; Stefanutti, C; Violi, F | 1 |
| Leekha, S; Lena, YL; Ong, LM; Punithavathi, N | 1 |
| Arazi, SS; Bernik, MM; Bertolami, MC; Cerda, A; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD | 1 |
| Bays, HE; Carter, RN; Doyle, RT; Maki, KC; McKenney, J; Stein, E | 1 |
| Goldberg, RB; Guyton, JR; Mazzone, T; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE; Weinstock, RS | 1 |
| Calciu, CD; Langer, A; Leiter, LA; Rabkin, SW; Ur, E | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Dhumma-Upakorn, R; Putwai, P; Sansanayudh, N; Wongwiwatthananukit, S | 1 |
| Chae, JK; Choi, JY; Hong, TJ; Jeong, MH; Kim, DS; Kim, KY; Kim, YJ; Kim, YN; Oh, SK; Park, JS; Seong, IW | 1 |
| Arvanitakis, Z; Knopman, DS | 1 |
| Shimano, H; Teramoto, T; Urashima, M; Yokote, K | 1 |
| Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| King, S; Superko, HR | 1 |
| Chang, LL; Chen, HW; Cheng, WL; Kuo, CL; Lii, CK; Liu, CS; Su, SL; Tsai, CW | 1 |
| Han, SH; Kim, SJ; Koh, KK; Lee, Y; Quon, MJ; Shin, EK | 1 |
| Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K; Wierzbicki, AS | 1 |
| Benner, JS; Chapman, RH; Foody, JM; Hussein, MA; Joyce, A; Solomon, HA; Tang, SS | 1 |
| Cipollone, F; Faggin, E; Ganassin, L; Grego, F; Mezzetti, A; Pauletto, P; Plebani, M; Puato, M; Rattazzi, M; Zambon, A | 1 |
| Chaiyaroj, SC; Chansrichavala, P; Chantharaksri, U; Ngaosuwankul, N; Sritara, P | 1 |
| Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P | 1 |
| Watson, KE | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T | 1 |
| Cao, G; Konrad, RJ; Pacanowski, MA; Troutt, JS; Welder, G; Zineh, I | 1 |
| Derosa, G; Maffioli, P | 1 |
| Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K | 1 |
| Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM | 1 |
| Holford, TR; Kane, JP; Kocherla, M; Pullinger, CR; Ruaño, G; Seip, RL; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Beadle, K; Gurnsey, C; Hoenig, MR; Johnson, L; Walker, PJ | 1 |
| Clarkson, PM; Grimaldi, AS; Haller, RG; Hoffman, EP; Levine, BD; Parker, BA; Pescatello, LS; Thompson, PD; White, CM | 1 |
| Kruger, A; Ostadal, P; Vondrakova, D | 1 |
| Mehta, JL | 1 |
| Baer, A; Ky, B; Millar, JS; Pruscino, L; Rader, DJ; Wolfe, ML | 1 |
| El-Shenawy, SM; ElRokh, el-SM; Ibrahim, BM; Yassin, NA | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Bartimoccia, S; Basili, S; Carnevale, R; Di Santo, S; Napoleone, L; Pignatelli, P; Sanguigni, V; Tanzilli, G; Violi, F | 1 |
| Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Tershakovec, AM | 1 |
| Arazi, SS; Bernik, MM; Cerda, A; Curi, R; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, R; Rodrigues, AC; Willrich, MA | 1 |
| Bays, H; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Adewale, AJ; Brown, WV; Flaim, D; Foody, JM; Jones-Burton, C; Lowe, RS; Tershakovec, AM; Zieve, F | 1 |
| Belgamwar, V; Maurya, D; Tekade, A | 1 |
| Chen, P; Duan, S; Gan, Y; Jiang, LZ; Li, GY; Wu, SJ; Zhang, J; Zhang, Y; Zhao, SP | 1 |
| Brunet, M; Cofán, F; Cofán, M; Guillén, D; Millán, O; Ros, E | 1 |
| Auteri, A; Ciabattoni, G; Ciani, F; Davì, G; Ferrante, E; Ghezzi, A; Lattanzio, S; Liani, R; Pasqui, AL; Puccetti, L; Santilli, F; Scarpini, F | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Cho, YS; Hong, SJ; Hyon, MS; Kim, DW; Kim, HS; Kim, SH; Lee, MY; Moon, GW; Park, K; Sung, JD; Yoon, MH | 1 |
| Sasaki, J | 1 |
| Blanco-Vaca, F; Chacón, P; Ciudin, A; Francisco, G; Hernández, C; Llaverias, G; Montoro, B; Simó, R | 1 |
| Cámara, C; Costo, A; Crespo, L; Fernández Pereira, L; Pereira, G; Sánchez Muñoz-Torrero, JF | 1 |
| Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Betteridge, J | 1 |
| Higa, M; Masuzaki, H; Shimabukuro, M; Shimabukuro, T; Tanaka, H; Yamakawa, K | 1 |
| Furusawa, T; Inazu, T; Kawahara, T; Nishikawa, M; Suzuki, G | 1 |
| Choi, D; Chung, N; Jang, Y; Kang, SM; Lee, SH; Park, S | 1 |
| Babaoglu, MO; Bozkurt, A; Kilicarslan, A; Sain-Guven, G; Yardimci, Y; Yasar, U | 1 |
| Campo, N; Campo-Bustillo, I; Forteza, A; Gutierrez, J; Haussen, DC; Koch, S; Romano, JG | 1 |
| Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T | 1 |
| Boncler, M; Czyz, M; Luzak, B; Rysz, J; Rywaniak, J; Stanczyk, L; Watala, C; Wilk, R | 1 |
| Bayés, B; Egido, J; Lauzurica, R; Martínez-Cáceres, E; Mas, S; Navarro-Muñoz, M; Pastor, MC; Pérez, V; Romero, R | 1 |
| Caretta, G; Dei Cas, L; Della Pina, P; Gorga, E; Madureri, A; Raddino, R | 1 |
| Berkowitz, DE; Holowatz, LA; Kenney, WL; Santhanam, L; Webb, A | 1 |
| Noda, K; Saku, K; Zhang, B | 2 |
| Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Arazi, SS; Bernik, MM; Cerda, Á; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, Rd; Rodrigues, AC; Willrich, MA | 1 |
| Ayaori, M; Ikewaki, K | 1 |
| Anzivino, C; Baldelli, E; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Galli Kienle, M; Loria, P | 1 |
| Sillence, D; Tchan, M | 1 |
| Kadoglou, NP; Kapelouzou, A; Kostakis, A; Lampropoulos, S; Liapis, CD; Sailer, N; Vrabas, IS | 1 |
| Holowatz, LA; Kenney, WL | 2 |
| Nart, D; Onat, T; Sezer, ED; Sozmen, EY | 1 |
| Caulfield, M; Chang, CL; Chapman, N; Dahlöf, B; Feder, G; Poulter, NR; Sever, PS | 1 |
| Chang, CL; Hingorani, A; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P | 1 |
| Chang, CL; Gupta, AK; Poulter, NR; Sever, PS; Whitehouse, A | 1 |
| Georgianos, PI; Kanaki, AI; Kanavos, K; Lasaridis, AN; Sarafidis, PA; Stafylas, PC; Tziolas, IM | 1 |
| Chacra, AP; Gagliardi, AC; Krieger, JE; Miname, MH; Pereira, AC; Santos, PC; Santos, RD | 1 |
| Bang, OY; Huh, W; Kim, HG; Kim, JW; Kim, SR; Ko, JW; Lee, SC; Lee, SY; McLeod, HL; O'Connell, TM; Won, HH | 1 |
| Tanaka, M | 1 |
| Arazi, SS; Bernik, MM; Bertolami, MC; Carracedo, A; Dorea, EL; Faludi, AA; Fondevila, M; Freire, A; Genvigir, FD; Hirata, MH; Hirata, RD; Lareu, MV; Luchessi, AD; Perin, PM; Phillips, C; Porras-Hurtado, L; Purim, SG; Rodrigues, AC; Salas, A; Santos, C; Silbiger, VN; Willrich, MA | 1 |
| Anderson, L; Bhattacharya, S; Bose, N; Fraser, E; Graham, K; Lumsden, G; McClue, L; Robertson, L; Tho, LM; Yosef, H | 1 |
| Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P | 1 |
| Arazi, SS; Bernik, MM; Bertolami, MC; Cerda, A; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Willrich, MA | 1 |
| Bertolami, MC; Cavalli, SA; Cerda, A; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Issa, MH | 1 |
| Leekha, S; Lena, YL; Mahanim, O; Ong, LM; Punithavathi, N | 1 |
| Alvear, M; Cuevas, A; Rosales, A; Saavedra, N; Salazar, LA; Zambrano, T | 1 |
| Saito, Y | 1 |
| Hayashi, K; Ikewaki, K; Inazu, A; Kawashiri, MA; Kobayashi, J; Konno, T; Mabuchi, H; Miwa, K; Nakanishi, C; Noguchi, T; Nohara, A; Tada, H; Takata, M; Terao, Y; Tsuchida, M; Yamagishi, M | 1 |
| Allahkhah, AA; Enshaei, A; Falahatkar, S; Farhat, B; Heidari Bateni, Z; Khosropanah, D; Khosropanah, I | 1 |
| Krasznai, Z; Toth, P | 1 |
| Bao, W; Benessiano, J; Mallat, Z; Olsson, AG; Ryu, SK; Schwartz, GG; Tedgui, A; Tsimikas, S | 1 |
| Deli, CK; Fatouros, IG; Fotopoulou, N; Jamurtas, AZ; Koutedakis, Y; Nikolaidis, MG; Panayiotou, G; Paschalis, V; Sampanis, M; Theodorou, AA | 1 |
| Bada, V; Božek, P; Kucharská, J; Šikurová, L; Uličná, O; Vančová, O; Waczulíková, I | 1 |
| Civeira, F; Dan, AG; De Tilleghem, Cle B; Hanson, ME; Hing Ling, PK; Massaad, R; Milardo, C; Triscari, J | 1 |
| Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Okada, K; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Lee, T | 1 |
| Choudhury, RP; Iacob, AO | 1 |
| Du, Y; Gasparino, E; Gutierrez, M; Kranz, T; Lisbon, E; Logan, D; Mellis, S; Smith, WB; Stahl, N; Stein, EA; Swergold, GD; Webb, C; Wu, R; Yancopoulos, GD | 1 |
| Nachtigal, P; Rathouska, J; Strasky, Z; Zemankova Vecerova, L | 1 |
| Ferrand, AC; Hanotin, C; Kereiakes, DJ; Koren, MJ; McKenney, JM; Stein, EA | 1 |
| Vogel, RA | 1 |
| Davies, GR | 1 |
| Fenech, ME; Mackay, JW; Myint, KS | 1 |
| Covelli, D; Crisanti, F; De Vuono, S; Lupattelli, G; Mannarino, E; Pirro, M; Roscini, AR; Siepi, D | 1 |
| Gugliucci, A; Ishibashi, S; Kotani, K; Miyamoto, M; Taniguchi, N; Yamada, T | 1 |
| Boussoula, E; Boutsikou, M; Giannakopoulou, V; Katsiki, N; Kollia, A; Kolovou, G; Kolovou, V; Mavrogeni, S; Mihas, C; Vasiliadis, I | 1 |
| Bartimoccia, S; Basili, S; Cangemi, R; Carnevale, R; Napoleone, L; Nocella, C; Pastori, D; Pignatelli, P; Violi, F | 1 |
| El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A | 1 |
| Bruckert, E; Dallongeville, J; Rosenbaum, D; Sabouret, P | 1 |
| Kilpatrick, ES; Narayanan, D | 1 |
| Bereal-Williams, C; Cannon, RO; Chi, A; Dalby, CK; Hauser, KP; Hunter, CJ; Hunter, L; Kato, GJ; Machado, RF; McGowan, V; Tailor, A | 1 |
| Ghosh, AK; Kumar, KK; Kumar, KV; Prusty, P | 1 |
| Chen, P; Chen, XD; Jiang, XY; Li, SY; Lu, M; Wang, GC; Wang, HB; Zhang, NN; Zhang, Q; Zhuang, MQ | 1 |
| Hirayama, A; Nagao, K; Tani, S | 1 |
| Gong, FY; Lu, YS; Qu, RB | 1 |
| Christensen, JH; Lundbye-Christensen, S; Lysgaard, C; Nielsen, MS; Riahi, S; Schmidt, EB | 1 |
| Adámková, V; Ceška, R; Dlouhá, D; Hubáček, JA; Lánská, V; Prusíková, M; Rynekrová, J; Vrablík, M; Zlatohlávek, L | 1 |
| Asset, G; Hanotin, C; McKenney, JM; Roth, EM; Stein, EA | 1 |
| Furutani, N; Ikewaki, K; Ito, K; Kurata, H; Shoda, T; Tada, N; Tsimikas, S; Witztum, JL; Yanai, H; Yoshida, H | 1 |
| Simoens, S; Sinnaeve, PR | 1 |
| Ahmed, W; Ali, IS; Ali, SH; Azam, M; Niazi, AK; Niazi, SH; Qamar, R; Riaz, M; Sadeque, A; Younas, A | 1 |
| Choi, DH; Hong, TJ; Kim, HS; Kim, SH; Seo, MK; Yoon, MH | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| García-Estévez, DA; Navarro, C; San Millán, B; Sogo, T | 1 |
| Chatlaong, B; Laothavorn, P; Nasawadi, C; Piamsomboon, C; Pongsiri, K; Saguanwong, S; Tanprasert, P | 1 |
| Aviram, M; Fuhrman, B; Hayek, T; Keidar, S; Koren, L; Volkova, N | 1 |
| Berra, C; Branchi, A; Colombo, E; Dalla Valle, E; Fiorenza, AM; Muzio, F; Rovellini, A; Sommariva, D; Torri, A | 2 |
| Velussi, M | 1 |
| Segal, AS | 1 |
| González, M; González-Santos, P; Márquez, M; Palacios, R; Ruiz, J; Santos, J; Valdivielso, P | 1 |
| Cayssials, A; Ferraris, JR; Krmar, RT; Legal, S; Ramirez, JA; Sorroche, P | 1 |
| Chapman, MJ; Doucet, C; Gonbert, S; Laouenan, H; Malinsky, S; Sposito, AC; Thillet, J | 1 |
| Dick, JB; Patterson, D; Struthers, AD | 1 |
| Francis, PJ; Parmar, B; Ragge, NK | 1 |
| Hin, AT; Lee, YT; Suyono, S; Sy, R; Tanphaichitr, V; Wu, CC | 1 |
| Mercuro, G; Rosano, GM; Saiu, F; Sarais, C; Zoncu, S | 1 |
| Deedwania, PC; Matalka, MS; Ravnan, MC | 1 |
| Altavilla, D; Bonaiuto, M; Campo, S; Castaldo, M; Cinquegrani, M; Maesano, A; Nicocia, G; Saitta, A; Sardo, MA; Spadaro, M; Versace, A | 1 |
| Ammirati, F; Colivicchi, F; Guido, V; Montefoschi, N; Santini, M; Tubaro, M; Varveri, A | 1 |
| Shah, PK | 1 |
| Nordøy, A | 1 |
| Chmielewski, M; Rutkowski, B; Zdrojewski, Z | 1 |
| Raison, J; Rudnichi, A; Safar, ME | 1 |
| Ceska, R; Kasalová, Z; Marinov, I; Stulc, T; Vrablík, M | 1 |
| Istad, H; Luurila, O; Olsson, AG; Ose, L; Pears, J; Southworth, H; Stender, S; Tuomilehto, J; Wiklund, O; Wilpshaar, JW | 1 |
| Ostroumova, OD | 1 |
| At'kov, OIu; Balakhonova, TV; Kobylianskiĭ, AG; Kukharchuk, VV; Kuznetsova, TV; Masenko, VP; Pogorelova, OA; Susekov, AV; Titov, VN; Tvorogova, MG | 1 |
| Frolkis, JP; Minor, S; Nambi, V; Pearce, GL; Sprecher, DL | 1 |
| Ballantyne, CM; Chitra, RR; Knopp, RH; McPherson, R; Schneck, DW; Simonson, SG | 1 |
| Angori, P; Auteri, A; Bova, G; Bruni, F; Cercignani, M; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Derhaschnig, U; Dorner, GT; Jilma, B; Joukhadar, C; Petternel, V; Rassoul, F; Richter, V; Wagner, OF; Wolzt, M | 1 |
| Chin-Dusting, JP; Kaye, DM; Parnell, MM; Starr, J | 1 |
| Krane, V; Wanner, C | 1 |
| Bianchi, S; Bigazzi, R; Caiazza, A; Campese, VM | 1 |
| Ishii, T; Miyauchi, A; Nagakura, C; Sakurai, S; Tsujibayashi, T; Yoshitomi, Y | 1 |
| Eriksson, M; Johnson, O; Kjellström, T; Lanke, J; Larsen, ML; Olsson, AG; Pedersen, T; Tikkanen, MJ; Wiklund, O | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Stein, EA | 1 |
| Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA | 1 |
| Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J | 1 |
| Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ | 1 |
| Fuller, S; Gillen, D; Lacey, L; Marriott, J; Wilson, K | 1 |
| Buller, N; Casciano, R; Doyle, J; Gillen, D; Wilson, K | 1 |
| McBurney, CR; Smith, DG | 1 |
| Bolaman, Z; Kadikoylu, G; Yavasoglu, I; Yukselen, V | 1 |
| Athyros, VG; Boudoulas, H; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Gokce, N; Goormastic, M; Hazen, SL; Keaney, JF; Pearce, GL; Penn, MS; Shishehbor, MH; Sprecher, DL; Vita, JA | 1 |
| Dratwa, M; Lameire, NH; Lins, RL; Matthys, KE; Peeters, PC; Stolear, JC; Verpooten, GA | 1 |
| Bendahan, D; Bernard, V; Cozzone, PJ; Figarella-Branger, D; Guis, S; Kozak-Ribbens, G; Lando, A; Mattei, JP; Pellissier, JF; Treffouret, S | 1 |
| Ballantyne, CM; Houri, J; LeBeaut, AP; Lipka, LJ; Melani, L; Notarbartolo, A; Sager, PT; Sun, S; Suresh, R; Veltri, EP | 1 |
| SoRelle, R | 1 |
| Gilchrist, JM | 1 |
| Berry, DA; Berry, SM; McKellar, J; Pearson, TA | 1 |
| Ahmadi-Kashani, M; Balian, H; Bashir, M; Ebrahimi, R; Jafari, M | 1 |
| Gill, MJ; Mah Ming, JB | 1 |
| Aragoncillo, P; Cachofeiro, V; Cediel, E; de las Heras, N; Díaz, C; Hernández, G; Lahera, V; Oubiña, MP; Sanz-Rosa, D | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Davidson, MH; Jones, PH; McKenney, JM; Miller, E; Stein, EA | 1 |
| Ballantyne, CM; Gumbiner, B; Hunninghake, DB; Maccubbin, DL; Mitchel, YB; Shah, AK | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Hazen, SL; Penn, MS; Shishehbor, MH; Sprecher, DL | 1 |
| Hedner, T; Himmelman, A; Kjeldsen, SE | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA | 1 |
| Ceska, R; Kasalová, Z; Prázný, M; Skrha, J; Stulc, T; Vrablík, M | 1 |
| Marais, AD; McCrindle, BW; Ose, L | 1 |
| Annuar, R; Khalid, BA; Nawawi, H; Osman, NS; Yusoff, K | 1 |
| Malkan, D; McDonnell, CG; Shorten, GD; Van Pelt, FD | 1 |
| Bax, JJ; Biagini, E; Boersma, E; Bountioukos, M; Kertai, MD; Krenning, BJ; Poldermans, D; Rizzello, V; Roelandt, JR; Schinkel, AF; Vourvouri, EC | 1 |
| Khalid, BA; Nawawi, H; Osman, NS; Yusoff, K | 1 |
| Baumbach, A; Fitzke, M; Herdeg, C; Karsch, KR; Oberhoff, M; Schroeder, S | 1 |
| Zhang, DQ; Zhao, SP | 2 |
| CarloTonolo, G; Carrozza, C; Lulli, P; Musumeci, S; Santini, SA; Zuppi, C | 1 |
| Collisson, EA; De, A; Gambhir, SS; Kleer, C; Kolodney, MS; Merajver, SD; Wu, M | 1 |
| Nasu, M; Tamura, A; Watanabe, T | 1 |
| Fukuda, N; Nada, T; Sakabe, K; Shinohara, H; Tamura, Y; Wakayama, K | 3 |
| Aviram, M; Hayek, T; Hussein, K; Rosenblat, M | 1 |
| Ballantyne, CM; Blazing, MA; Davidson, MH; DeLucca, P; Hunninghake, DB; Hustad, CM; Palmisano, J; Ramsey, KE; Yuan, Z | 1 |
| Gylling, H; Miettinen, TA | 1 |
| Bertolami, MC; Cihon, F; Davidson, MH; Dujovne, CA; Escobar, ID; Frohlich, J; Maccubbin, DL; Mercuri, M; Ose, L; Scott, RS | 1 |
| Ceska, R; Fialová, L; Malbohan, I; Malík, J; Soukupová, J; Stulc, T | 1 |
| Gupta, S | 1 |
| Bolaman, Z; Kadikoylu, G | 1 |
| Antonini-Canterin, F; Cervesato, E; Granata, G; Nicolosi, GL; Pavan, D; Piazza, R; Popescu, BA; Zuppiroli, A | 1 |
| Alexy, T; Horvath, B; Kesmarky, G; Marton, Z; Szapary, L; Toth, K | 1 |
| Asai, T; Iguchi, A; Kanda, S; Koike, T; Kuzuya, M; Nakamura, A; Satake, S; Suzuki, Y; Umegaki, H | 1 |
| Adamczyk, MA; Blasetto, JW; Bryzinski, BS; Cain, VA; Jones, PH; McKenney, JM | 1 |
| García-Idoate, G; Mora, C; Muros, M; Navarro, JF | 1 |
| Böhm, M; Faul, A; Laufs, U; Nickenig, G; Ribaudo, N; Wassmann, S | 1 |
| Brousseau, ME; Kajinami, K; Ordovas, JM; Schaefer, EJ | 3 |
| Brousseau, ME; Kajinami, K; Nartsupha, C; Ordovas, JM; Schaefer, EJ | 1 |
| Ayan, F; Curgunlu, A; Ertürk, N; Karter, Y; Mihmanli, I; Vehid, S | 1 |
| Gershovich, OE; Lyman, AE | 1 |
| Blasetto, J; Caplan, R; Dane, A; Hutchison, H; Strutt, K | 1 |
| Bernaud, C; Boutouyrie, P; Christin-Maitre, S; Gompel, A; Jaillon, P; Laurent, S; Simon, T; Thuillez, C; Zannad, F | 1 |
| Kröger, K; Wittlinger, T | 1 |
| Edwards, JE; Moore, RA | 1 |
| Blennow, K; Eikenberg, O; Höglund, K; Vanderstichele, H; Vanmechelen, E; Wiklund, O | 1 |
| Tellier, P | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F | 1 |
| Daida, H; Miyauchi, K; Shimada, K | 1 |
| Kulbertus, H; Scheen, AJ | 1 |
| Mason, P | 1 |
| Auteri, A; Bova, G; Bruni, F; Cercigani, M; Di Renzo, M; Leo, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Ballantyne, CM; Blazing, MA; Brady, WE; King, TR; Palmisano, J | 1 |
| Desai, A; Gawde, A; Jain, MM; Jayaram, S; Naikawadi, AA | 1 |
| Bocksch, W; Fateh-Moghadam, S; Schartl, M | 1 |
| Guay, AT; Jacobson, J; Saltzman, EA | 1 |
| Coates, K; DiMauro, S; Naini, A; Rundek, T; Sacco, R | 1 |
| Bolognese, MA; Caplan, R; Cressman, M; Hutchinson, H; Raza, A; Schwartz, GG; Tremblay, BP | 1 |
| Nissen, S | 1 |
| Akin, M; Aliyev, E; Altuglu, I; Ercan, E; Ercan, HE; Sekuri, C; Tengiz, I | 1 |
| Carlier, M; Claeys, MJ; Cools, F; Cosyns, B; De Meester, A; Dewit, B; Gobin, E; Hoffer, E; Missault, L; Vermeersch, P | 1 |
| Ceyhan, C; Ercan, E; Onbasili, AO; Tekten, T; Turkoglu, C | 1 |
| Chen, YF; Hwang, YS; Lin, CC; Lu, YH; Tsai, WC | 1 |
| Alizadeh, J; Ballantyne, CM; Lipka, LJ; Sager, PT; Strony, J; Suresh, R; Veltri, EP | 1 |
| Elly, I; Frieman, A; Gavish, D; Hazanov, N; Leibovitz, E | 1 |
| Levy, Y | 1 |
| Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A | 1 |
| Lipka, L; Maccubbin, D; Mata, P; Melani, L; Ponsonnet, D; Sager, P; Stein, E; Stender, S; Suresh, R; Veltri, E | 1 |
| Diz-Lois, F | 1 |
| Egido, J; Tuñón, J | 1 |
| Abdalla, DS; Aldrighi, JM; Bertolami, MC; Faludi, AA; Nakamura, Y; Pereira, IR; Ramires, JA; Saleh, MH; Silva, RA; Sousa, JE | 1 |
| Ascer, E; Bertolami, MC; Buccheri, V; Nicolau, JC; Ramires, JA; Serrano, CV; Souza, J; Venturinelli, ML | 1 |
| Billiouw, JM; Carpentier, YA; Dratwa, M; Ducobu, J; Dupont, P; Lameire, NH; Lins, RL; Maes, B; Matthys, KE; Peeters, PC; Stolear, JC; Tielemans, C; Verpooten, GA | 1 |
| Deac, R; Dobreanu, M; Gălăţeanu, C; Simionescu, A | 1 |
| März, W | 1 |
| Klose, G | 1 |
| Blasetto, JW; Caplan, RJ; Ferdinand, KC; Gold, A; Hunninghake, DB; Jones, PH; Stein, EA | 1 |
| Angelico, F; Arca, M; Burattin, M; Ceci, F; Del Ben, M; Violi, F | 1 |
| Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM | 1 |
| Laskowitz, DT; Lynch, JR; McGirt, MJ; Woodworth, GF | 1 |
| Couture, P; Lamarche, B; Mauger, JF; Paradis, ME | 1 |
| Herman, ZS; Krysiak, R; Okopien, B | 1 |
| Bäcklund, T; Kahri, J; Kivistö, KT; Valkonen, M; Vuoristo, M | 1 |
| Hitsumoto, T; Iizuka, T; Nakamura, K; Noike, H; Ohsawa, H; Sakurai, T; Satoh, S; Shimizu, K; Shirai, K; Sugiyama, Y; Takahashi, M; Watanabe, H | 1 |
| Auteri, A; Bruni, F; Pasqui, AL; Pastorelli, M; Puccetti, L; Sawamura, T | 1 |
| Feely, J; Sigurdsson, EL; Strandberg, TE | 1 |
| Endo, K; Ito, Y; Koide, N; Miyashita, Y; Otsuka, M; Oyama, T; Ozaki, H; Saiki, A; Shirai, K | 1 |
| Aznar, J; Gabriel, F; Guiral, V; Labiós, M; Martínez, E; Martínez, M | 1 |
| Sawicki, PT; Weizel, A | 1 |
| Fitchett, DH; Goodman, S; Langer, A; Leiter, LA; Tardif, JC | 1 |
| Bellia, A; Carnevale, R; Ferro, D; Lauro, R; Lenti, L; Pignatelli, P; Sanguigni, V; Sorge, R; Tesauro, M; Violi, F | 1 |
| Ganda, OP | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Chu, CS; Lai, WT; Lee, KT; Sheu, SH; Tsai, LY; Voon, WC; Yen, HW | 1 |
| Bonow, RH; Bonow, RO; Caira, F; Makkena, B; Rajamannan, NM; Salti, H; Spelsberg, TC; Subramaniam, M; Thennapan, S | 1 |
| Ahotupa, M; Nuotio, I; Strandberg, T; Tikkanen, MJ; Vanhanen, H; Vasankari, T; Viikari, J; Vuorenmaa, T | 1 |
| Ayaori, M; Fayad, ZA; Higashi, K; Iwamoto, N; Kihara, T; Kusuhara, M; Momiyama, Y; Nagata, M; Nakamura, H; Ogura, M; Ohmori, R; Ohsuzu, F; Sawada, S; Tamai, S; Taniguchi, H; Yonemura, A | 1 |
| Geiss, HC; Hund-Wissner, E; Otto, C; Parhofer, KG | 1 |
| Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C | 1 |
| Chin, H; Denu-Ciocca, CJ; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS; Pieper, JA | 1 |
| Delles, C; Jacobi, J; John, S; Schmieder, RE; Schneider, MP | 1 |
| Barut, A; Sarikaya, S; Tanriverdi, HA | 1 |
| Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Bonow, RO; Ignatiev, KI; McConnell, JP; Rajamannan, NM; Singh, RJ; Spelsberg, TC; Springett, M; Stock, SR; Stone, NJ; Subramaniam, M | 1 |
| Berna, C; Calmy, A; Junod, AF; Peytremann-Bridevaux, I | 1 |
| Bigazzi, F; Bionda, A; Chella, E; Dal Pino, B; Puntoni, MR; Rossi, G; Sampietro, T; Sbrana, F | 1 |
| Franken, AA; Vincent, HH; Wolffenbuttel, BH | 1 |
| Adgey, J; Allen, C; Bedarida, GV; Cruz-Fernández, JM; Johnson-Levonas, AO; Massaad, R | 1 |
| Rosenberg, R | 1 |
| Higashikata, T; Inazu, A; Katsuda, S; Kawashiri, M; Kobayashi, J; Koizumi, J; Mabuchi, H; Mizuno, M; Nohara, A | 1 |
| Cannon, CP; Ray, KK | 1 |
| Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C | 1 |
| Kastelein, JJ; van Leuven, SI | 1 |
| Jarernsiripornkul, N; Kiatchusakul, S; Ojongpian, S; Srinakarin, J; Tantikosoom, W; Thinkhamrop, B | 1 |
| Bitto, A; Bonaiuto, A; Bonaiuto, M; Campo, S; Castaldo, M; Cinquegrani, M; Saitta, A; Saitta, C; Sardo, MA; Trimarchi, G | 1 |
| Cho, KH; Jung, WS; Kang, HS; Moon, SK; Park, SU | 1 |
| De Paepe, B; Laakso, J; Laaksonen, R; Lehtimäki, T; Lütjohann, D; Mattila, KM; Päivä, H; Smet, J; Thelen, KM; Van Coster, R; von Bergmann, K | 1 |
| Hirose, T; Kawamori, R; Ohmura, C; Tanaka, Y; Watada, H | 1 |
| Wu, ZH; Zhao, SP | 1 |
| Deng, P; Hong, SC; Wu, J; Wu, ZH; Zhao, SP | 1 |
| Climent, VE; de Teresa, L; García-Herola, A; Lorenzo, S; Marín, F; Roldán, V; Sogorb, F; Tello, A | 1 |
| Cardona-Muñoz, EG; Fonseca, FA; Fuenmayor, N; Marotti, M; Ruiz, A; Silva, JM | 1 |
| Courtney, BK; Fitzgerald, PJ; Koizumi, T; Komiyama, N; Komuro, I; Kuriyama, N; Nakayama, T; Nameki, M; Namikawa, S; Yokoyama, M | 1 |
| Bertolami, MC; Faludi, AA; Hirata, MH; Hirata, RD; Rebecchi, IM; Rodrigues, AC | 1 |
| Ceska, R; Malik, J; Stulc, T | 1 |
| Caira, F; Rajamannan, NM; Spelsberg, TC; Stock, SR; Subramaniam, M | 1 |
| Chiou, KR; Huang, WC; Lin, SL; Liu, CP; Shiang, JC; Wu, SC; Wu, TL | 1 |
| van Heyningen, C | 1 |
| Adinaro, J; Beck, R; Doeppenschmidt, D; Henry, JS; Krasuski, RA; Smith, PB; Thompson, CM | 1 |
| Hirsch, M; O'donnell, J; Olsson, A | 1 |
| Baldassarre, S; Carpentier, YA; Deckelbaum, RJ; Ducobu, J; Dupont, IE; Scruel, O | 1 |
| Burnett, JR | 1 |
| Bays, HE; Davidson, MH; McKenney, JM; Saponaro, J; Thompson, PD | 1 |
| Juszczyk, MA; Seip, RL; Thompson, PD | 1 |
| Pai, RG | 1 |
| Phillips, PS | 1 |
| Auteri, A; Bruni, F; Ciani, F; Gioffrè, W; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Buchetti, B; Lenti, L; Pignatelli, P; Sanguigni, V; Violi, F | 1 |
| Bertolami, MC; Cavalli, SA; Forestiero, FJ; Guzmán, EC; Hirata, MH; Hirata, RD; Salazar, LA; Sorkin, SC | 1 |
| Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Nosaka, S; Ueki, M; Ushiroyama, T | 1 |
| Ahumada, M; Arcas, R; Arribas, JM; Gomez-Plana, J; Marín, F; Martínez, P; Oliver, C; Pascual, DA; Tornel, PL; Valdes, M | 1 |
| Graselli, U; Joukhadar, C; Kostner, K; Lackner, E; Thallinger, C; Urbauer, E; Wolzt, M | 1 |
| de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A | 1 |
| Błaszczyk, J; Cegliński, T; Grycewicz, J; Irzmański, R; Kowalczyk, E; Kowalski, J; Liban-Gałka, B; Pawlicki, L | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Koter-Michalak, M | 1 |
| Fukazawa, M; Ishikawa, M; Kubota, T; Moroi, M; Namiki, A; Sugi, K; Yajima, S | 1 |
| Biggi, A; Chauvie, S; Feola, M; La Scala, E; Papaleo, A; Rolfo, F; Uslenghi, E | 1 |
| Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M | 1 |
| Haghfelt, TH | 1 |
| Badziński, A; Dyrbuś, K; Mercik, G; Nowak, J; Nowalany-Kozielska, E; Poloński, L; Rozek, MM; Szyguła-Jurkiewicz, B; Wilczek, K; Wodniecki, J; Wojnicz, R; Zembala, M | 1 |
| Balla, J; Dorosz, J; Dulak, J; Jazwa, A; Jozkowicz, A; Loboda, A; Molema, G | 1 |
| Gregoor, PJ | 1 |
| Busseuil, D; Collin, B; Cottin, Y; Duvillard, L; Korandji, C; Pitois-Merli, I; Rioufol, G; Rochette, L; Zeller, M | 1 |
| de Teresa, E; Farsang, C; Gaw, A; Gensini, GF; Langer, A; Leiter, LA; Martineau, P | 1 |
| Galin, ID; Smith, DA | 1 |
| Bruckert, E; Carreau, V; Chauvenet, M; Faltaos, DW; Giral, P; Hulot, JS; Lechat, P; Urien, S | 1 |
| Kimura, M; Okamura, A; Takahashi, M; Takano, T; Yamakawa, T | 1 |
| Plans-Rubió, P | 1 |
| Becx, MC; Kuypers, KC; Seldenrijk, CA; Stolk, MF | 1 |
| Ritsch, A; Tancevski, I | 1 |
| Allemann, C; Babiychuk, EB; Draeger, A; Hoppeler, H; Mohaupt, M; Monastyrskaya, K; Savolainen, H | 1 |
| Asai, K; Ito, T; Kosaka, T; Kuhara, Y; Kuroda, Y; Ozaki, Y; Shinjo, H; Takashima, H; Wakita, Y; Waseda, K; Yasukawa, T | 1 |
| Arteaga Ll, A; Maiz G, A; Rigotti R, A | 1 |
| Laaksonen, R; Lehtimäki, T; Lütjohann, D; Päivä, H; Thelen, KM | 1 |
| Bianchi, C; Boodhwani, M; Feng, J; Laham, R; Li, J; Mieno, S; Nakai, Y; Ramlawi, B; Sellke, FW; Voisine, P | 1 |
| Ayaori, M; Kusuhara, M; Momiyama, Y; Nakamura, H; Ogura, M; Ohmori, R; Ohsuzu, F; Sawada, S; Tanaka, N; Yonemura, A | 1 |
| Hey-Hadavi, JH; Kuntze, E; Lepetri, B; Luo, D; Pittman, D; Silverman, P | 1 |
| Chu, CS; Lai, WT; Lee, KT; Lee, MY; Sheu, SH; Su, HM; Voon, WC | 1 |
| Alemao, E; Attard, C; Bourgault, C; Cook, J; Huse, D; Kohli, M; Lam, A; Marentette, M; Yin, D | 1 |
| Aizawa, Y; Fukaya, H; Imaki, R; Izumi, T; Kubo, T; Ohtaki, K; Ozaki, K; Ozaki, S; Shinagawa, H | 1 |
| Bolaman, Z; Kadikoylu, G; Ozgel, N; Yenisey, C | 1 |
| Davidson, MH; Robinson, JG | 1 |
| Pogacnik, T; Pretnar-Oblak, J; Sabovic, M; Sebestjen, M; Zaletel, M | 1 |
| Carod-Artal, FJ | 1 |
| Knopp, RH; Paramsothy, P | 1 |
| Abraham, J; Alla, V; Bonkovsky, HL; Chalasani, NP; Raina, D; Siddiqui, J; Wu, GY | 1 |
| Deig, E; Guelar, A; Guil, J; Pedrol, E; Rodríguez-Martín, M; Soler, A | 1 |
| Palacios Muñoz, R; Santos González, J | 1 |
| Haffner, S; Lloret, R; Stein, M; Ycas, J | 1 |
| Guthrie, RM | 1 |
| Edwards, C; Gladding, PA; Kerr, A | 1 |
| Lloyd, K | 1 |
| Abramowicz, D; Berkenboom, G; Broeders, N; Carpentier, Y; Ghisdal, L; Unger, P; Wissing, KM | 1 |
| Laaksonen, R; Lehtimäki, T; Luomala, M; Lütjohann, D; Päivä, H; Peltonen, N; Thelen, K | 1 |
| Auteri, A; Bruni, F; Ciani, F; Ghezzi, A; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Pontani, A; Puccetti, L | 1 |
| Cubeddu, LX; Cubeddu, RJ; Heimowitz, T; Lamas, GA; Restrepo, B; Weinberg, GB | 1 |
| Alemao, E; Jousilahti, P; Salomaa, V; Sintonen, H; Yin, D | 1 |
| Boodhwani, M; Feng, J; Li, J; Mieno, S; Sellke, FW; Sodha, N; Voisine, P | 1 |
| Agustín Herrero, J; Cámara Hijón, C; Costo Campoamor, A; Crespo Rincón, L; Fernández Pereira, L; Pereira Navarro, G; Sánchez Muñoz-Torrero, JF; Torres Pérez, F | 1 |
| Checa, JC; Fernández de Bobadilla, J; Navarro Artieda, R; Sicras Mainar, A | 1 |
| Moriguchi, H; Sato, C; Uemura, T | 1 |
| Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Fukunami, M; Kioka, H; Masuda, M; Mine, T; Morita, T; Node, K; Okuda, K; Tamaki, S; Tsukamoto, Y; Yamada, T | 1 |
| Fukao, A; Komatsu, Y; Majima, T; Matsumura, T; Nakao, K; Ninomiya, K | 1 |
| Imaizumi, T; Ishida, S; Jinnouchi, J; Jinnouchi, Y; Takeuchi, M; Yamagishi, S | 1 |
| Andrys, C; Jamborova, G; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P | 2 |
| Benndorf, R; Böger, RH; Kom, GD; Maas, R; Schneider, L; Schwedhelm, E | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA | 1 |
| Leiter, LA; Miller, P; Palmer, M; Reckless, JP; Rosenson, RS; Schleman, M; Schulte, KL; Sosef, F; Stein, E | 1 |
| Asztalos, BF; Dallal, GE; Horvath, KV; Jones, PH; Le Maulf, F; McTaggart, F; Schaefer, EJ; Stein, E | 1 |
| Côté, HC; Frohlich, JJ; Humphries, KH; Laaksonen, R; Lehtimäki, T; Päivä, H; Schick, BA | 1 |
| Alber, HF; Dichtl, W; Dörler, J; Frick, M; Pachinger, O; Stocker, EM; Süssenbacher, A; Weidinger, F | 1 |
| Fischer, S; Jaster, M; Martus, P; Morguet, AJ; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C | 1 |
| Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K | 1 |
| Carnevale, R; Lenti, L; Loffredo, L; Pignatelli, P; Sanguigni, V; Sorge, R; Violi, F | 1 |
| Couderc, R; Cynober, L; Martin, C; Moinard, C; Rasmusen, C; Tricottet, V | 1 |
| Fukuda, N; Fukuda, Y; Morishita, S; Nada, T; Sakabe, K; Shinohara, H; Tamura, Y; Wakayama, K | 2 |
| Blagden, MD; Chipperfield, R | 1 |
| McMahon, DE | 1 |
| Abe, M; Hirose, T; Kawamori, R; Mita, T; Nakayama, S; Ogihara, T; Shimizu, T; Uchino, H; Watada, H | 1 |
| Ceska, R; Kasalová, Z; Marinov, I; Stulc, T; Svobodová, H; Vrablík, M | 1 |
| Chen, SH; Chu, CS; Kou, HS; Lai, WT; Lee, CJ; Lee, KT; Sheu, SH; Voon, WC | 1 |
| Vos, E | 1 |
| von Eckardstein, A | 2 |
| Chu, CS; Lai, WT; Lee, KT; Lee, ST; Lin, TH; Lu, YH; Sheu, SH; Voon, WC | 1 |
| Deedwania, PC; Gold, A; Gupta, M; Stein, M; Ycas, J | 1 |
| Altug, T; Aslan, M; Balci, H; Bolayirli, IM; Hacibekiroglu, M; Seven, A | 1 |
| Czepluch, FS; Waltenberger, J | 1 |
| Frial, T; Miller, PS; Tran, YB | 1 |
| Ballantyne, C; Maccubbin, D; Pearson, T; Shah, A; Sisk, C; Veltri, E | 1 |
| Gao, RL | 1 |
| Aznaouridis, K; Dagre, A; Masoura, C; Pitsavos, C; Skoumas, J; Stefanadi, E; Stefanadis, C; Vasiliadou, C; Vlachopoulos, C | 1 |
| Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Athyros, V; Farsang, C; Gaw, A | 1 |
| Inazu, A; Katsuda, S; Kawashiri, MA; Kobayashi, J; Koizumi, J; Mabuchi, H; Nohara, A | 1 |
| Andreasson, A; Andrén, L; Eggertsen, R | 1 |
| Bolognese, MA; Bone, HG; Kiel, DP; Leary, ET; Lewiecki, EM; Lindsay, RS; Lowe, W; McClung, MR | 1 |
| Jayaram, S; Langade, DG; Mane, PR; Prasad, HB; Sovani, VB | 1 |
| George, J; Keren, G; Luboshits, G; Mausner-Fainberg, K; Maysel-Auslender, S; Mor, A; Rubinstein, A | 1 |
| Cuccurullo, F; Di Febbo, C; Di Nisio, M; Guglielmi, MD; Moretta, V; Porreca, E; Stuppia, L | 1 |
| Dallinga-Thie, GM; de Haan, W; Havekes, LM; Hoekstra, M; Jukema, JW; Princen, HM; Rensen, PC; Romijn, JA; van der Hoogt, CC; Westerterp, M | 1 |
| Che, D; Sun, Y; Zhang, D; Zhao, S | 1 |
| Emanuele, E; Geroldi, D | 1 |
| Averna, MR; Bucciarelli, L; Cefalù, AB; Ciabattoni, G; Davì, G; Davì, V; Ferrante, E; Noto, D; Pettinella, C; Santilli, F | 1 |
| Barter, P; Bittner, V; Fruchart, JC; Gotto, AM; Grundy, SM; Kastelein, JJ; LaRosa, JC; Maroni, J; Szarek, M | 1 |
| Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E | 1 |
| Betteridge, DJ; Gibson, JM; Sager, PT | 1 |
| Arnaboldi, L; Corsini, A; Guzzetta, M; Paoletti, R; Pazzucconi, F; Radaelli, G; Sirtori, CR | 1 |
| Date, AA; Nagarsenker, MS | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Chin, H; Denu-Ciocca, C; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS | 1 |
| Azuma, A; Matsubara, H; Sasaki, S; Sawada, T; Yamada, T | 1 |
| Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Cangemi, R; Carnevale, R; Loffredo, L; Patrizi, MP; Perri, L; Pignatelli, P; Sanguigni, V; Violi, F | 1 |
| Ghattas, AE; Pimenta, J | 1 |
| Davidson, MH; Fox, KM; Gandhi, SK; Ohsfeldt, RL | 1 |
| Ahn, TH; Cha, KS; Choi, SW; Chung, N; Han, SW; Ho Yun, K; Hyon, MS; Kim, CJ; Kim, DI; Kim, HS; Kim, WH; Kwan, J; Lee, SH; Park, SH; Seo, HS; Shim, WJ; Shin, DG; Shin, YW; Yoon, MH | 1 |
| Acampa, M; Auteri, A; Bruni, F; Ciani, F; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Bruschi, P; Ferdinand, KC; Flack, JM; Jamieson, MJ; Saunders, E; Shi, H; Tarasenko, L; Victor, R; Watson, K | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlof, B; Kjeldsen, SE; Kristinsson, A; McInnes, G; Mehlsen, J; Nieminen, MS; O'Brien, ET; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Lee, YT; Ro, YM; Sim, KH; Sriratanasathavorn, C; Tomlinson, B; Zhu, JR | 1 |
| Shaley, FM | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J | 1 |
| Dupliakov, DV | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K | 1 |
| Bacarea, A; Dobreanu, D; Dobreanu, M; Fodor, A | 1 |
| Bolewski, A; Burchardt, P; Lipiecki, J; Plewa, R; Siminiak, T | 1 |
| Abe, Y; Furukado, S; Hori, M; Hoshi, T; Hougaku, H; Kitagawa, K; Sakaguchi, M; Yamagami, H | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF | 1 |
| Allina, J; Bach, N; Bodenheimer, H; Bodian, C; Odin, JA; Stanca, CM | 1 |
| Ando, H; Fujimura, A; Kaneko, S; Saito, T; Sugimoto, K; Takamura, T; Tsuruoka, S; Yanagihara, H | 1 |
| Anagnostis, P; Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, C; Mikhailidis, DP; Pagourelias, E; Papageorgiou, AA; Paraskevas, KI; Tziomalos, K | 1 |
| Asmar, R; Duffield, E; Faergeman, O; Hill, L; Sosef, F; Wiklund, O; Windler, E | 1 |
| Arazi, SS; Bernik, M; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Willrich, MA | 1 |
| Breazna, A; Deedwania, PC; Kostis, JB; LaRosa, JC | 1 |
| Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Bujo, H; Hanaoka, H; Kodama, T; Mikami, K; Miyashita, Y; Nishikawa, T; Saito, Y; Shinomiya, M; Tada, N; Yokote, K | 1 |
| Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL | 1 |
| Derdak, Z; Harangi, M; Mirdamadi, HZ; Paragh, G; Seres, I; Sztanek, F | 1 |
| Auerbach, BJ; Bisgaier, CL; Krause, BR; Newton, RS | 1 |
| Black, DM; Davidson, MH; Haber, HE; Jones, PH; Lupien, PJ; Nawrocki, JW; Schwartz, SL; Sprecher, DL; Weiss, SR | 1 |
| Ciaravino, V; Hovey, CA; Kropko, ML; Rothwell, CE; Theiss, JC | 1 |
| Abe, Y; Ballantyne, CM; Dunn, K; Gotto, AM; Hackman, A; Insull, W; Pownall, H; Smith, L | 1 |
| Krause, BR; Newton, RS | 1 |
| Bertolini, S; Bon, GB; Campbell, LM; Egros, F; Farnier, M; Fayyad, R; Langan, J; Mahla, G; Nawrocki, JW; Pauciullo, P; Sirtori, C | 1 |
| Bakker-Arkema, R; Black, D; Davidson, M; Fayyad, R; McKenney, J; Schrott, H; Stein, E | 1 |
| Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M | 1 |
| Alaupovic, P; Black, DM; Heinonen, T; Shurzinske, L | 1 |
| Calder, RA | 1 |
| Hunninghake, D; Jones, P; Kafonek, S; Laurora, I | 1 |
| Celermajer, DS; Simons, J; Simons, LA; Sullivan, D | 1 |
| Tucker, G | 1 |
| Black, DM; Mahla, G; Muller, D; Pentrup, A; Wolffenbuttel, BH | 1 |
| Simons, LA | 1 |
| Pincus, J | 1 |
| Ghali, JK | 1 |
| Fong, NT; Yee, HS | 1 |
| Malinowski, JM | 1 |
| Liguori, E; Sarcinella, R | 1 |
| Geiss, HC; Parhofer, KG; Schwandt, P | 1 |
| Bakker-Arkema, RG; Black, DM; Davidson, MH; Henley, RW; Hunninghake, DB; Koren, MJ; McKenney, JM; McLain, RW; Schrott, HG; Smith, DG; Tresh, P; Weiss, SR | 1 |
| Bataille, L; Hamoir, V; Horsmans, Y; Nakad, A; Sempoux, C | 1 |
| Brown, WV; Eisenberg, D; McCormick, LS; Pitt, B; Schwartz, L; Shurzinske, L; Title, LM; van Boven, AJ; Waters, D | 1 |
| Kostner, KM | 1 |
| Alvarez, ML; Ballester, B; Errasti, P; García, I; García, N; Gómez, G; Lavilla, FJ; Purroy, A | 1 |
| Branchi, A; Fiorenza, AM; Macor, S; Muzio, F; Rovellini, A; Sommariva, D; Torri, A | 1 |
| Attanasio, E; Badia, X; Russo, P | 1 |
| Bäumer, AT; Böhm, M; Jockenhövel, F; Kebben, D; Nickenig, G; Temur, Y | 1 |
| Carpentier, Y; Ducobu, J; Sternon, J | 1 |
| Cheung, R; Mutus, B; Tannous, M; Vignini, A | 1 |
| Baim, DS; Carrozza, JP; Cohen, DJ | 1 |
| Davidson, CJ; Ricciardi, MJ | 1 |
| Bloom, JM | 1 |
| Eminton, Z; Fowler, G; Maton, S; Neil, HA; Patel, H | 1 |
| Furberg, CD; Rodrigues, M; Sinzinger, H | 1 |
| Crook, MA; Mikhailidis, DP; Nair, DR; Wierzbicki, AS; Winder, AF | 1 |
| Farnier, M; Maigret, P; Portal, JJ | 1 |
| Jones, PH | 1 |
| Bakker-Arkema, RG; Black, DM; Nawrocki, JW | 1 |
| Barter, PJ; O'Brien, RC | 1 |
| Kolsky, MP; Laureno, R; Negevesky, GJ; Yau, TH | 1 |
| Cernigoi, AM; Merni, M; Tortul, C; Velussi, M | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van den Berkmortel, FW; van Langen, H; Wollersheim, H | 1 |
| Blair, SN; Capuzzi, DM; Cater, NB; Gottlieb, SO; Morgan, JM; Nguyen, T | 1 |
| Black, DM; Davidson, MH; Hunninghake, D; Isaacsohn, JL; McLain, R; Singer, R | 1 |
| Calviño, J; Rodriguez, J; Romero, R; Sánchez-Guisande, D | 1 |
| Candigliota, M; Ceravolo, R; Chello, M; Cloro, C; Maio, R; Mastroroberto, P; Mattioli, PL; Mongiardo, A; Perticone, F; Scozzafava, A | 1 |
| Acosta, S; Dobs, A; Recto, CS | 1 |
| Lupattelli, G; Mannarino, E; Marchesi, S; Roscini, AR; Schillaci, G; Siepi, D; Sinzinger, H; Vaudo, G | 1 |
| Cromwell, WC; Ziajka, PE | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Black, DM | 1 |
| Strandberg, TE; Tikkanen, MJ; Vanhanen, H | 1 |
| Dzurick, J; Hiller, D; Peralta, B; Rindone, JP | 1 |
| Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M | 1 |
| Marschall, HU | 1 |
| Celada Rodríguez, A; Cerdán Oliver, M; de Miguel Clavé, J; Ocaña López, JM; Solera Albero, J; Tárraga López, PJ | 1 |
| Autin, JM; Bruniquel, F; Colpaert, FC; Degryse, AD; Delhon, A; Junquero, D; N'Guyen, X; Patoiseau, JF | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Arai, Y; Funatsu, T; Kakuta, H; Miyata, K; Suzuki, K; Tanaka, H | 1 |
| Bairaktari, ET; Chatzidimou, KG; Elisaf, MS; Goudevenos, JA; Mikhailidis, DP; Milionis, HJ | 1 |
| Allen, SE; Attanasio, E; Russo, P | 1 |
| Bachmann, GA; Callister, TQ; Davidson, M; Kafonek, S; Laskey, R; Pittman, D; Raggi, P; Scott, R; Welty, FK | 1 |
| Wierzbicki, AS | 1 |
| Kajinami, K; Takekoshi, N | 1 |
| Brohet, C; De Backer, G; Heller, F; Muls, E | 1 |
| Aragoncillo, P; Cachofeiro, V; Cediel, E; de Las Heras, N; Díaz, C; Hernández, G; Lahera, V; Navarro-Cid, J; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S | 1 |
| Angus, C; Genest, J; McPherson, R; Murray, P | 1 |
| Farnier, M; Mercuri, M; Stein, EA; Waldstreicher, J | 1 |
| Ito, MK | 1 |
| Crouse, JR; Davidson, MH; Escobar, ID; Hunninghake, DB; Illingworth, DR; Liu, M; Ma, PT; Melino, MR; Mercuri, M; Mitchel, YB; O'Grady, L; Paragh, G; Stalenhoef, AF | 1 |
| Athyros, VG; Bouloukos, VJ; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Susekov, AV | 1 |
| Bakker-Arkema, RG; Black, DM; Corella, D; Ordovas, JM; Pedro-Botet, J; Schaefer, EJ; Stein, EM | 1 |
| McKellar, J; Mizan, J; Olsson, AG; Pears, J; Raza, A | 1 |
| Davidson, M; Hunninghake, D; Insull, W; Jones, P; Kafonek, S; Knopp, R; Lohrbauer, L | 1 |
| Akanuma, Y; Kawakami, M; Ohashi, Y; Saito, Y; Tanaka, A; Yamada, N | 1 |
| Burke, SK; Davidson, D; Donovan, JM; Hunninghake, D; Insull, W; Toth, P | 1 |
| Hsue, PY; Waters, DD | 1 |
| Deedwania, P | 1 |
| Grundy, SM | 1 |
| Criqui, MH | 1 |
| Erkelens, DW | 1 |
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| Alfón, J; Badimon, L; Berrozpe, M; Martínez-González, J | 1 |
| Goa, KL; Malhotra, HS | 1 |
| Bernini, F; Paoletti, R; Poli, A | 1 |
| Gavish, D; Hazanov, N; Leibovitz, E; Shargorodsky, M; Zimlichman, R | 1 |
| Chitra, R; Davidson, M; Gotto, AM; Hutchinson, H; Ma, P; Raza, A; Stein, EA | 1 |
| Ting, CT; Wang, KY | 1 |
| Hurt-Camejo, E; Mattsson-Hultén, L; Oscarsson, J; Wiklund, O | 1 |
| Castro, JG; Gutierrez, L | 1 |
| Almenar Bonet, L; Arnau Vives, MA; Dicenta Gisbert, F; Martínez-Dolz, L; Osa Sáez, A; Palencia Pérez, M; Rueda Soriano, J | 1 |
| Caccese, D; Lauro, R; Lenti, L; Magnaterra, R; Martini, F; Pignatelli, P; Pulcinelli, FM; Sanguigni, V; Violi, F | 1 |
| Bellosta, S; Corsini, A; Paoletti, R | 1 |
| Bonow, RO; McConnell, JP; Niekrasz, M; Rajamannan, NM; Sebo, TC; Singh, RJ; Spelsberg, TC; Springett, M; Stone, NJ; Subramaniam, M | 1 |
| Auteri, A; Bova, G; Bruni, F; Cercignani, M; Console, E; Palazzuoli, A; Pasqui, AL; Puccetti, L | 1 |
| Hinman, J; Scanu, AM | 1 |
| Gavish, D; Harats, D; Leibovitz, E | 1 |
| Mikhailidis, DP; Wierzbicki, AS | 1 |
74 review(s) available for atorvastatin and Elevated Cholesterol
| Article | Year |
|---|---|
Therapeutic effects of statins on osteoarthritis: A review.
Topics: Atorvastatin; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Osteoarthritis; Oxidoreductases; Simvastatin | 2022 |
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; United Kingdom; United States | 2018 |
Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Triglycerides | 2018 |
An evaluation of pitavastatin for the treatment of hypercholesterolemia.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Quinolines; Treatment Outcome | 2019 |
Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations.
Topics: Atorvastatin; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium; Treatment Outcome | 2020 |
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Risk Factors; Simvastatin | 2019 |
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Topics: Acute Kidney Injury; Adult; Aged; Atorvastatin; British Columbia; Cohort Studies; Confidence Intervals; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Safety; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United Kingdom; United States | 2013 |
Liptruzet: a combination of ezetimibe and atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Combinations; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
Topics: Aged; Aging; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cytosine; Databases, Factual; Dose-Response Relationship, Drug; Female; Genetic Association Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Single Nucleotide; Prospective Studies; Pyrroles; Risk Factors; Sex Characteristics; Simvastatin; Thymine | 2014 |
[Statins after intracerebral haemorrhage: is this safe?].
Topics: Atorvastatin; Cerebral Hemorrhage; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Stroke | 2015 |
Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
[A new approach to the treatment of dyslipidemia].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Factors | 2008 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2008 |
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Fluorobenzenes; Gene Frequency; Haplotypes; HeLa Cells; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
New evidence on pitavastatin: efficacy and safety in clinical studies.
Topics: Animals; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Pyrroles; Quinolines | 2010 |
Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intracranial Hemorrhages; Primary Prevention; Pyrroles; Risk Factors; Secondary Prevention; Stroke | 2010 |
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pyrroles | 2010 |
Atorvastatin: safety and tolerability.
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Meta-Analysis as Topic; Product Surveillance, Postmarketing; Pyrroles; Randomized Controlled Trials as Topic | 2010 |
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States | 2010 |
Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2010 |
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Pitavastatin - results from phase III & IV.
Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin | 2010 |
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention | 2010 |
Pitavastatin: an overview.
Topics: Antioxidants; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Endothelium, Vascular; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Japan; Metabolic Syndrome; Molecular Structure; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Receptors, LDL | 2011 |
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
The role of endoglin in atherosclerosis.
Topics: Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Endoglin; Endothelium, Vascular; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Proteoglycans; Pyrroles; Receptors, Cell Surface; Receptors, Transforming Growth Factor beta; Swine | 2012 |
Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Belgium; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Heptanoic Acids; Humans; Hypercholesterolemia; Marketing of Health Services; Pyrroles | 2013 |
Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2002 |
Benefits and menaces related to the use of statins in patients after renal transplantation.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin | 2002 |
Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Renal Dialysis; Simvastatin | 2003 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2003 |
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 2003 |
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Pyrimidines; Pyrroles; Racial Groups; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2004 |
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
[The role of intestinal absorption blockade in hypercholesterolemia treatment].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Intestinal Obstruction; Pyrroles | 2004 |
Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?
Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Maximum Tolerated Dose; Practice Guidelines as Topic; Pravastatin; Prognosis; Pyrroles; Quebec; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome | 2005 |
The role of lipid management in diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Diabetic Angiopathies; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Pyrroles; Simvastatin; Triglycerides | 2005 |
["Treating to New Targets": plea for a LDL cholesterol target of or below 75 mg/dl in any patient with coronary heart disease].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles | 2005 |
Atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Statins and aortic stenosis progression: are biologic targets still an option?
Topics: Aortic Valve Stenosis; Atorvastatin; Disease Progression; Echocardiography, Doppler; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2005 |
[Intensive cholesterol lowering therapy to reduce cardiovascular risk].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2006 |
Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Diseases; Male; Musculoskeletal Diseases; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies | 2006 |
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin | 2006 |
How safe is aggressive statin therapy?
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2007 |
The genetic determinants of atorvastatin response.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cholesterol; Genetic Variation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Muscular Diseases; Pyrroles; Risk Factors | 2007 |
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medical Records Systems, Computerized; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
[Clopidogrel and statins or once more on the danger of direct transfer of results of experimental studies in clinical practice].
Topics: Atorvastatin; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2008 |
Statins revisited.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Naphthalenes; Pyrroles | 1998 |
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Treatment Outcome | 1998 |
Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Pyrroles | 1998 |
[Aggressive therapy and combination therapy in severe hyperlipidemia].
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 1999 |
[Atorvastatin (Lipitor)].
Topics: Anticholesteremic Agents; Atorvastatin; Belgium; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Pyrroles | 1999 |
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Treatment Outcome | 2000 |
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
[Atorvastatin (Lipitor): a review of its pharmacological and clinical profile].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, VLDL; Liver; Pyrroles; Receptors, LDL; Triglycerides | 2001 |
Atorvastatin.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2001 |
[Atorvastatin].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic | 2001 |
[Substantiation of increasing doses of statins in clinical practice].
Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2001 |
What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Treatment Outcome | 2001 |
United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pyrroles | 2001 |
Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arterial Occlusive Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Survival Rate | 2001 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Pyrroles | 2001 |
Safety of HMG-CoA reductase inhibitors: focus on atorvastatin.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2001 |
Pharmacological interactions of statins.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Tolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Muscular Diseases; Pyrroles; Rhabdomyolysis | 2002 |
353 trial(s) available for atorvastatin and Elevated Cholesterol
| Article | Year |
|---|---|
High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study.
Topics: Atorvastatin; Cardiovascular Diseases; Cholestanol; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sterols | 2022 |
Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients.
Topics: Anticholesteremic Agents; Atorvastatin; China; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Treatment Outcome | 2022 |
[Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia: a multicenter, randomized, double-blind, double-dummy, parallel-controlled phase Ⅲ clinical trial].
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2023 |
Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus.
Topics: Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2022 |
Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Treatment Outcome | 2023 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Health Centers; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Medically Underserved Area; Medication Adherence; Middle Aged | 2019 |
Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Biomarkers; Double-Blind Method; Humans; Hypercholesterolemia; Japan; PCSK9 Inhibitors; Treatment Outcome | 2019 |
Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrroles; Quinolines; Treatment Outcome | 2020 |
Comparing the Effect of Combining Exercise with Rosuvastatin versus Atorvastatin on Lipid Profile and Functional Capacity: A Retrospective Cohort Study.
Topics: Aged; Atorvastatin; Exercise Therapy; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Retrospective Studies; Rosuvastatin Calcium | 2020 |
Statin-induced microRNAome alterations modulating inflammation pathways of peripheral blood mononuclear cells in patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Plaque, Atherosclerotic; Quinolines; Taiwan | 2020 |
A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Prognosis; Republic of Korea | 2021 |
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
Topics: Anticholesteremic Agents; Atorvastatin; Dicarboxylic Acids; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Treatment Outcome | 2021 |
Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dietary Supplements; Double-Blind Method; Dyslipidemias; Fatty Alcohols; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Vitamin K 2; Vitamins | 2021 |
A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections, Subcutaneous; Male; Middle Aged; PCSK9 Inhibitors; Proprotein Convertase 9; Treatment Outcome; Young Adult | 2017 |
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p
Topics: Adult; Aged; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Hematologic Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Lymphatic Diseases; Male; Middle Aged; Muscular Diseases; Nocebo Effect; Risk Factors; Sleep Wake Disorders; Treatment Outcome | 2017 |
Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Rand
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Asian People; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Treatment Outcome | 2017 |
Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; PCSK9 Inhibitors; Young Adult | 2017 |
Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomized, double-blind, active-controlled study.
Topics: Aged; Asian People; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Rosuvastatin Calcium; Treatment Outcome | 2018 |
The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastati
Topics: Administration, Intravenous; Adult; Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, LDL; Down-Regulation; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; PCSK9 Inhibitors; Proprotein Convertase 9; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome | 2018 |
Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Life Style; Lipids; Male; Middle Aged; Prospective Studies; Rosuvastatin Calcium; Thyroid Function Tests; Thyroid Gland; Thyroid Nodule | 2018 |
The effect of high-dose atorvastatin on neural activity and cognitive function.
Topics: Adult; Atorvastatin; Brain; Cognition; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Task Performance and Analysis; Withholding Treatment | 2018 |
Drug effect of atorvastatin on middle cerebral atherosclerotic stenosis and high resolution NMR diagnosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Constriction, Pathologic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Middle Cerebral Artery; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2018 |
Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.
Topics: Adult; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperprolactinemia; Lipids; Metabolic Diseases; Middle Aged; Prolactin; Risk Factors | 2019 |
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Risk Factors; United Kingdom | 2018 |
Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Surveys and Questionnaires | 2019 |
Intensive lipid lowering therapy reduces large, but not small, dense low-density lipoprotein particles measured by gel electrophoresis, in elderly patients with atrial fibrillation.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Cholesterol, LDL; Cholesterol, VLDL; Electrophoresis; Humans; Hypercholesterolemia | 2019 |
Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemodynamics; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Pyrroles; Treatment Outcome; Vascular Stiffness | 2013 |
Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Atorvastatin; Bone Density; Calcinosis; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Organ Specificity; Plaque, Atherosclerotic; Prospective Studies; Pyrroles | 2013 |
Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Endpoint Determination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Quinolines; Young Adult | 2013 |
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Databases, Factual; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linear Models; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasm Proteins; Organic Anion Transporters; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Atorvastatin and hormone therapy influence expression of ABCA1, APOA1 and SCARB1 in mononuclear cells from hypercholesterolemic postmenopausal women.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; ATP Binding Cassette Transporter 1; Cells, Cultured; Estradiol; Female; Heptanoic Acids; Heterocyclic Compounds; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Middle Aged; Postmenopause; Pyrroles; Scavenger Receptors, Class B; Transcriptome | 2013 |
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Triglycerides | 2013 |
Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Canada; Cholesterol, LDL; Double-Blind Method; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Treatment Outcome | 2014 |
The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Matrix Metalloproteinase 7; Matrix Metalloproteinase 8; Middle Aged; Pyrroles | 2014 |
N-of-1 (single-patient) trials for statin-related myalgia.
Topics: Aged; Aged, 80 and over; Atorvastatin; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Sulfonamides | 2014 |
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2014 |
Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelial Progenitor Cells; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: comparative study of pitavastatin and atorvastatin.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Prospective Studies; Quinolines; Regression Analysis | 2015 |
Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabete
Topics: Asian People; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydrophobic and Hydrophilic Interactions; Hypercholesterolemia; Japan; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Patient Acceptance of Health Care; Pravastatin; Recurrence; Single-Blind Method; Solubility | 2015 |
A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.
Topics: Adolescent; Atorvastatin; Child; Cholesterol, LDL; Combined Modality Therapy; Diabetes Mellitus, Type 1; Diet, Diabetic; Diet, Fat-Restricted; Double-Blind Method; Drug Monitoring; Exercise; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Pilot Projects; Pyrroles | 2015 |
Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged | 2015 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome | 2014 |
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin | 2014 |
Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; Cell Adhesion Molecules; Cell Line; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Male; Middle Aged; RNA, Messenger; Simvastatin; Treatment Outcome | 2015 |
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Oxazolidinones; Pyrroles; Time Factors; Triglycerides | 2015 |
Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Patient Care Planning; Practice Patterns, Physicians'; Rosuvastatin Calcium; Surveys and Questionnaires | 2015 |
Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Insulin Resistance; Male; Prognosis; Prospective Studies; Quinolines | 2015 |
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Dopamine Agonists; Exercise; Female; Fibrinogen; Homocysteine; Humans; Hypercholesterolemia; Hyperprolactinemia; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Middle Aged; Premenopause; Risk Factors; Uric Acid | 2015 |
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
Atorvastatin Reduces Circulating Osteoprogenitor Cells and T-Cell RANKL Expression in Osteoporotic Women: Implications for the Bone-Vascular Axis.
Topics: Aged; Atorvastatin; Biomarkers; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Jurkat Cells; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Stem Cells; T-Lymphocytes; Time Factors; Treatment Outcome | 2016 |
A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Triglycerides; United States | 2016 |
Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Biomarkers; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Middle Aged; Nuclear Magnetic Resonance, Biomolecular; Particle Size; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Serine Proteinase Inhibitors; Treatment Outcome | 2015 |
Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Down-Regulation; Drug Substitution; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Rosuvastatin Calcium; Treatment Outcome | 2016 |
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, LDL; Creatine Kinase; Cross-Over Studies; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Myalgia; Myositis; Rhabdomyolysis; Time Factors | 2016 |
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atorvastatin; Cholesterol; Female; HIV Infections; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lopinavir; Male; Middle Aged; Ritonavir | 2016 |
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Simvastatin; Treatment Outcome | 2016 |
Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factorial, Multicenter Phase III Study.
Topics: Aged; Antihypertensive Agents; Atorvastatin; Biphenyl Compounds; Blood Pressure; Cholesterol; Double-Blind Method; Drug Combinations; Female; Humans; Hypercholesterolemia; Hypertension; Irbesartan; Male; Middle Aged; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome | 2016 |
Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Coagulation; Blood Platelets; Cell Membrane; Chile; Cholesterol; Cholesterol, HDL; Factor Xa; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation; Platelet Glycoprotein GPIb-IX Complex; Rosuvastatin Calcium; Thromboplastin; Time Factors; Treatment Outcome | 2017 |
Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2017 |
Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Regression Analysis; Triglycerides | 2008 |
A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density li
Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Enzyme Inhibitors; Female; Follow-Up Studies; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrroles; Quinolines; Time Factors; Treatment Outcome | 2008 |
Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.
Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol; Combined Modality Therapy; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; P-Selectin; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2008 |
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |
Effect of atorvastatin on LDL & hs-CRP in a selected Thai population.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Thailand; Treatment Outcome | 2008 |
Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia.
Topics: Atorvastatin; Belgium; Cholesterol, LDL; Female; Fluorobenzenes; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Logistic Models; Male; Markov Chains; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Heptanoic Acids; Hospitals, Veterans; Humans; Hypercholesterolemia; Male; Pyrroles | 2008 |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Pyrroles; Regional Blood Flow; Severity of Illness Index; Vasodilation | 2008 |
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome | 2008 |
Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.
Topics: Adiponectin; Adult; Aged; Atorvastatin; Biomarkers; Brachial Artery; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation Mediators; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2009 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2009 |
Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI.
Topics: Aged; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Aortography; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2009 |
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Risk Factors; Secondary Prevention; Stroke; Treatment Outcome; Triglycerides; Young Adult | 2009 |
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult | 2009 |
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Topics: Adolescent; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Young Adult | 2009 |
Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).
Topics: Atherosclerosis; Atorvastatin; Diabetes Mellitus, Type 2; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Outcome | 2009 |
The influence of atorvastatin on walking performance in peripheral arterial disease.
Topics: Aged; Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Cholesterol, LDL; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Test; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intermittent Claudication; Male; Middle Aged; Pyrroles; Statistics, Nonparametric; Walking | 2009 |
Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Baroreflex; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Pressoreceptors; Pyrroles | 2009 |
Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment.
Topics: Atorvastatin; Blood Vessels; Cardiovascular Diseases; Cholestasis; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Cirrhosis, Biliary; Male; Middle Aged; Prospective Studies; Pyrroles | 2010 |
Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia.
Topics: Antioxidants; Atorvastatin; Biomarkers; Blood Platelets; Blotting, Western; Case-Control Studies; Cholesterol; Combined Modality Therapy; Cross-Sectional Studies; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoprecipitation; Isoprostanes; Leukocytes, Mononuclear; Male; Membrane Glycoproteins; Middle Aged; NADPH Oxidase 2; NADPH Oxidases; Pyrroles; Time Factors; Treatment Outcome | 2010 |
A multicenter study in Malaysia to determine the efficacy and safety of a generic atorvastatin.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2009 |
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.
Topics: Analysis of Variance; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Prescriptions; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Pyrroles; Treatment Outcome; United States | 2010 |
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Black People; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2010 |
Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titr
Topics: Adult; Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult | 2010 |
Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cholesterol, LDL; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Treatment Outcome | 2010 |
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
Topics: Atorvastatin; Blood Glucose; Cholesterol, LDL; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Insulin; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cluster Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Internationality; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Surveys and Questionnaires | 2010 |
Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Deoxyguanosine; Erythrocytes; Female; Glutathione; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles; Ubiquinone; Vitamin E | 2010 |
Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.
Topics: Adult; Aged; Atorvastatin; Blood Glucose; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Insulin Resistance; Male; Middle Aged; Pyrroles; Treatment Outcome | 2010 |
Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Cholestyramine Resin; Endarterectomy, Carotid; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lymphocyte Count; Macrophages; Male; Pyrroles; Sitosterols | 2010 |
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome | 2010 |
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Triglycerides | 2010 |
Markers of cholesterol absorption and synthesis predict the low-density lipoprotein cholesterol response to atorvastatin.
Topics: Absorption; Aged; Atorvastatin; Biomarkers; Cholestanol; Cholesterol; Cholesterol, LDL; Desmosterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Prognosis; Prospective Studies; Pyrroles | 2010 |
A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Creatine Kinase; Decision Trees; Double-Blind Method; Exercise Test; Female; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isometric Contraction; Male; Motor Activity; Muscle Strength; Muscle Strength Dynamometer; Muscle Weakness; Muscle, Skeletal; Physical Endurance; Pyrroles; Research Design; Surveys and Questionnaires | 2010 |
Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Triglycerides | 2010 |
Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Leukocytes; Male; Middle Aged; Pyrroles; Young Adult | 2010 |
Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients.
Topics: Adiponectin; Aged; Antioxidants; Atorvastatin; Blood Platelets; Case-Control Studies; Cross-Sectional Studies; Female; Free Radicals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Membrane Glycoproteins; Middle Aged; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Pyrroles | 2010 |
Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease.
Topics: Adolescent; Adult; Age Factors; Aged; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Racial Groups; Risk Factors; Sex Factors; Treatment Outcome; Young Adult | 2011 |
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Logistic Models; Male; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2010 |
Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.
Topics: Adenosine Triphosphate; Adult; Aged; Atorvastatin; Biomarkers; Cell Proliferation; Culture Media, Conditioned; Cytokines; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tacrolimus; Transplantation | 2010 |
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.
Topics: 3' Untranslated Regions; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Oxidative Stress; Platelet Activation; Polymorphism, Genetic; Prospective Studies; Prostaglandins A; Pyrimidines; Pyrroles; Regression Analysis; Rosuvastatin Calcium; Sulfonamides; Thromboxane B2 | 2011 |
Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Therapeutic Equivalency; Treatment Outcome; Young Adult | 2010 |
Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Interleukin-10; Lipoprotein(a); Male; Middle Aged; Placebos; Pyrroles | 2011 |
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome | 2011 |
The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A₂.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers, Pharmacological; Chemokine CCL2; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2011 |
High-dose atorvastatin enhances impaired cerebral vasomotor reactivity.
Topics: Aged; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Flow Velocity; Blood Pressure; Brain Infarction; Cerebrovascular Circulation; Chi-Square Distribution; Cholesterol, LDL; Female; Florida; Hemodynamics; Heptanoic Acids; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Middle Cerebral Artery; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2012 |
The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients.
Topics: Acetylation; Aspirin; Atorvastatin; Blood Platelets; Blood Proteins; Cholesterol; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2011 |
Proteomic approach to the study of statin pleiotropy in kidney transplant patients.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Immunoenzyme Techniques; Kidney Function Tests; Kidney Transplantation; Lipids; Male; Middle Aged; Molecular Weight; Peptide Fragments; Prospective Studies; Proteomics; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans.
Topics: Administration, Oral; Adult; Analysis of Variance; Arginase; Arginine; Atorvastatin; Biomarkers; Biopsy; Blood Flow Velocity; Cholesterol; Down-Regulation; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Microcirculation; Microdialysis; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type III; Pennsylvania; Pyrroles; Regional Blood Flow; Skin; Time Factors; Treatment Outcome; Triglycerides | 2011 |
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
Topics: Aged; Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Patient Selection; Prospective Studies; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Cytokines; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Prospective Studies; Pyrroles; Regression Analysis; Risk Factors; Risk Reduction Behavior; Serpins | 2011 |
Oral atorvastatin therapy increases nitric oxide-dependent cutaneous vasodilation in humans by decreasing ascorbate-sensitive oxidants.
Topics: Administration, Oral; Adult; Analysis of Variance; Antioxidants; Arginase; Ascorbic Acid; Atorvastatin; Enzyme Inhibitors; Female; Heating; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Microdialysis; Microvessels; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Pennsylvania; Pyrroles; Skin; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2011 |
Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Topics: Aged; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Ireland; Male; Middle Aged; Pyrroles; Racial Groups; Treatment Outcome; United Kingdom | 2011 |
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Stroke; Treatment Outcome | 2012 |
Acute localized administration of tetrahydrobiopterin and chronic systemic atorvastatin treatment restore cutaneous microvascular function in hypercholesterolaemic humans.
Topics: Anticholesteremic Agents; Arginase; Arginine; Atorvastatin; Biopterins; Cholesterol; Female; Heating; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Microcirculation; Microdialysis; Middle Aged; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Regional Blood Flow; Skin; Vasodilation | 2011 |
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
Topics: Adult; Aged; Atorvastatin; Cause of Death; Coronary Disease; Double-Blind Method; Early Termination of Clinical Trials; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2011 |
Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2012 |
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atorvastatin; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Tetrahydronaphthalenes; Treatment Outcome | 2012 |
Atorvastatin and hormone therapy effects on APOE mRNA expression in hypercholesterolemic postmenopausal women.
Topics: Aged; Amplified Fragment Length Polymorphism Analysis; Apolipoproteins; Apolipoproteins E; Atorvastatin; Brazil; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Liver X Receptors; Middle Aged; Orphan Nuclear Receptors; Polymorphism, Single Nucleotide; Postmenopause; Pyrroles; RNA, Messenger | 2012 |
Long-term efficacy and safety of a generic atorvastatin in usual clinical care setting.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Drug Administration Schedule; Drugs, Generic; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2011 |
Assessment of atorvastatin effectiveness on serum PSA level in hypercholesterolemic males.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Pyrroles; Triglycerides | 2011 |
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
[Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: sub-analysis of the TWINS study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Ultrasonography, Interventional | 2012 |
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Injections, Intravenous; Injections, Subcutaneous; Least-Squares Analysis; Lipoproteins; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Receptors, LDL; Serine Endopeptidases | 2012 |
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Synergism; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Time Factors; Treatment Outcome | 2012 |
Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Lipids; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols | 2012 |
Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients.
Topics: Antioxidants; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Pyrroles; Serum Amyloid A Protein | 2012 |
Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2.
Topics: Aged; Aged, 80 and over; Antioxidants; Atorvastatin; Combined Modality Therapy; Diet, Mediterranean; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Membrane Glycoproteins; Middle Aged; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Platelet Activation; Pyrroles; Treatment Outcome | 2012 |
Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2012 |
Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study.
Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocyte Count; Lipids; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Pravastatin; Pyrroles; Regression Analysis; Risk Factors | 2012 |
No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Calcimycin; Calcium Ionophores; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukotriene B4; Male; Middle Aged; Neutrophil Activation; Neutrophils; Pyrroles | 2012 |
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Treatment Outcome | 2012 |
Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia.
Topics: Atorvastatin; Biomarkers; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Pyrroles; Quinolines | 2013 |
Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Apolipoproteins B; Asian People; Atorvastatin; Biomarkers; C-Reactive Protein; Chemistry, Pharmaceutical; Cholesterol, HDL; Cholesterol, LDL; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Republic of Korea; Therapeutic Equivalency; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2013 |
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides | 2013 |
Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients.
Topics: Adolescent; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child; Child, Preschool; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension, Renal; Kidney Transplantation; Male; Prospective Studies; Pyrroles; Treatment Outcome | 2002 |
Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk.
Topics: Adult; Aged; Apolipoproteins A; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Logistic Models; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2002 |
Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2002 |
Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels.
Topics: Acetylcholine; Anticholesteremic Agents; Arginine; Atorvastatin; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Nitroprusside; omega-N-Methylarginine; Postmenopause; Pyrroles; Reference Values; Regional Blood Flow; Treatment Outcome; Vasodilation; Vasodilator Agents | 2002 |
Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS).
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Pyrroles | 2002 |
Effects of atorvastatin treatment on sICAM-1 and plasma nitric oxide levels in hypercholesterolemic subjects.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Nitric Oxide; Placebos; Pyrroles; Time Factors | 2002 |
Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pyrroles; Recurrence; Survival Rate | 2002 |
Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study.
Topics: Adult; Aged; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Double-Blind Method; Elasticity; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pulse; Pyrroles; Statistics, Nonparametric; Treatment Outcome | 2002 |
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2002 |
[Effect of atorvastatin on endothelial function in patients with familial hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2002 |
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2003 |
Time-dependent effect of statins on platelet function in hypercholesterolaemia.
Topics: Adult; Analysis of Variance; Antiporters; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol; Cross-Sectional Studies; Double-Blind Method; E-Selectin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
Low-dose atorvastatin therapy does not augment endothelial function in active hypercholesterolaemic males.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2003 |
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrroles | 2003 |
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Cost-Benefit Analysis; Double-Blind Method; Endpoint Determination; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hypercholesterolemia; Myocardial Ischemia; Pyrroles; Treatment Outcome; United Kingdom | 2003 |
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
Hemostatic effects of atorvastatin versus simvastatin.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemostasis; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2003 |
Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Cardiovascular Diseases; Echocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Time; United States | 2003 |
Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Tolerance; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis | 2003 |
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Digestive System; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Musculoskeletal Diseases; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2003 |
Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Function Tests; Middle Aged; Prospective Studies; Pyrroles; Triglycerides | 2003 |
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2003 |
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Time Factors; Triglycerides | 2003 |
Statins promote potent systemic antioxidant effects through specific inflammatory pathways.
Topics: Antioxidants; Arteriosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Pyrroles; Reactive Oxygen Species; Signal Transduction; Statistics, Nonparametric; Tyrosine | 2003 |
[Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Disease; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Platelet Aggregation; Pravastatin; Pyrroles; Time Factors | 2003 |
Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Apolipoproteins B; Atorvastatin; Child; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrroles; Severity of Illness Index; Triglycerides | 2003 |
Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; E-Selectin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrroles; Vascular Cell Adhesion Molecule-1; Vasodilation | 2003 |
Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin.
Topics: Adult; Aged; Alfentanil; Analgesics, Opioid; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Chromatography, Gas; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Infusions, Intravenous; Male; Middle Aged; Pyrroles; Time Factors | 2003 |
Effect of atorvastatin on myocardial contractile reserve assessed by tissue Doppler imaging in moderately hypercholesterolemic patients without heart disease.
Topics: Aged; Atorvastatin; Blood Flow Velocity; Blood Pressure; Cardiotonic Agents; Cholesterol, HDL; Cholesterol, LDL; Diastole; Diet, Fat-Restricted; Dobutamine; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Contraction; Pyrroles; Stroke Volume; Systole; Treatment Outcome; Triglycerides | 2003 |
Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia.
Topics: Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; E-Selectin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Male; Middle Aged; Multivariate Analysis; Pyrroles; Vascular Cell Adhesion Molecule-1 | 2003 |
Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Gonadal Steroid Hormones; Gonads; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Severity of Illness Index | 2003 |
Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles | 2003 |
Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; Cholesterol; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Thiobarbituric Acid Reactive Substances; Time Factors | 2003 |
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).
Topics: Adult; Aged; Alkaline Phosphatase; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Diarrhea; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Musculoskeletal Diseases; Nausea; Pyrroles; Simvastatin | 2003 |
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 2003 |
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2003 |
Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dl.
Topics: Administration, Oral; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperemia; Male; Middle Aged; Nitroglycerin; Pulsatile Flow; Pyrroles; Treatment Outcome; Triglycerides; Vasodilation | 2004 |
Effects of low and high doses of atorvastatin on arterial compliance.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Artery, Common; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Compliance; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides; Ultrasonography, Doppler, Color; Ultrasonography, Interventional | 2003 |
Rationale, design and methods of the CASHMERE study.
Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Endpoint Determination; Estrogen Replacement Therapy; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Prospective Studies; Pyrroles; Research Design; Treatment Outcome | 2004 |
Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Mutation; Phenotype; Pyridines; Pyrroles; Time Factors | 2004 |
Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.
Topics: Adult; Aged; Amyloid beta-Peptides; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Peptide Fragments; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
[Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects.
Topics: Adult; Analysis of Variance; Atorvastatin; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Statistics, Nonparametric | 2004 |
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study.
Topics: Apolipoproteins B; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2004 |
Effects of lipid-lowering therapy on coronary artery remodeling.
Topics: Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Longitudinal Studies; Male; Middle Aged; Pyrroles; Statistics as Topic; Treatment Outcome; Ultrasonography, Interventional | 2004 |
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Logistic Models; Male; Middle Aged; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2004 |
Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Matrix Metalloproteinase 9; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2004 |
Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease.
Topics: Aged; Angina Pectoris; Atorvastatin; Cholesterol, LDL; Disease Progression; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Ischemia; Pyrroles; Time Factors | 2004 |
Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Treatment Outcome | 2004 |
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Therapy, Combination; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Tissue Plasminogen Activator | 2004 |
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2004 |
Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects.
Topics: Aged; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Estrogens; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Norethindrone; Progesterone; Pyrroles; Vasodilation | 2004 |
Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study.
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis; Time Factors; Treatment Outcome | 2004 |
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinetics; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2005 |
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2004 |
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein Lipase; Middle Aged; Pravastatin; Pyrroles | 2004 |
Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
Topics: Adenosine Diphosphate; Atorvastatin; Biomarkers; Blood Coagulation; Blood Platelets; CD40 Ligand; Collagen; Coronary Disease; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Multifactorial Inheritance; Peptide Fragments; Prothrombin; Pyrroles; Solubility; Thrombin; Thromboplastin; Treatment Outcome | 2005 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Effects of statin therapy on circulating conjugated dienes, a measure of LDL oxidation.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Simvastatin | 2005 |
Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging.
Topics: Aged; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Image Enhancement; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Treatment Outcome | 2005 |
Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Combined Modality Therapy; Cross-Over Studies; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2005 |
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Chronic Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Particle Size; Phenotype; Pilot Projects; Pyrroles; Renal Dialysis; Risk Factors; Triglycerides | 2005 |
Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.
Topics: Acetylcholine; Adult; Aged; Ascorbic Acid; Atorvastatin; Biological Availability; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Nitric Oxide; Nitroprusside; omega-N-Methylarginine; Pyridines; Pyrroles; Regional Blood Flow; Vasodilation | 2005 |
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Topics: Atorvastatin; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Postmenopause; Pyrroles; Risedronic Acid | 2005 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention; Statistics as Topic; Survival Rate; Treatment Outcome | 2005 |
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2005 |
A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Double-Blind Method; Female; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Placebos; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Sex Factors; Treatment Outcome | 2005 |
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Safety | 2005 |
Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; Cholesterol; Coenzymes; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrroles; Risk Factors; Treatment Outcome; Ubiquinone | 2005 |
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Pyrroles; Vascular Diseases | 2005 |
Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
Topics: Anticholesteremic Agents; Aryldialkylphosphatase; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Oxidation-Reduction; Placebos; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Vitamin E | 2005 |
Efficacy and safety of chunghyul-dan (qingwie-dan) in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2005 |
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
Topics: Adult; Age Factors; Aged; Atorvastatin; Biopsy; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Citrate (si)-Synthase; Dose-Response Relationship, Drug; Double-Blind Method; Electron Transport; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscles; Patient Selection; Phytosterols; Pyrroles; Sex Factors; Simvastatin; Sitosterols; Succinate Cytochrome c Oxidoreductase; Time Factors; Ubiquinone | 2005 |
The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Program Evaluation; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Comorbidity; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Radio Waves; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2005 |
Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Pyrroles; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2005 |
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2005 |
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors | 2005 |
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
Topics: Adult; Atorvastatin; Blood Coagulation; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Female; Fibrinolysis; Gonadal Steroid Hormones; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Inflammation; Lipids; Lipoproteins; Malondialdehyde; Middle Aged; Plasminogen Activator Inhibitor 1; Postmenopause; Premenopause; Prospective Studies; Pyrroles; Time Factors; Tissue Plasminogen Activator; Triglycerides | 2006 |
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Comorbidity; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Hospital Mortality; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Premedication; Preoperative Care; Prospective Studies; Pyrroles; Risk Assessment; Simvastatin; Systemic Inflammatory Response Syndrome; Troponin T | 2006 |
The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin; Thiobarbituric Acid Reactive Substances | 2005 |
[Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on lipid peroxidation].
Topics: Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Coronary Artery Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Free Radical Scavengers; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Primary Prevention; Pyrroles; Treatment Outcome | 2005 |
[Erythrocyte fluidity in patients with hyperlipidemia during statins therapy].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Statistics, Nonparametric; Triglycerides | 2005 |
Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Biomarkers; Deoxyguanosine; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Oxidative Stress; Probucol; Pyrroles; Treatment Outcome | 2006 |
Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels.
Topics: Adult; Atorvastatin; Cardiomyopathy, Dilated; Cholesterol, LDL; Drug Therapy, Combination; Endpoint Determination; Evaluation Studies as Topic; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Myocardium; Pyrroles; Quality of Life; Treatment Outcome; Ventricular Function, Left | 2006 |
Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome | 2007 |
Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; CD40 Ligand; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Resistin; Substance Withdrawal Syndrome; Triglycerides | 2006 |
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia].
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atorvastatin; Female; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles | 2006 |
Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2006 |
Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
Topics: Adult; Apolipoproteins; Atorvastatin; Body Mass Index; Creatinine; Cross-Over Studies; Drug Therapy, Combination; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunosuppressive Agents; Kidney Transplantation; Lipids; Male; Middle Aged; Pyrroles; Tacrolimus; Triglycerides | 2006 |
Plasma-soluble CD40 is related to cholesterol metabolism in patients with moderate hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; CD40 Antigens; Cholesterol; Cholesterol, Dietary; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Severity of Illness Index; Simvastatin; Solubility | 2006 |
Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fatty Alcohols; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia.
Topics: Aged; Alkaline Phosphatase; Anticholesteremic Agents; Atorvastatin; Biomarkers; Bone Remodeling; Collagen Type I; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Peptides; Pyrroles; Time Factors | 2007 |
Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Matched-Pair Analysis; Pyrroles | 2006 |
Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2007 |
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, HDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2007 |
Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin.
Topics: Adult; Aged; Atorvastatin; DNA, Mitochondrial; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Mitochondria, Muscle; Pyrroles; Retrospective Studies; Simvastatin; Ubiquinone | 2007 |
Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Brachial Artery; C-Reactive Protein; Coronary Disease; Double-Blind Method; E-Selectin; Endothelium, Vascular; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pyrroles; Vasodilation | 2007 |
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Topics: Atorvastatin; Azetidines; Blood Chemical Analysis; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2007 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; PPAR alpha; Propionates; Pyrroles; Triazoles | 2007 |
Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin.
Topics: Atorvastatin; Autoantibodies; Blood Platelets; Case-Control Studies; CD40 Ligand; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Male; Middle Aged; NADPH Oxidases; Oxidative Stress; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Superoxides; Up-Regulation | 2007 |
Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Time Factors; Vasodilation | 2008 |
Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2007 |
Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia.
Topics: Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hypercholesterolemia; Insulin-Secreting Cells; Japan; Patient Compliance; Pravastatin; Pyrroles | 2007 |
Leukocyte and endothelial adhesion molecules in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cell Adhesion Molecules; E-Selectin; Endothelial Cells; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Integrins; Intercellular Adhesion Molecule-1; L-Selectin; Leukocytes; Male; Matched-Pair Analysis; Middle Aged; Pyrroles; Reference Values; Statistics, Nonparametric; von Willebrand Factor | 2008 |
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoprotein A-I; Asian People; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2007 |
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Topics: Adult; Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Models, Economic; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
[The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double-blind, multi-center clinical trial].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Asian People; Atorvastatin; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2007 |
Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects.
Topics: Adult; Atorvastatin; Brachial Artery; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Oxidative Stress; Pyrroles; Salmonella typhi; Salmonella Vaccines; Systemic Inflammatory Response Syndrome; Vascular Diseases; Vasodilation | 2007 |
Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Function Tests; Male; Middle Aged; Muscles; Myoglobin; Pyrroles; Ubiquinone; Vitamins | 2007 |
Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Female; Heptanoic Acids; Herb-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypericum; Intestinal Mucosa; Intestines; Liver; Male; Middle Aged; Plant Preparations; Pyrroles; Time Factors; Treatment Outcome; Triglycerides; Up-Regulation | 2007 |
Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
Topics: Absorptiometry, Photon; Adult; Aged; Atorvastatin; Biomarkers; Bone and Bones; Bone Density; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Middle Aged; Postmenopause; Pyrroles; Spine | 2007 |
Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Psyllium; Pyrroles; Treatment Outcome | 2007 |
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins.
Topics: Anticholesteremic Agents; Arginine; Atherosclerosis; Atorvastatin; Cross-Sectional Studies; Dinoprost; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2007 |
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multivariate Analysis; Pyrroles; Risk | 2007 |
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Collagen; Coronary Disease; Diabetes Complications; Drug Resistance; Epinephrine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyrroles; Smoking | 2009 |
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; England; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North Carolina; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation.
Topics: Adult; Aged; Atorvastatin; Cell Line; Cell Proliferation; Cholesterol; Cross-Over Studies; Double-Blind Method; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocytes, Smooth Muscle; Pyrroles; Serum; Simvastatin | 2007 |
Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins; Male; Middle Aged; Pyrroles; Renal Dialysis; Serum Albumin | 2008 |
Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Ultrasonography, Interventional | 2007 |
Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol, LDL; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Isoprostanes; Male; Middle Aged; NADPH Oxidases; Oxidative Stress; Pyrroles; Superoxides; Vitamin E | 2008 |
Efficacy of atorvastatin when not administered daily.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Pyrroles; Quinolines; Triglycerides | 2007 |
Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; Polymorphism, Genetic; Pyrroles; Scavenger Receptors, Class E | 2008 |
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2008 |
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Epidemiologic Methods; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke | 2008 |
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
Topics: Anticholesteremic Agents; Asia; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2007 |
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke | 2008 |
Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Regional Blood Flow; Time Factors; Treatment Outcome | 2008 |
Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Stenosis; Cholesterol; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-18; Interleukin-6; Male; Middle Aged; Pravastatin; Probability; Prospective Studies; Pyrroles; Simvastatin; Triglycerides; Tunica Intima; Ultrasonography | 2008 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Uric Acid; Ventricular Remodeling | 2008 |
Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Topics: Adipokines; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Cross-Over Studies; Female; Glucose Intolerance; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Pravastatin; Pyrroles | 2008 |
Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Outcome Assessment, Health Care; Pyrroles; Sex Factors | 2008 |
Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
Topics: Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Disease; European Union; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2008 |
The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Systole; Time Factors; Treatment Outcome | 2008 |
Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis preventi
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Body Mass Index; Body Weight; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrroles; Quinolines; Waist Circumference | 2008 |
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Middle Aged; Pyrroles | 1995 |
Atorvastatin--a new lipid-lowering drug.
Topics: Anti-Bacterial Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Ketoconazole; Pyrroles | 1997 |
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Double-Blind Method; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides | 1997 |
Efficacy of atorvastatin in primary hypercholesterolemia. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group.
Topics: Aged; Apolipoproteins; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides | 1997 |
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrroles; Treatment Outcome | 1997 |
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Arthralgia; Atorvastatin; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperhidrosis; Hyperlipidemias; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pyrroles; Simvastatin; Triglycerides | 1997 |
Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Topics: Adolescent; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles | 1997 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Arthralgia; Atorvastatin; Brachial Artery; Cholestyramine Resin; Drug Therapy, Combination; Endothelium, Vascular; Exanthema; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Ultrasonography | 1998 |
Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Rationale and design of the Myocardial Ischemia Reduction With Aggressive Cholesterol lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Research Design | 1998 |
Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Pyrroles; Simvastatin; Treatment Outcome | 1999 |
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Policy; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin; United States | 1998 |
[Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Indoles; Pyrroles | 1999 |
[AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 1999 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Quality of Life; Risk; Treatment Outcome | 1999 |
Effect of atorvastatin of the treatment of hypercholesterolemia after renal transplantation.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Pyrroles; Time Factors; Triglycerides | 1999 |
Lowering effects of four different statins on serum triglyceride level.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1999 |
A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 1999 |
Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Blood Proteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Induction; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidation-Reduction; Pyrroles; Treatment Outcome; Triglycerides; Tyrosine; Vasodilation | 1999 |
An assessment of the efficacy of atorvastatin in achieving LDL cholesterol target levels in patients with coronary heart disease: a general practice study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Family Practice; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Patient Compliance; Pyrroles; Treatment Outcome | 1999 |
Dosing of atorvastatin and increases in fibrinogen level.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Reference Values; Treatment Outcome | 1999 |
Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Single-Blind Method | 2000 |
Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Linear Models; Logistic Models; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2000 |
Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 1999 |
The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Pressure; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Elasticity; Family Health; Female; Femoral Artery; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides; Tunica Intima | 2000 |
Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Margarine; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Sitosterols; Treatment Outcome; Triglycerides | 2000 |
Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients.
Topics: Acetylcholine; Adult; Anticholesteremic Agents; Antioxidants; Ascorbic Acid; Atorvastatin; Blood Flow Velocity; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Infusions, Intra-Arterial; Male; Middle Aged; Nitroprusside; omega-N-Methylarginine; Plethysmography; Pyrroles; Vasodilation; Vasodilator Agents | 2000 |
Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Statistics, Nonparametric | 2000 |
Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Middle Aged; Postmenopause; Pyrroles; Vasodilation | 2000 |
Associations between change in C-reactive protein and serum lipids during statin treatment.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors | 2000 |
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome | 2001 |
[Cost-effectiveness of atorvastatin against simvastatin as hypolipemic treatment in hypercholesterolemic patients in primary care].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Triglycerides | 2001 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Drug Monitoring; Fasting; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type V; Lipids; Lipoprotein(a); Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome | 2001 |
Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost Control; Drug Costs; Europe; Heptanoic Acids; Humans; Hypercholesterolemia; Peripheral Vascular Diseases; Pyrroles; Simvastatin | 2001 |
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Postmenopause; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Reproducibility of Results; Safety; Tomography, X-Ray Computed | 2001 |
The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2001 |
Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholest
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Canada; Cardiovascular Diseases; Cholesterol, LDL; Female; Health Education; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Factors; Women's Health | 2001 |
Effects of statins on biomarkers of bone metabolism: a randomised trial.
Topics: Adult; Aged; Alkaline Phosphatase; Anticholesteremic Agents; Atorvastatin; Biomarkers; Bone and Bones; Bone Development; Bone Resorption; Collagen; Collagen Type I; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Peptides; Pyrroles; Simvastatin | 2001 |
Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2001 |
The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Serine Proteinase Inhibitors; Simvastatin | 2001 |
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; United States | 2001 |
Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.
Topics: Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Double-Blind Method; Female; Genotype; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Pyrroles; Sex Factors | 2001 |
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Reference Values; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2001 |
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyridines; Pyrroles; Treatment Outcome; Triglycerides; United States | 2001 |
A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2001 |
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.
Topics: Adult; Aged; Allylamine; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Colesevelam Hydrochloride; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides | 2001 |
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Canada; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States | 2002 |
A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides | 2001 |
Effects of simvastatin and atorvastatin on inflammation markers in plasma.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Pyrroles; Simvastatin | 2002 |
Lipid-lowering effect of atorvastatin in heart transplantation.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Heart Transplantation; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Postoperative Complications; Pyrroles; Time Factors | 2002 |
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin; Thrombin; Treatment Outcome | 2001 |
Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2002 |
416 other study(ies) available for atorvastatin and Elevated Cholesterol
| Article | Year |
|---|---|
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
Topics: Animals; Cholesterol, LDL; Cricetinae; Guinea Pigs; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Liver; Male; Mesocricetus; Muscle Cells; Pyrazoles; Rats; Stereoisomerism; Structure-Activity Relationship | 2008 |
A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Monitoring; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medication Adherence; Middle Aged; Monte Carlo Method | 2021 |
MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy.
Topics: Atorvastatin; Down-Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; MicroRNAs | 2022 |
Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Perindopril | 2022 |
Physicians and pharmacists' clinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice.
Topics: Atorvastatin; Cholesterol; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pharmacists | 2023 |
Investigation of the effects of atorvastatin and Lactobacillus acidophilus on some hormones and oxidative stress in experimental hypercholesterolemia.
Topics: Animals; Antioxidants; Atorvastatin; Cholesterol; Ghrelin; Hypercholesterolemia; Insulins; Lactobacillus acidophilus; Leptin; Oxidative Stress; Probiotics; Rats; Serotonin | 2023 |
Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis.
Topics: Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cholesterol; Female; Fibrinogen; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors; Thyroiditis, Autoimmune; Uric Acid | 2023 |
Fatal hepatic failure following atorvastatin treatment: A case report.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Failure; Male; Middle Aged | 2023 |
Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cells, Cultured; Cytochrome P-450 CYP3A; Diabetes Mellitus, Experimental; Diet, High-Fat; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Mucosa; Male; Microsomes, Liver; Models, Biological; Primary Cell Culture; Rats; Solute Carrier Organic Anion Transporter Family Member 1B3; Streptozocin | 2019 |
Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hyperprolactinemia; Incidence; Insulin Resistance; Middle Aged; Poland; Prolactin; Risk Factors | 2019 |
Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway.
Topics: Apoptosis; Atorvastatin; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mitochondria; NF-E2-Related Factor 2 | 2019 |
Probiotic strains improve high-fat diet-induced hypercholesterolemia through modulating gut microbiota in ways different from atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bacteria; Cricetinae; Cytokines; Diet, High-Fat; Dysbiosis; Feces; Gastrointestinal Microbiome; Glucose; Hypercholesterolemia; Lactobacillus plantarum; Male; Mesocricetus; Pediococcus; Pediococcus acidilactici; Pediococcus pentosaceus; Probiotics; Weight Gain | 2019 |
Impaired Endothelium-Dependent Hyperpolarization Underlies Endothelial Dysfunction during Early Metabolic Challenge: Increased ROS Generation and Possible Interference with NO Function.
Topics: Animals; Atorvastatin; Endothelium, Vascular; Energy Intake; Gap Junctions; Hypercholesterolemia; Hyperinsulinism; Male; Nitric Oxide; Potassium Channels, Inwardly Rectifying; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Vasodilation | 2019 |
Peripheral polyneuropathy in patients receiving long-term statin therapy.
Topics: Atorvastatin; Case-Control Studies; Drug Administration Schedule; Electromyography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Male; Middle Aged; Peripheral Nervous System Diseases; Risk Factors; Rosuvastatin Calcium; Turkey | 2019 |
Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Female; Humans; Hypercholesterolemia; Japan; Liver-Specific Organic Anion Transporter 1; Male; Neoplasm Proteins; Pharmacogenetics; Polymorphism, Single Nucleotide | 2019 |
LOX-1, the Common Therapeutic Target in Hypercholesterolemia: A New Perspective of Antiatherosclerotic Action of Aegeline.
Topics: Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cell Line; Diet, High-Fat; Disease Models, Animal; Humans; Hypercholesterolemia; Lipoproteins, LDL; Macrophages; Male; Mice; Molecular Targeted Therapy; Rats; Rats, Wistar; Scavenger Receptors, Class E | 2019 |
Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene.
Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Mutation | 2020 |
[Atorvastatin-induced anemia accompanied by elevated serum LDH levels].
Topics: Aged; Anemia; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin | 2020 |
Evaluation of Orally Administered Atorvastatin on Plasma Lipid and Biochemistry Profiles in Hypercholesterolemic Hispaniolan Amazon Parrots (
Topics: Administration, Oral; Amazona; Animals; Atorvastatin; Bird Diseases; Cholesterol; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male | 2020 |
Immune Modulatory Effects of Hypercholesterolemia: Can Atorvastatin Convert the Detrimental Effect of Hypercholesterolemia on the Immune System?
Topics: Adult; Antigens, CD; Atorvastatin; Cholesterol; Cytokines; Female; Humans; Hypercholesterolemia; Immunologic Factors; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Middle Aged; Th1 Cells; Th2 Cells | 2019 |
Synergistic effects of pomegranate juice and atorvastatin for improving cerebellar structure and function of breast-feeding rats maternally fed on a high cholesterol diet.
Topics: Animals; Atorvastatin; Caspase 3; Cerebellum; Cholesterol; Diet, High-Fat; Drug Synergism; Female; Fruit and Vegetable Juices; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lactation; Oxidative Stress; Pomegranate; Pregnancy; Rats; Rats, Wistar | 2020 |
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
Homozygous autosomal recessive hypercholesterolaemia in a South Asian child presenting with multiple cutaneous xanthomata.
Topics: Adaptor Proteins, Signal Transducing; Asia, Southeastern; Atorvastatin; Child; Cholesterol, LDL; Elbow; Female; Frameshift Mutation; Genetic Testing; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type III; Knee; Receptors, LDL; Skin; Treatment Outcome; Xanthomatosis | 2021 |
The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats.
Topics: Animals; Atherosclerosis; Atorvastatin; Hypercholesterolemia; Hyperlipidemias; Inflammation; Melatonin; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Rats | 2023 |
Top product forecasts for 2021.
Topics: Anticholesteremic Agents; Atorvastatin; Forecasting; Humans; Hypercholesterolemia | 2021 |
The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Hypercholesterolemia; Hyperlipidemias; Inflammation; Male; Metabolic Syndrome; Oxidative Stress; Rats; Silymarin; Triglycerides | 2021 |
Lipid-lowering therapies: Better together.
Topics: Atorvastatin; Dicarboxylic Acids; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia | 2021 |
New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins.
Topics: Aged; Asian People; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Registries; Republic of Korea; Rosuvastatin Calcium; Secondary Prevention; Treatment Outcome | 2021 |
Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Differentiation; Cell Line, Tumor; Down-Regulation; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Liver; MicroRNAs; RNA, Messenger; Simvastatin; Up-Regulation | 2021 |
Grape seed extract improved the fertility-enhancing effect of atorvastatin in high-fat diet-induced testicular injury in rats: involvement of antioxidant and anti-apoptotic effects.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apoptosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Grape Seed Extract; Hypercholesterolemia; Infertility, Male; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Testis | 2021 |
The impact of hypotestosteronemia on cardiometabolic effects of atorvastatin in men with hypercholesterolemia: a pilot study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pilot Projects; Risk Factors; Testosterone | 2021 |
Atorvastatin reverses high cholesterol-induced cardiac remodelling and regulates mitochondrial quality-control in a cholesterol-independent manner: An experimental study.
Topics: Animals; Atorvastatin; Diet, High-Fat; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Mice; Mice, Inbred C57BL; Ventricular Remodeling | 2021 |
Studying the Effect of Taking Statins before Infection in the Severity Reduction of COVID-19 with Machine Learning.
Topics: Aged; Algorithms; Atorvastatin; COVID-19; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iran; Machine Learning; Male; Middle Aged; Retrospective Studies; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin | 2021 |
Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Rosuvastatin Calcium; Simvastatin | 2017 |
How has the treatment of hypercholesterolemia in Poland changed over the last six years?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Incidence; Lipoproteins, LDL; Male; Middle Aged; Patient Compliance; Poland; Registries; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Surveys and Questionnaires; Time Factors | 2017 |
10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Drug Utilization; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; National Health Programs; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Taiwan | 2017 |
Generic atorvastatin is as effective as the brand-name drug (LIPITOR
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Drugs, Generic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Triglycerides | 2017 |
Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Cohort Studies; Computer Simulation; Databases, Factual; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monte Carlo Method; Patient Care Planning; PCSK9 Inhibitors | 2017 |
Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cholesterol, LDL; Female; Gene Frequency; Genotype; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Triglycerides | 2018 |
Complete resolution of extensive xanthomas associated with primary sclerosing cholangitis following liver transplantation.
Topics: Atorvastatin; Cholangitis, Sclerosing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Transplantation; Male; Treatment Outcome; Xanthomatosis; Young Adult | 2017 |
Efficacy of functional foods mixture in improving hypercholesterolemia, inflammatory and endothelial dysfunction biomarkers-induced by high cholesterol diet.
Topics: Animals; Atorvastatin; Cholesterol; Creatine Kinase; Diet, High-Fat; Dietary Fats; Drug Administration Schedule; Functional Food; Homocysteine; Hypercholesterolemia; L-Lactate Dehydrogenase; Male; Nitric Oxide Synthase Type III; Rats; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2017 |
Anti-atherosclerotic effect of Longxuetongluo Capsule in high cholesterol diet induced atherosclerosis model rats.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Hypercholesterolemia; Inflammation; Lipid Metabolism; Lipids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Plaque, Atherosclerotic; Rats; Rats, Sprague-Dawley | 2018 |
Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
Topics: Adipose Tissue; Adipose Tissue, Brown; Animals; Atherosclerosis; Atorvastatin; Calorimetry, Indirect; Cholesterol Ester Transfer Proteins; Female; Gene Expression Profiling; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lipids; Lipoproteins; Liver; Mice; Mice, Knockout, ApoE; Proprotein Convertase 9; Receptors, Adrenergic, beta-3; Triglycerides | 2017 |
Gender-Specific Association Between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Chile; Cholesterol; Down-Regulation; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Sex Factors; Time Factors; Treatment Outcome; Triglycerides | 2018 |
LDL cholesterol levels after switch from atorvastatin to rosuvastatin.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Monitoring; Drug Substitution; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; United States | 2018 |
Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bacteria; Diet, High-Fat; Disease Models, Animal; DNA, Bacterial; DNA, Ribosomal; Gastrointestinal Microbiome; Hypercholesterolemia; Male; Phylogeny; Rats; RNA, Ribosomal, 16S; Sequence Analysis, DNA | 2018 |
Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Line; Cholesterol; Diet, High-Fat; Dose-Response Relationship, Drug; Glucose; Glucose Transporter Type 4; Hypercholesterolemia; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal | 2018 |
Atorvastatin Treatment Modulates the Gut Microbiota of the Hypercholesterolemic Patients.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Bacteria; Cholesterol; Female; Gastrointestinal Microbiome; Humans; Hypercholesterolemia; Inflammation; Lipid Metabolism; Male; Middle Aged; RNA, Ribosomal, 16S; Young Adult | 2018 |
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Coronary Disease; Drug Therapy, Combination; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Maximum Tolerated Dose; Middle Aged; PCSK9 Inhibitors; Peripheral Arterial Disease; Risk; Rosuvastatin Calcium; Simvastatin; Stroke; Treatment Outcome | 2018 |
Statin use in Brazil: findings and implications.
Topics: Adult; Aged; Atorvastatin; Brazil; Cardiovascular Diseases; Cross-Sectional Studies; Drug Utilization Review; Female; Health Equity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medication Adherence; Middle Aged; Primary Health Care; Rosuvastatin Calcium; Simvastatin | 2018 |
What is the role of PCSK9 inhibitors in treating hypercholesterolemia?
Topics: Anticholesteremic Agents; Atorvastatin; Humans; Hypercholesterolemia; Male; Middle Aged; PCSK9 Inhibitors | 2018 |
All-trans retinoic acid effectively reduces atheroma plaque size in a rabbit model of high-fat-induced atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Diet, High-Fat; Hypercholesterolemia; Lipids; Plaque, Atherosclerotic; Rabbits; Random Allocation; Tretinoin; Tunica Intima | 2018 |
The effect of atorvastatin on sexual function and depressive symptoms in young women with elevated cholesterol levels - a pilot study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Depression; Female; Humans; Hypercholesterolemia; Pilot Projects; Sexual Dysfunction, Physiological; Surveys and Questionnaires | 2018 |
KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Cholesterol, LDL; DNA; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinesins; Male; Middle Aged; Mutation, Missense; Pharmacogenomic Testing; Prospective Studies; Rosuvastatin Calcium; Simvastatin | 2018 |
AIBP-mediated cholesterol efflux instructs hematopoietic stem and progenitor cell fate.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Base Sequence; Cholesterol; Chromatin Immunoprecipitation; Coronary Artery Disease; Gene Expression Regulation; Hematopoiesis; Hematopoietic Stem Cells; Hypercholesterolemia; Racemases and Epimerases; Receptors, Notch; Sterol Regulatory Element Binding Protein 2; Zebrafish; Zebrafish Proteins | 2019 |
Statins Can Lead to Acute Hemolysis.
Topics: Adult; Anemia, Hemolytic; Atorvastatin; Female; Hemolysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Rosuvastatin Calcium | 2018 |
Combined Effect of Diosgenin Along with Ezetimibe or Atorvastatin on the Fate of Labelled Bile Acid and Cholesterol in Hypercholesterolemic Rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol; Diosgenin; Ezetimibe; Hypercholesterolemia; Liver; Male; Rats; Rats, Wistar | 2019 |
The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study.
Topics: Adrenal Hyperplasia, Congenital; Adult; Androgens; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pilot Projects; Risk Factors; Testosterone; Uric Acid; Vitamin D | 2019 |
Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Benzoates; Benzylamines; Berberine; Cholesterol; Chromosomes, Human, Pair 11; Coronary Disease; Gene Expression Regulation; Genome-Wide Association Study; Hep G2 Cells; Hepatocyte Nuclear Factor 1-alpha; Hepatocytes; Histone Code; Histone Demethylases; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Proprotein Convertase 9; Protein Binding; Protein Interaction Mapping; RNA Interference; RNA, Long Noncoding; RNA, Small Interfering | 2019 |
Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Comorbidity; Drug Combinations; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Perindopril; Prospective Studies | 2019 |
Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Cell Count; Erythrocyte Indices; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocyte Count; Male; Middle Aged; Platelet Activation; Pyrroles | 2013 |
Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease-Serial angioscopic and intravascular ultrasound analysis.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Time Factors; Ultrasonography, Interventional | 2013 |
Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Cytochrome P-450 CYP3A; Drug Administration Schedule; Female; Gene Expression; Genetic Heterogeneity; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Male; Middle Aged; Phenotype; Pyrroles; RNA, Messenger | 2013 |
Standards of statin usage in Poland in high-risk patients: 3ST-POL study results.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cohort Studies; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Patient Compliance; Poland; Population Surveillance; Primary Health Care; Pyrroles; Simvastatin; Surveys and Questionnaires; Treatment Failure | 2013 |
Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein E3; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, Dietary; Disease Models, Animal; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Mice, Transgenic; Osteoarthritis; Pyrroles | 2014 |
Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol, HDL; Cholesterol, LDL; Egypt; Female; Genetic Variation; Heptanoic Acids; Humans; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Genetic; Pyrroles; Risk Factors; Sex Characteristics; Triglycerides | 2013 |
Mean platelet volume measurement in patients with hypercholesterolemia: a methodological issue.
Topics: Anticholesteremic Agents; Atorvastatin; Erythrocyte Indices; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles | 2013 |
Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cells, Cultured; Endothelial Cells; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Reactive Oxygen Species; Scavenger Receptors, Class E | 2013 |
Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; CD40 Antigens; CD40 Ligand; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; P-Selectin; Plaque, Atherosclerotic; Platelet Activation; Platelet Factor 4; Pyrroles; Rats; Rats, Wistar | 2013 |
Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Muscular Diseases; Observation; Prospective Studies; Pyrroles; Surveys and Questionnaires | 2013 |
Long-term use of statins reduces the risk of hospitalization for dementia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Case-Control Studies; Dementia; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Italy; Logistic Models; Male; Middle Aged; Pravastatin; Pyrroles; Risk; Simvastatin; Time Factors | 2013 |
[A multi-device approach to an unusual case of left main thrombosis: when manual thrombectomy is not enough].
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Atorvastatin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Embolic Protection Devices; Embolism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoglobulin Fab Fragments; Infusions, Intra-Arterial; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Suction; Thrombectomy; Tomography, Optical Coherence | 2013 |
The effect of rosuvastatin and atorvastatin on erectile dysfunction in hypercholesterolaemic patients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Erectile Dysfunction; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Rosuvastatin Calcium | 2014 |
Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Apolipoproteins B; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemias; Lipoproteins, LDL; Male; Middle Aged; Pilot Projects; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2014 |
Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cell Adhesion; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Endothelial Cells; Heptanoic Acids; Hypercholesterolemia; Macrophages; Male; Monocytes; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Triglycerides; Tunica Intima | 2013 |
Statins decrease mean platelet volume irrespective of cholesterol lowering effect.
Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Female; Gene Frequency; Genetic Association Studies; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2014 |
Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet.
Topics: Animals; Atorvastatin; Cell Respiration; Cholesterol, Dietary; Cholesterol, HDL; Diet, High-Fat; Dietary Supplements; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Mitochondria, Liver; Pyrroles; Rats; Rats, Wistar; Triglycerides; Ubiquinone | 2014 |
Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.
Topics: Administration, Oral; Atenolol; Atorvastatin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Solubility | 2014 |
Influence of SREBP-2 and SCAP gene polymorphisms on lipid-lowering response to atorvastatin in a cohort of Chilean subjects with Amerindian background.
Topics: Atorvastatin; Cholesterol, LDL; Female; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Sterol Regulatory Element Binding Protein 2 | 2014 |
Characterization of the pharmaceutical effect of drugs on atherosclerotic lesions in vivo using integrated fluorescence imaging and Raman spectral measurements.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Blood Vessels; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Lipid Metabolism; Lipids; Microscopy, Confocal; Pyrroles; Spectrum Analysis, Raman; Zebrafish | 2014 |
No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Topics: Adult; Aged; Alleles; Atorvastatin; Cholesterol, LDL; Drug Administration Schedule; Female; Gene Frequency; Gene-Environment Interaction; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2014 |
Summaries for patients. Treatment trials to determine whether statins are the cause of a patient's discomfort.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Sulfonamides | 2014 |
Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Azetidines; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles | 2014 |
The Carotid intima-media thickness modification following atorvastatin is bound to the modification of the oxidative balance.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Cholesterol; Heptanoic Acids; Humans; Hypercholesterolemia; Italy; Male; Middle Aged; Oxidative Stress; Pyrroles; Registries; Treatment Outcome | 2014 |
[Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Databases, Factual; Drug Prescriptions; Drug Therapy, Combination; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Health; Male; Middle Aged; Patient Compliance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2014 |
Overview on pharmacological and nutraceutical strategies for treatment of borderline dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Dietary Supplements; Fatty Acids; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Male; Pyrroles; Risk Factors; Treatment Outcome | 2014 |
Evaluation of statin therapy on endothelial function in hypercholesterolemic rabbits by automatic measurement of arterial wall movement using ultrasound images.
Topics: Algorithms; Animals; Atorvastatin; Blood Flow Velocity; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Image Processing, Computer-Assisted; Male; Pyrroles; Rabbits; Ultrasonography, Doppler; Vasodilator Agents | 2014 |
Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Drug Evaluation, Preclinical; Heptanoic Acids; Hypercholesterolemia; Male; Metformin; Nitric Oxide; Pyrroles; Rats, Sprague-Dawley; rho-Associated Kinases | 2014 |
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comorbidity; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Drug Substitution; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Lipoproteins, LDL; Medicare; Models, Cardiovascular; Nuclear Magnetic Resonance, Biomolecular; Pyrroles; Quality-Adjusted Life Years; Risk; Risk Reduction Behavior; Simvastatin; Treatment Outcome; United States | 2014 |
Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cilostazol; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Immunohistochemistry; Lipids; Probucol; Pyrroles; Rabbits; Tetrazoles | 2014 |
Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brazil; Cholesterol; Creatine Kinase; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myalgia; Prospective Studies; Pyrroles; Sex Factors; Simvastatin | 2014 |
Disruption of ldlr causes increased LDL-c and vascular lipid accumulation in a zebrafish model of hypercholesterolemia.
Topics: Animals; Atorvastatin; Base Sequence; Blood Vessels; Cholesterol, LDL; Disease Models, Animal; Embryo, Nonmammalian; Gene Expression Regulation; Gene Knockdown Techniques; Hepatomegaly; Heptanoic Acids; Hypercholesterolemia; Liver; Molecular Sequence Data; Morpholinos; Oxidation-Reduction; Pyrroles; Receptors, LDL; Veins; Zebrafish | 2014 |
No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
Topics: Atorvastatin; Cholesterol; Cholesterol, LDL; Cohort Studies; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Gene Frequency; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Introns; Male; Middle Aged; Polymorphism, Genetic; Simvastatin; Treatment Outcome | 2015 |
Upregulated expression of human alpha-defensins 1, 2 and 3 in hypercholesteremia and its relationship with serum lipid levels.
Topics: Aged; alpha-Defensins; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Cholesterol, LDL; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Neutrophils; Pyrroles | 2014 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Giant cell arteritis and polymyalgia rheumatica after reexposure to a statin: a case report.
Topics: Aged; Atorvastatin; Female; Fluorobenzenes; Giant Cell Arteritis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Polymyalgia Rheumatica; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
The effect of atorvastatin and atorvastatin-ezetimibe combination therapy on androgen production in hyperandrogenic women with elevated cholesterol levels.
Topics: Adult; Androgens; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperandrogenism; Hypercholesterolemia; Middle Aged; Pyrroles; Sex Hormone-Binding Globulin; Treatment Outcome; Young Adult | 2015 |
High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Statistics, Nonparametric | 2015 |
Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease?
Topics: Atorvastatin; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Male; Myocardial Infarction; Pravastatin | 2015 |
Atorvastatin in the management of tinnitus with hyperlipidemias.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Hearing Loss, Noise-Induced; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Surveys and Questionnaires; Tinnitus | 2014 |
[Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2014 |
Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drugs, Generic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; United Kingdom | 2015 |
Different effects of atorvastatin on metabolic and cardiovascular risk factors in hypercholesterolemic women with normal thyroid function and subclinical hypothyroidism.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Comorbidity; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypothyroidism; Middle Aged; Risk Factors; Treatment Outcome | 2015 |
Acute anti-fibrillating and defibrillating potential of atorvastatin, melatonin, eicosapentaenoic acid and docosahexaenoic acid demonstrated in isolated heart model.
Topics: Animals; Anti-Arrhythmia Agents; Atorvastatin; Cardiac Pacing, Artificial; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Guinea Pigs; Heart Rate; Hypercholesterolemia; Isolated Heart Preparation; Male; Melatonin; Rats; Time Factors; Ventricular Fibrillation | 2015 |
[Fasciculations, cramps, and statins].
Topics: Atorvastatin; Drug Substitution; Electromyography; Fasciculation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leg; Middle Aged; Muscle Cramp; Phytosterols; Quinolines; Rosuvastatin Calcium; Toes | 2015 |
APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects.
Topics: Apolipoproteins E; Atorvastatin; Chile; DNA, Mitochondrial; Female; Haplotypes; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, LDL | 2015 |
High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cytokines; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lebanon; Male; Middle Aged; Peptidyl-Dipeptidase A; Plasminogen Activator Inhibitor 1; Polymorphism, Single Nucleotide; Ramipril; Treatment Outcome; Young Adult | 2015 |
Identifying Vulnerable Atherosclerotic Plaque in Rabbits Using DMSA-USPIO Enhanced Magnetic Resonance Imaging to Investigate the Effect of Atorvastatin.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Atherosclerosis; Atorvastatin; CD40 Ligand; Cholesterol; Contrast Media; Dextrans; Diet, High-Fat; Disease Models, Animal; Gene Expression; Hypercholesterolemia; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Matrix Metalloproteinase 9; Plaque, Atherosclerotic; Rabbits; Succimer; Transgenes; Tumor Suppressor Protein p53 | 2015 |
Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia.
Topics: Animals; Apolipoprotein A-I; Aryldialkylphosphatase; Atorvastatin; Blood Glucose; Cholesterol, HDL; Drug Synergism; Fenofibrate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Kinetics; Lipids; Male; Rabbits | 2015 |
Atorvastatin Attenuates Bone Loss and Aortic Valve Atheroma in LDLR Mice.
Topics: Animals; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Calcinosis; Cholesterol, Dietary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Macrophages; Mice; Osteogenesis; Osteoporosis; Plaque, Atherosclerotic; X-Ray Microtomography | 2015 |
The Arginine/ADMA Ratio Is Related to the Prevention of Atherosclerotic Plaques in Hypercholesterolemic Rabbits When Giving a Combined Therapy with Atorvastatine and Arginine.
Topics: Animals; Anticholesteremic Agents; Arginine; Atorvastatin; Cholesterol; Dietary Supplements; Hypercholesterolemia; Nitric Oxide; Nitric Oxide Synthase; Plaque, Atherosclerotic; Rabbits | 2015 |
Atorvastatin delays the glucose clearance rate in hypercholesterolemic rabbits.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Atorvastatin; Blood Glucose; Diet; Feeding Behavior; Glucose; Glucose Tolerance Test; Hypercholesterolemia; Insulin; Lipids; Male; Organ Size; Rabbits | 2015 |
The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics.
Topics: Adult; Anticholesteremic Agents; Arginine; Atorvastatin; Drug Monitoring; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins, HDL; Male; Malondialdehyde; Middle Aged; Nitric Oxide; Oxidative Stress; Pyrroles; Treatment Outcome | 2015 |
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hypercholesterolemia; Inflammation; Lipids; Male; Oxidation-Reduction; Oxidative Stress; Probucol; Rabbits; Tetrazoles | 2015 |
Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Patterns, Physicians'; Pravastatin; Qatar | 2015 |
ESR1 polymorphisms and statin therapy: a sex-specific approach.
Topics: Aged; Atorvastatin; Biomarkers; Brazil; Estrogen Receptor alpha; Female; Gene Frequency; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linkage Disequilibrium; Lipids; Male; Middle Aged; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Prospective Studies; Sex Factors; Simvastatin; Treatment Outcome | 2016 |
SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
Topics: Aged; Atorvastatin; Chile; Cholesterol, HDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Public Health Surveillance; Treatment Outcome | 2015 |
HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals.
Topics: Anticholesteremic Agents; Atorvastatin; Chile; Cholesterol, LDL; Female; Genome-Wide Association Study; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Proprotein Convertase 9; Treatment Outcome | 2016 |
Ameliorative effect of statin therapy on oxidative damage in heart tissue of hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aryldialkylphosphatase; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diet; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Malondialdehyde; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Rabbits; Superoxide Dismutase | 2015 |
Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS).
Topics: Adult; Aged; Atorvastatin; Blood Glucose; Cholesterol, LDL; Cross-Sectional Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Internationality; Lipids; Male; Middle Aged; Prospective Studies; Regression Analysis; Risk; Risk Factors; Rosuvastatin Calcium; Simvastatin | 2016 |
Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture.
Topics: Animal Feed; Animals; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cholesterol; Disease Models, Animal; Female; Fibrillin-1; Hypercholesterolemia; Kaplan-Meier Estimate; Mice, Knockout; Plaque, Atherosclerotic; Survival Analysis | 2016 |
A Translational Model for Diet-related Atherosclerosis: Effect of Statins on Hypercholesterolemia and Atherosclerosis in a Minipig.
Topics: Animals; Animals, Genetically Modified; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Femoral Artery; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Receptors, LDL; Swine; Swine, Miniature; Translational Research, Biomedical | 2016 |
Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.
Topics: Aged; Alleles; Atorvastatin; Cholesterol, LDL; Female; Genetic Variation; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; India; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome | 2016 |
[One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Linear Models; Male; Medication Adherence; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2016 |
[FIXED COMBINATION ATORVASTATIN-EZETIMIBE (ATOZET®)].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors | 2016 |
Effects of atorvastatin and artichoke leaf tincture on oxidative stress in hypercholesterolemic rats.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Atorvastatin; Cynara scolymus; Disease Models, Animal; Drug Monitoring; Drug Synergism; Herb-Drug Interactions; Hypercholesterolemia; Oxidative Stress; Phytotherapy; Plant Extracts; Plant Leaves; Rats; Treatment Outcome | 2016 |
Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Case-Control Studies; Disease Management; Drug Administration Schedule; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles | 2016 |
Nonenzymatic Mechanism of Statins in Modulating Cholesterol Particles Formation.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Lovastatin; Pilot Projects; Prodrugs; Simvastatin | 2016 |
Protective effects of mitochondria-targeted antioxidants and statins on cholesterol-induced osteoarthritis.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoproteins E; Atorvastatin; Bone Remodeling; Cholesterol; Chondrocytes; Dietary Fats; Hypercholesterolemia; Male; Mice; Mice, Knockout; Mitochondria; Osteoarthritis; Rats; Rats, Wistar | 2017 |
Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered SHR.Cg-Lepr
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Dietary Fats; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Food-Drug Interactions; Gene Expression Regulation; Hypercholesterolemia; Male; Metabolic Syndrome; Rats; Rats, Inbred Strains | 2017 |
[Pleotropic Effects of Atorvastatin in Patients With Chronic Ischemic Heart Disease].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Myocardial Ischemia; Pyrroles | 2016 |
Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Echocardiography; Heptanoic Acids; Hypercholesterolemia; Losartan; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cognition; Diagnostic Techniques, Neurological; Female; Heptanoic Acids; Hippocampus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pilot Projects; Psychological Tests; Psychophysiology; Pyrroles; Risk Factors | 2008 |
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Impotence, Vasculogenic; Male; Middle Aged; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Pyrroles; Sildenafil Citrate; Sulfones; Ultrasonography, Doppler, Duplex | 2008 |
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; British Columbia; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2008 |
Ptosis, diplopia and statins: an association?
Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus | 2008 |
CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
Topics: Aged; Alleles; Atorvastatin; Black People; Body Mass Index; Brazil; Cholesterol, LDL; Cytochrome P-450 CYP3A; DNA; DNA Primers; Female; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Stenosis; Cerebral Hemorrhage; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Treatment Outcome | 2008 |
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Glucose Intolerance; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Retrospective Studies | 2008 |
Statin therapy works for patients who have type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2008 |
Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study.
Topics: Achilles Tendon; Adult; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk; Ultrasonography; Xanthomatosis | 2009 |
Coronary plaque stabilization followed by Color Code Plaque analysis with 64-slice multidetector row computed tomography.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Stenosis; Coronary Vasospasm; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Tomography, X-Ray Computed; Ultrasonography | 2009 |
On call. I am pretty healthy for a 73-year-old, but my cholesterol is 280, and my doctor wants me to take Lipitor. I'm willing to do so, but I need to know what tests I should have to be sure I'm not getting side effects. What do you suggest?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Liver; Male; Pyrroles | 2008 |
[High dosage stain protects heart and brain from recurrence].
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention | 2008 |
Short-term effects of atorvastatin on hemorheologic parameters and endothelial dysfunction in patients with hypercholesterolemia. Lower is better?
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cohort Studies; Dose-Response Relationship, Drug; Endothelium, Vascular; Erythrocyte Deformability; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Platelet Aggregation; Pyrroles; von Willebrand Factor | 2008 |
Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Hypercholesterolemia; Macaca fascicularis; Male; Organophosphonates; Phenols; Prodrugs; Pyrroles; Rabbits; Thyroid Hormone Receptors beta | 2009 |
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.
Topics: Animals; Atorvastatin; Azetidines; Brain; Capillary Permeability; Diet; Disease Models, Animal; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Maze Learning; Mice; Mice, Transgenic; Neurofibrillary Tangles; Pyrroles; Simvastatin; Spinal Cord; Tauopathies | 2009 |
Effect of very low LDL-cholesterol on cortisol synthesis.
Topics: Adrenocorticotropic Hormone; Adult; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Dose-Response Relationship, Drug; Endocrine System Diseases; Female; Heptanoic Acids; Humans; Hydrocortisone; Hypercholesterolemia; Male; Middle Aged; Pituitary-Adrenal Function Tests; Pyrroles | 2008 |
Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia.
Topics: Atorvastatin; C-Reactive Protein; Chemokine CCL2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pyrroles | 2009 |
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
Topics: Age Factors; Aged; Atorvastatin; Causality; Cerebral Hemorrhage; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Iatrogenic Disease; Intracranial Arteriosclerosis; Male; Pyrroles; Sex Factors | 2009 |
Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
Topics: Animals; Atherosclerosis; Atorvastatin; Capillary Permeability; Cattle; Cells, Cultured; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Farnesol; Female; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Protein Kinase C; Protein Kinase Inhibitors; Protein-Lysine 6-Oxidase; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Risk Factors; RNA, Messenger; Simvastatin; Swine; Transfection; Tumor Necrosis Factor-alpha | 2009 |
Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anticholesteremic Agents; Atorvastatin; Deoxyguanosine; DNA Damage; Glutathione; Heptanoic Acids; Hypercholesterolemia; Lipid Peroxidation; Liver; Male; Malondialdehyde; Oxidation-Reduction; Oxidative Stress; Protein Carbonylation; Pyrroles; Rabbits; Random Allocation; Sulfhydryl Compounds | 2009 |
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Atorvastatin; Azetidines; Cell Line, Tumor; Ezetimibe; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Lovastatin; Male; Mice; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transfection | 2009 |
Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Sensitivity and Specificity; Simvastatin; Tandem Mass Spectrometry | 2009 |
[Effect of atorvastatin on inflammatory infiltration in the lung of rabbits with hypercholesterolemia].
Topics: Animals; Atorvastatin; Bronchoalveolar Lavage; Heptanoic Acids; Hypercholesterolemia; Inflammation; Lung; Macrophages, Alveolar; Male; NF-kappa B; Pyrroles; Rabbits; Random Allocation | 2009 |
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2009 |
[Atorvastatin dreduces sympathetic activity and improves baroreceptor reflex sensitivity in patients with hypercholesterolemia and hypertension].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Baroreflex; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Pressoreceptors; Pyrroles | 2009 |
Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; LDL-Receptor Related Proteins; Leukocytes, Mononuclear; Male; Middle Aged; Pyrroles; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2010 |
Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood; Brazil; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Gene Frequency; Genotype; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Linkage Disequilibrium; Lipid Metabolism; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Scavenger Receptors, Class B; Triglycerides | 2010 |
Clinical trial efforts in Alzheimer disease: why test statins?
Topics: Alzheimer Disease; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic | 2010 |
Letter by Superko and King regarding article, "Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals".
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Genetic Predisposition to Disease; Goals; Guideline Adherence; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinesins; Male; Middle Aged; Mutation, Missense; Patient Selection; Pravastatin; Pyrroles; Risk | 2010 |
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Managed Care Programs; Medication Adherence; Middle Aged; Odds Ratio; Pyrroles; Retrospective Studies | 2010 |
Atorvastatin affects TLR4 clustering via lipid raft modulation.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Blocking; Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hypercholesterolemia; Lipopolysaccharides; Membrane Microdomains; Mevalonic Acid; Mice; Precursor Cells, B-Lymphoid; Protein Transport; Pyrroles; Receptor Aggregation; Toll-Like Receptor 4 | 2010 |
Pitavastatin: the newest HMG-CoA reductase inhibitor.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Product Surveillance, Postmarketing; Pyrroles; Quinolines; Simvastatin | 2010 |
Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2010 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Bisoprolol; Bone Neoplasms; Capecitabine; Colic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Heptanoic Acids; Humans; Hypercholesterolemia; Ileus; Leucovorin; Lymphatic Metastasis; Middle Aged; Nausea; Pyrroles; Ventricular Premature Complexes; Vomiting | 2011 |
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
Topics: Acetyl-CoA Carboxylase; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Sectional Studies; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Statins and altered glucose metabolism: a laboratory curiosity or a new disease?
Topics: Atorvastatin; Blood Glucose; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Male; Middle Aged; Pyrroles | 2010 |
Antihypercholesterolaemic effect of ginger rhizome (Zingiber officinale) in rats.
Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Dose-Response Relationship, Drug; Heptanoic Acids; Hypercholesterolemia; Hypolipidemic Agents; Phytotherapy; Plant Preparations; Pyrroles; Rats; Rats, Sprague-Dawley; Rhizome; Triglycerides; Zingiber officinale | 2010 |
Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.
Topics: Absorption; Anticholesteremic Agents; Atorvastatin; ATP-Binding Cassette Transporters; Azetidines; Biological Transport; Cholesterol; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Gene Expression; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Lipid Metabolism; Male; Middle Aged; Orphan Nuclear Receptors; Pyrroles; RNA, Messenger; Simvastatin; Up-Regulation | 2010 |
Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biological Availability; Calcium; Chemistry, Pharmaceutical; Crystallization; Disease Models, Animal; Dosage Forms; Heptanoic Acids; Hypercholesterolemia; Male; Microwaves; Polyethylene Glycols; Polymers; Pyrroles; Rats; Rats, Wistar; Solubility | 2010 |
Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits.
Topics: Animals; Atorvastatin; Body Weight; Bronchoalveolar Lavage Fluid; Cell Proliferation; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Lung; Lung Diseases; Macrophages, Alveolar; Male; NF-kappa B; Proliferating Cell Nuclear Antigen; Pulmonary Artery; Pyrroles; Rabbits; Random Allocation | 2010 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
[Atorvastatin and oxidized low density lipoprotein antibody. Relationship to age].
Topics: Adult; Age Factors; Aged; Atherosclerosis; Atorvastatin; Autoantibodies; Autoantigens; Blood Glucose; C-Reactive Protein; Creatinine; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Risk Factors; Waist Circumference | 2011 |
Effect of atorvastatin and etidronate combination therapy on regression of aortic atherosclerotic plaques evaluated by magnetic resonance imaging.
Topics: Aorta; Atorvastatin; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome | 2011 |
Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C9; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Losartan; Male; Middle Aged; Pyrroles; Retrospective Studies | 2011 |
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoglycemic Agents; Imidazoles; Lipids; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyrroles; Quinolines; Resins, Synthetic; Retrospective Studies; Treatment Outcome | 2011 |
Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound.
Topics: Analysis of Variance; Angioscopy; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Rupture, Spontaneous; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; DNA; Ezetimibe; Female; Hep G2 Cells; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; RNA, Messenger; Scavenger Receptors, Class B; Simvastatin | 2011 |
Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?
Topics: Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Patient Selection; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Female; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxylation; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Fabry disease and Factor V Leiden: a potent vascular risk combination.
Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defibrillators, Implantable; Drug Therapy, Combination; Enzyme Replacement Therapy; Fabry Disease; Factor V; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metoprolol; Middle Aged; Perindopril; Pyrroles; Quality of Life; Recurrence; Sequence Deletion; Stents; Stroke; Stroke Rehabilitation; Thrombophilia; Warfarin | 2011 |
Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.
Topics: Animals; Antioxidants; Aorta; Aortic Diseases; Aryldialkylphosphatase; Atherosclerosis; Atorvastatin; Catalase; Disease Models, Animal; Erythrocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Oxidation-Reduction; Plaque, Atherosclerotic; Pyrroles; Rabbits; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Time Factors | 2011 |
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Brazil; Female; Genetic Diseases, Inborn; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Pyrroles | 2012 |
Differentially expressed genes in human peripheral blood as potential markers for statin response.
Topics: Adult; Atorvastatin; Biomarkers, Pharmacological; Cholesterol; Gene Expression; Gene Expression Profiling; Genes, MHC Class II; Genome, Human; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles | 2012 |
Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Function Tests; Male; Middle Aged; Prognosis; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Triglycerides | 2011 |
Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Gene Frequency; Genotype; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Linkage Disequilibrium; Liver-Specific Organic Anion Transporter 1; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2011 |
Trastuzumab-related palmar plantar erythrodysaesthesia.
Topics: Aged; Amlodipine; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Antihypertensive Agents; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Foot Dermatoses; Hand Dermatoses; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Trastuzumab | 2012 |
Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Case-Control Studies; Female; Gene Expression; Genetic Association Studies; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; RNA, Messenger | 2011 |
Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Chile; Cytochrome P-450 CYP3A; Female; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2012 |
Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hypercholesterolemia; Isotope Labeling; Kinetics; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pedigree; Pyrroles | 2012 |
Myocardial infarction in an young patient associated with oral contraceptive, smoking and elevated cholesterol level.
Topics: Abortion, Induced; Adult; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Clopidogrel; Contraceptives, Oral; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pregnancy; Pyrroles; Smoking; Ticlopidine | 2012 |
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Coronary Syndrome; Aged; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Oxidation-Reduction; Phospholipases A2, Secretory; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Risk Factors; Survival Analysis | 2012 |
No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study.
Topics: Adipose Tissue; Aged; Atorvastatin; Body Constitution; Body Mass Index; Case-Control Studies; Diet Records; Energy Metabolism; Exercise; Exercise Test; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Maximal Voluntary Ventilation; Muscle, Skeletal; Pyrroles | 2013 |
Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin.
Topics: Animals; Atorvastatin; Cholesterol; Diet; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Micronutrients; Mitochondria, Liver; Pyrroles; Rats; Ubiquinone | 2012 |
Ask the doctor. After a heart attack six years ago, I went on Lipitor (atorvastatin) because my doctor said it was proven to reduce the risk of a second heart attack in high-risk people like me. Three years ago, I switched to a generic (simvastatin) to sa
Topics: Atorvastatin; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pyrroles | 2012 |
PCSK9 inhibition: the next statin?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2012 |
Reversible dysphasia and statins.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Anxiety; Aphasia; Atorvastatin; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Indapamide; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; Drug Interactions; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Rhabdomyolysis; Warfarin | 2012 |
[In addition to atorvastatin. Innovative antibody lowers LDL around 72%].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2012 |
Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy: time for genotype-guided therapy?
Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biomarkers; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Patient Selection; Phenotype; Polymorphism, Genetic; Precision Medicine; Pyrroles; Simvastatin; Treatment Outcome | 2013 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
Discontinuation of statin therapy due to muscular side effects: a survey in real life.
Topics: Adult; Aged; Atorvastatin; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Motor Activity; Muscle Cramp; Muscle Weakness; Muscle, Skeletal; Musculoskeletal Diseases; Pain; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2013 |
Atorvastatin-related thrombocytopenic purpura.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Purpura, Thrombocytopenic; Pyrroles | 2010 |
Tendinous xanthoma.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Angiography; Coronary Stenosis; Echocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Pyrroles; Stents; Tendons; Treatment Outcome; Xanthomatosis | 2012 |
CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.
Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; China; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Cytochrome P-450 CYP3A; Female; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles | 2012 |
[Effects of atorvastatin and CoQ(10) on myocardial energy metabolism in rabbits with hypercholesterolemia].
Topics: Animals; Atorvastatin; Energy Metabolism; Heptanoic Acids; Hypercholesterolemia; Male; Mitochondria, Heart; Myocardium; Pyrroles; Rabbits; Ubiquinone | 2012 |
Impact of variants within seven candidate genes on statin treatment efficacy.
Topics: Aged; Alleles; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Genetic Variation; Genome, Human; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2012 |
Association of ANRIL polymorphism (rs1333049:C>G) with myocardial infarction and its pharmacogenomic role in hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Drug Resistance; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pakistan; Polymorphism, Single Nucleotide; Pyrroles; Risk; RNA, Long Noncoding; Sequence Analysis, DNA; Triglycerides | 2013 |
[Myopathy due to deficiency of desaminase myoadenilate induced by atorvastatine].
Topics: Aged; Amino Acid Substitution; AMP Deaminase; Atorvastatin; Biopsy; Causality; Creatine Kinase, MM Form; Exercise Tolerance; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Mitochondria, Muscle; Models, Genetic; Muscle, Skeletal; Mutation, Missense; Myalgia; Organic Anion Transporters; Parkinsonian Disorders; Point Mutation; Polymorphism, Single Nucleotide; Purine-Pyrimidine Metabolism, Inborn Errors; Pyrroles; Ubiquinone | 2013 |
Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2002 |
Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.
Topics: Adult; Atorvastatin; CD36 Antigens; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Macrophages; Male; Middle Aged; Monocytes; Oxidation-Reduction; Pyrroles; Receptors, Immunologic; Receptors, Scavenger; RNA | 2002 |
Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Regression Analysis; Triglycerides | 2002 |
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides | 2002 |
Alopecia associated with atorvastatin.
Topics: Adult; Alopecia; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Assessment | 2002 |
Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Female; Heptanoic Acids; HIV Infections; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2002 |
[Absolutely essential in cardiovascular high risk patients. Statins--more than only anticholesteremic drugs].
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Risk; Survival Rate | 2002 |
Intensive statin treatment improves baroreflex sensitivity: another cardioprotective mechanism for statins?
Topics: Anticholesteremic Agents; Atorvastatin; Baroreflex; Blood Pressure; Cholestyramine Resin; Heart Rate; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Norepinephrine; Pyrroles; Sympathomimetics | 2002 |
Statins, fibrates, and ocular myasthenia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Myasthenia Gravis; Pyrroles | 2002 |
Low-density lipoprotein lowering and atherosclerosis progression: does more mean less?
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Pravastatin; Pyrroles; Ultrasonography | 2002 |
[Stable angina pectoris. PTCA improves symptoms, but not prognosis].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Combined Modality Therapy; Heptanoic Acids; Humans; Hypercholesterolemia; Prognosis; Pyrroles; Recurrence; Risk Factors; Stents; Treatment Outcome | 2002 |
Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia.
Topics: Atorvastatin; Cell Adhesion Molecules; Cholesterol, LDL; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2003 |
[Some new data concerning effectiveness of amlodipine, atorvastatine and quinaprile for heart diseases].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Isoquinolines; Pyrroles; Quinapril; Tetrahydroisoquinolines | 2002 |
Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice.
Topics: Aged; Atorvastatin; Cardiology; Cholesterol, LDL; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Observer Variation; Patient Compliance; Pravastatin; Probability; Prospective Studies; Pyrroles; Reference Values; Simvastatin; Treatment Failure; Treatment Outcome | 2002 |
[Ezetimib plus statin combination. A strong duo].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Factors; Simvastatin | 2002 |
Related factors of meeting National Cholesterol Education Program-recommended goals with atorvastatin.
Topics: Aged; Atorvastatin; Body Mass Index; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; National Health Programs; Pyrroles; Risk Factors; Safety | 2003 |
Introduction: rosuvastatin--an efficacy assessment based on pooled trial data.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Meta-Analysis as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2003 |
A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Models, Economic; Pravastatin; Pyrroles; Simvastatin; United Kingdom | 2003 |
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tyrosine | 2003 |
Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility.
Topics: Atorvastatin; Cholinesterase Inhibitors; Disease Susceptibility; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Malignant Hyperthermia; Middle Aged; Pain; Pyrroles; Rhabdomyolysis | 2003 |
New lipid-lowering combo proves successful.
Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome | 2003 |
Time course of serum CK immediately before and after a single muscle cramp.
Topics: Amyotrophic Lateral Sclerosis; Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Muscle Cramp; Muscle, Skeletal; Pyrroles; Time Factors; Up-Regulation | 2003 |
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.
Topics: Adult; Anti-Bacterial Agents; Atorvastatin; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lopinavir; Male; Pyrimidinones; Pyrroles; Rhabdomyolysis; Ritonavir | 2003 |
Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits.
Topics: Acyl Coenzyme A; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Arteriosclerosis; Atorvastatin; Blood Pressure; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fibrinolysis; Heptanoic Acids; Hypercholesterolemia; In Vitro Techniques; Inflammation Mediators; Male; Pyrroles; Quinapril; Rabbits; Tetrahydroisoquinolines; Tunica Intima; Vasodilation | 2003 |
In light of ALLHAT and ASCOT: are there benefits of statins as add-on treatment in hypertensives?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperemia; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pilot Projects; Pyrroles; Skin | 2003 |
Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits.
Topics: Animals; Atorvastatin; Cholinergic Antagonists; Constriction, Pathologic; Femoral Artery; Heptanoic Acids; Hypercholesterolemia; Muscle, Smooth, Vascular; Pyrroles; Rabbits; Stents | 2003 |
Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits.
Topics: Adipocytes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Cholesterol, Dietary; Gene Expression; Heptanoic Acids; Hypercholesterolemia; Interleukin-6; Male; Pyrroles; Rabbits; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors | 2003 |
Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.
Topics: Animals; Atorvastatin; Cell Movement; Green Fluorescent Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoblotting; Immunohistochemistry; Luciferases; Luminescent Proteins; Melanoma; Mice; Mice, SCID; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Plasmids; Protein Processing, Post-Translational; Pyrroles; ras Proteins; rho GTP-Binding Proteins; rhoC GTP-Binding Protein; Serum Response Factor; Subcellular Fractions; Time Factors; Tumor Cells, Cultured | 2003 |
Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy.
Topics: Adult; Aryldialkylphosphatase; Atorvastatin; Cholesterol; Enzyme Induction; Foam Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Macrophages; Male; Middle Aged; Oxidative Stress; Pyrroles | 2004 |
Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Feces; Heptanoic Acids; Humans; Hypercholesterolemia; Intestinal Absorption; Lipids; Lipoproteins; Liver; Male; Middle Aged; Phytosterols; Pyrroles; Squalene | 2003 |
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Case-Control Studies; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pregnancy-Associated Plasma Protein-A; Pyrroles | 2003 |
Statin face-off. Surprises from the first head-to-head comparison.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Treatment Outcome; United States | 2003 |
Effects of simvastatin and atorvastatin in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin; Triglycerides | 2003 |
Effect of statins on the progression of bioprosthetic aortic valve degeneration.
Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atorvastatin; Bioprosthesis; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prosthesis Failure; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography | 2003 |
Short-term effects of atorvastatin on haemorheologic parameters, platelet aggregation and endothelium dysfunction in patients with hypercholesterolaemia.
Topics: Anticholesteremic Agents; Antigens; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Platelet Aggregation; Pyrroles; von Willebrand Factor | 2004 |
Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Atorvastatin; Biomarkers; Bone Density; Bone Resorption; Case-Control Studies; Collagen; Collagen Type I; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Peptides; Prospective Studies; Pyrroles; Treatment Outcome | 2003 |
Atorvastatin enhances cellular uptake of oxidized LDL in adipocytes from hypercholesterolemic rabbits.
Topics: Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Heptanoic Acids; Hypercholesterolemia; Iodine Radioisotopes; Lipoproteins, LDL; Pyrroles; Rabbits; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors | 2004 |
Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Homocysteine; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Renal Dialysis; Risk Factors | 2003 |
CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; ATP-Binding Cassette Transporters; Drug Resistance; Female; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linkage Disequilibrium; Lipoproteins; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles | 2004 |
Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature.
Topics: Administration, Oral; Aged; Alanine Transaminase; Atorvastatin; Drug Monitoring; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Liver; Liver Function Tests; Pruritus; Pyrroles | 2004 |
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.
Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones | 2004 |
Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Anion Exchange Resins; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; CD4 Lymphocyte Count; Coronary Disease; Epichlorohydrin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Imidazoles; Immunophenotyping; Male; Prospective Studies; Pyrroles; Resins, Synthetic; Th1 Cells; Th2 Cells | 2004 |
Update on statins.
Topics: Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation.
Topics: Adult; Atorvastatin; Comorbidity; Erectile Dysfunction; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Penile Erection; Pyrroles | 2004 |
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Stroke; Ubiquinone | 2004 |
[Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Risk; Survival Analysis; Survival Rate | 2004 |
[Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Ultrasonography, Interventional | 2004 |
[Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
The effect of atorvastatin on platelet function in patients with coronary artery disease.
Topics: Atorvastatin; Blood Platelets; Case-Control Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation; Prospective Studies; Pyrroles | 2004 |
Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin.
Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia.
Topics: Adult; Atorvastatin; Biomarkers; Case-Control Studies; CD40 Ligand; Cohort Studies; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; P-Selectin; Probability; Prognosis; Pyrroles; Reference Values; Sensitivity and Specificity; Severity of Illness Index | 2004 |
Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Basilar Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Endothelium, Vascular; Female; Fibrinolysis; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Thiobarbituric Acid Reactive Substances; Treatment Outcome; Triglycerides; Vasodilation | 2004 |
Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia: additional evidence to support the anti-inflammatory effects of statins.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Severity of Illness Index | 2004 |
Beyond cholesterol lowering: effect of statins on markers of cardiovascular disease.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; C-Reactive Protein; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Risk Factors | 2004 |
[Endothelial dysfunction, inflammation and statins: new evidences].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Circulation; Endothelium, Vascular; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Interleukin-6; Pravastatin; Pyrroles; Rabbits; Time Factors | 2004 |
Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients.
Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Interleukin-1; Interleukin-6; Male; Middle Aged; Pyrroles; Tumor Necrosis Factor-alpha | 2004 |
Effects of Atorvastatin on some inflammatory parameters in severe primary hypercholesterolemia.
Topics: Adult; Atorvastatin; Biomarkers; Coronary Stenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2002 |
[Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Approval; Drugs, Generic; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles | 2004 |
[Sequelae of the CARDS Study. LDL of 110 mg/dl still too high?].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Treatment of severe hypercholesterolemia with atorvastatin in congenital analbuminemia.
Topics: Adult; Albumins; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoproteinemia; Male; Pyrroles | 2004 |
[Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Simvastatin; Time Factors | 2004 |
Synthes Award for Resident Research in Spinal Cord & Spinal Column Injury: Statins for the treatment of neurological injury: a role beyond cholesterol lowering.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Awards and Prizes; Brain Injuries; Heptanoic Acids; Hypercholesterolemia; Immunoblotting; Interleukin-6; Internship and Residency; Mice; Pyrroles; Research; RNA, Messenger; Simvastatin; Spinal Cord Injuries; Subarachnoid Hemorrhage | 2004 |
Effect of monthly atorvastatin treatment on hemostasis.
Topics: Adult; Aged; Atorvastatin; Blood Coagulation Factors; Case-Control Studies; Female; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors | 2004 |
Rhabdomyolysis in a patient receiving atorvastatin and fluconazole.
Topics: Antifungal Agents; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Synergism; Fatal Outcome; Fluconazole; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mycoses; Pyrroles; Rhabdomyolysis | 2005 |
[A relationship between insulin resistance and reduction in oxidative stress in vivo by atorvastatin].
Topics: Aged; Atorvastatin; Dinoprost; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles | 2004 |
Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Blood Platelets; CD36 Antigens; Citrulline; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pyrroles; Receptors, LDL; Receptors, Oxidized LDL; Scavenger Receptors, Class E | 2005 |
Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry.
Topics: Adenosine Diphosphate; Adult; Aged; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Risk Factors; Thrombin; Thrombosis | 2005 |
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Cost Control; Drug Costs; Ezetimibe; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrroles; Simvastatin | 2004 |
Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation.
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Tissue Plasminogen Activator; Vascular Cell Adhesion Molecule-1 | 2005 |
Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Matrix; Calcinosis; Cell Division; Heart Valve Diseases; Heptanoic Acids; Hypercholesterolemia; Male; Mitral Valve; Pyrroles; Rabbits | 2005 |
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2005 |
Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve.
Topics: Animals; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Blotting, Western; C-Reactive Protein; Calcinosis; Cholesterol; Heart Valve Diseases; Heptanoic Acids; Hypercholesterolemia; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitrites; Pyrroles; Rabbits; Tomography, X-Ray Computed | 2005 |
[The PROVE IT-TIMI-22 study or the biter being bit].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles | 2005 |
Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Complement C3; Complement C4; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Immunity, Cellular; Intercellular Adhesion Molecule-1; Lipids; Male; Middle Aged; Pyrroles; Up-Regulation | 2005 |
Images in clinical medicine. A medical mystery--bradycardia.
Topics: Atorvastatin; Bradycardia; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2005 |
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Acute onset and worsening of diabetes concurrent with administration of statins.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles | 2005 |
Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits.
Topics: Adipocytes; Adipose Tissue; Animals; Atorvastatin; Cholesterol; Drug Evaluation, Preclinical; Heptanoic Acids; Hypercholesterolemia; Leptin; Pyrroles; Rabbits; RNA, Messenger | 2005 |
Effect of atorvastatin on tumor necrosis factor alpha serum concentration and mRNA expression of adipose in hypercholesterolemic rabbits.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; Cholesterol; Cholesterol, LDL; Disease Models, Animal; Heptanoic Acids; Hypercholesterolemia; Male; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha | 2005 |
[Effect of maximum dose of atorvastatin on inflammation, thrombogenesis and fibrinolysis in high-risk patients with ischemic heart disease].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Disease; Data Interpretation, Statistical; Enzyme-Linked Immunosorbent Assay; Female; Fibrinolysis; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunochemistry; Lipids; Male; Middle Aged; Prothrombin; Pyrroles; Risk Factors; Time Factors | 2005 |
High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brazil; Cholesterol, LDL; Female; Gene Frequency; Genes, MDR; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; White People | 2005 |
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Pravastatin; Pyrroles; Risk; Risk Factors; Time Factors | 2005 |
Matrix metalloproteinases in isolated hypercholesterolemia.
Topics: Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Matrix Metalloproteinases; Middle Aged; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinases | 2005 |
Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway.
Topics: Animals; Animals, Inbred Strains; Aortic Valve Stenosis; Atorvastatin; beta Catenin; Calcinosis; Cell Division; Cells, Cultured; Cholesterol, Dietary; Diet, Atherogenic; Fibroblasts; Gene Expression Regulation; Heptanoic Acids; Hypercholesterolemia; LDL-Receptor Related Proteins; Lipoproteins, LDL; Low Density Lipoprotein Receptor-Related Protein-5; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; Ossification, Heterotopic; Osteopontin; Pyrroles; Rabbits; Sialoglycoproteins; Sus scrofa | 2005 |
Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Function Tests; Middle Aged; Pyrroles | 2005 |
Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study.
Topics: Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Retrospective Studies; Simvastatin; Treatment Failure; Triglycerides | 2005 |
Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Torcetrapib + atorvastatin (Pfizer).
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines | 2005 |
Decreasing LDL cholesterol and medication cost with every-other-day statin therapy.
Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2005 |
How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Creatine Kinase; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States | 2005 |
3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects.
Topics: Adult; Alleles; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Chromatography, High Pressure Liquid; Citrulline; DNA; Female; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Intracellular Fluid; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrroles; Scavenger Receptors, Class E | 2005 |
Early anticoagulant effect of atorvastatin.
Topics: Anticholesteremic Agents; Anticoagulants; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles | 2005 |
APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Genetic Variation; Genomics; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Polymorphism, Genetic; Pyrroles; Sex Factors; Treatment Outcome; Triglycerides | 2005 |
Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice.
Topics: Amlodipine; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mice; Mice, Transgenic; Pyrroles; Serum Amyloid A Protein; von Willebrand Factor | 2006 |
Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carbohydrate Metabolism; Diabetes Mellitus; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Pravastatin; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
Atorvastatin improves myocardial perfusion in a patient with hypercholesterolemia and single-vessel coronary disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome | 2006 |
[Treatment of hypercholesterolemia--lower is better].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 2006 |
Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cells.
Topics: Atherosclerosis; Atorvastatin; Blotting, Western; Cells, Cultured; Endothelium, Vascular; Gene Expression Regulation, Enzymologic; Heme Oxygenase-1; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoxia; Microcirculation; Nitric Oxide Synthase Type III; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Atorvastatin may cause nightmares.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Night Terrors; Pyrroles | 2006 |
Short-term atorvastatin treatment does not modify neointimal morphology but reduces MMP-2 expression in normocholesterolemic rabbit stented arteries.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Muscle, Smooth, Vascular; Pyrroles; Rabbits; Stents; Tissue Inhibitor of Metalloproteinase-2; Tunica Intima | 2006 |
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 2006 |
Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
Topics: Adolescent; Adult; Aged; Atorvastatin; Child; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Male; Middle Aged; Models, Biological; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose Tolerance Test; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Severe hepatic side effects of ezetimibe.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Diseases; Male; Middle Aged; Pyrroles; Transaminases | 2006 |
Comment on 'Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits' by Zhao et al. (Clin Chim Acta 2006; 365: 119-24).
Topics: Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Cholesterol; Gene Expression Regulation; Heptanoic Acids; Hypercholesterolemia; Lipoproteins, HDL; Pyrroles; Rabbits; RNA, Messenger | 2006 |
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Annexins; Anticholesteremic Agents; Atorvastatin; Biomarkers; Calcium Channels, L-Type; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Receptors, LDL; Simvastatin | 2006 |
[Regression of a large lipid-rich pool in the coronary artery during treatment with statin detected by intravascular ultrasound: a case report].
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Disease; Coronary Vessels; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Stents; Ultrasonography, Interventional | 2006 |
High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Brain; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2006 |
High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Angiostatins; Animals; Apoptosis; Apoptosis Inducing Factor; Arterioles; Atorvastatin; Caspase 3; Caspases; Cholesterol; Coronary Circulation; Coronary Vessels; Drug Evaluation, Preclinical; Endostatins; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Matrix Metalloproteinase 9; Myocardial Ischemia; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Nitroprusside; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptor, TIE-2; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A; Vasodilation | 2006 |
Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Osteopontin; Pyrroles; Sialoglycoproteins | 2006 |
Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2006 |
The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Tunica Intima; Tunica Media | 2006 |
Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Coagulation; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
High-dose statins for diabetes.
Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2006 |
Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions.
Topics: Aged; Anticholesteremic Agents; Arginine; Atorvastatin; Blood Pressure; Carbon Dioxide; Cerebral Infarction; Cerebrovascular Circulation; Comorbidity; Endothelium, Vascular; Female; Follow-Up Studies; Heart Rate; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Single-Blind Method; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasodilator Agents | 2006 |
Statins and cerebral vasomotor reactivity: implications for a new therapy?
Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial | 2006 |
Autoimmune hepatitis triggered by statins.
Topics: Atorvastatin; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
[HIV infection: from Pneumocystis to statins].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pneumocystis Infections; Pyrroles; Risk Factors | 2006 |
Media report of rare rhabdomyolysis cases seems to have triggered reluctance among some New Zealanders to use statins.
Topics: Anticholesteremic Agents; Atorvastatin; Health Education; Health Knowledge, Attitudes, Practice; Heptanoic Acids; Humans; Hypercholesterolemia; Mass Media; New Zealand; Pyrroles; Rhabdomyolysis; Simvastatin | 2006 |
More on switching statins: comments from Pfizer.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 2006 |
Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Resistance; Female; Heptanoic Acids; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Retrospective Studies; Risk Factors; Scavenger Receptors, Class E; Simvastatin; Thrombosis | 2007 |
Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Coronary Disease; Female; Finland; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Surveys and Questionnaires; Treatment Outcome | 2006 |
High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Coronary Vessels; Female; Heptanoic Acids; Hypercholesterolemia; Male; Neovascularization, Physiologic; Pyrroles; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A | 2006 |
[Effects of atorvastatin in N-terminal pro-brain natriuretic peptide plasma levels in hypercholesterolemic patients with or without hypertension].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Pyrroles | 2006 |
[Effectiveness of atorvastatin compared to other statins of usual clinical practice in primary care].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Primary Health Care; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
Cholesterol: the good, the bad, and the stopped trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials, Phase III as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Failure | 2006 |
The MEGA study.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2006 |
Atorvastatin therapy associated with improvement in left ventricular remodeling in a case of idiopathic dilated cardiomyopathy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiomyopathy, Dilated; Cardiovascular Agents; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Ventricular Remodeling | 2006 |
Endoglin expression in hyper-cholesterolemia and after atorvastatin treatment in apoE-deficient mice.
Topics: Animals; Apolipoproteins E; Atorvastatin; Diet, Atherogenic; Endoglin; Gene Expression Regulation; Heptanoic Acids; Hypercholesterolemia; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles | 2006 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome | 2007 |
L-arginine plus atorvastatin for prevention of atheroma formation in genetically hypercholesterolaemic rabbits.
Topics: Animals; Arginine; Atherosclerosis; Atorvastatin; Cholesterol; Combined Modality Therapy; Dietary Supplements; Eating; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Nitric Oxide; Pyrroles; Rabbits | 2007 |
Gender differences in short-term effects of atorvastatin on lipid profile, fibrinolytic parameters, and endothelial function.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Pyrroles; Regional Blood Flow; Sex Factors; Thiobarbituric Acid Reactive Substances; Treatment Outcome | 2008 |
Did a flawed study design affect the results of the VYTAL study?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Random Allocation; Research Design; Simvastatin | 2007 |
Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Substance Withdrawal Syndrome; Triglycerides; Ubiquinone | 2006 |
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2007 |
[CME-Lab 2/Solution. Hypercholesteremia and therapy control].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypericum; Male; Middle Aged; Patient Compliance; Pyrroles; Triglycerides | 2007 |
[Hypercholesterolemia and control with therapy].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diagnosis, Differential; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Pyrroles; Treatment Refusal; Triglycerides | 2007 |
Effects of atorvastatin on ventricular late potentials and repolarization dispersion in patients with hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Electrocardiography; Female; Heart Ventricles; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2007 |
Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine.
Topics: Animals; Arginine; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Heptanoic Acids; Homocysteine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Male; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Pyrroles; Rabbits; Thiobarbituric Acid Reactive Substances; Triglycerides | 2007 |
High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine: relevance to the human situation?
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Coronary Vessels; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Neovascularization, Physiologic; Pyrroles; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A | 2007 |
Physiogenomic association of statin-related myalgia to serotonin receptors.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin | 2007 |
A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) s
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles | 2007 |
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells.
Topics: Adult; Animals; Atorvastatin; Forkhead Transcription Factors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; T-Lymphocytes, Regulatory; Up-Regulation | 2008 |
Effects of toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; P-Selectin; Phenotype; Polymorphism, Genetic; Pyrroles; Risk Factors; Toll-Like Receptor 4; Treatment Outcome; von Willebrand Factor | 2007 |
Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
Topics: Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Female; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrroles; RNA, Messenger | 2008 |
Effects of atorvastatin on C-reactive protein secretions by adipocytes in hypercholesterolemic rabbits.
Topics: Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Hypercholesterolemia; Male; Nephelometry and Turbidimetry; PPAR gamma; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2007 |
A novel mechanism of action of atorvastatin against cardiovascular risk: a commentary on "decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins".
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2007 |
Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment.
Topics: Animals; Atorvastatin; Endoglin; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Transforming Growth Factor beta | 2007 |
Novel delivery systems of atorvastatin should be evaluated for pharmacodynamics instead of pharmacokinetics.
Topics: Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Drug Delivery Systems; Emulsions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Pyrroles; Tissue Distribution | 2007 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Lowering LDL-C for optimal protection in high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Guideline Adherence; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Assessment | 2008 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome | 2008 |
Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin.
Topics: Adult; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cohort Studies; Coronary Artery Disease; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Integrin alpha Chains; Lymphocyte Activation; Male; Middle Aged; Monocytes; Pyrroles; T-Lymphocytes | 2007 |
The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; E-Selectin; Female; Follow-Up Studies; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Polymorphism, Genetic; Probability; Prospective Studies; Pyrroles; Receptors, LDL; Reference Values; Severity of Illness Index; Treatment Outcome | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Middle Aged; Pyrroles; Quality of Life; Retrospective Studies; Treatment Outcome | 2008 |
Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Base Sequence; DNA Primers; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Intracellular Signaling Peptides and Proteins; Lipids; Male; Membrane Proteins; Middle Aged; Polymerase Chain Reaction; Pyrroles; Sterol Regulatory Element Binding Protein 1 | 2008 |
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome | 2008 |
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.
Topics: Aryldialkylphosphatase; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Pyrroles; Simvastatin | 2008 |
Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Caseins; Cholesterol; Diet; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iodine Radioisotopes; Lipoproteins, LDL; Lovastatin; Male; Pyrroles; Rabbits; Random Allocation | 1995 |
The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cricetinae; Cricetulus; Escherichia coli; Female; Fibroblasts; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoxanthine Phosphoribosyltransferase; Lung; Male; Mice; Micronucleus Tests; Mutagenicity Tests; Pyrroles; Salmonella typhimurium | 1995 |
Levels of soluble cell adhesion molecules in patients with dyslipidemia.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1 | 1996 |
Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Liver; Lovastatin; Male; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Triglycerides | 1995 |
[Lowering cholesterol. New concepts with atorvastatin].
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Pyrroles; Treatment Outcome | 1997 |
[What is new? Therapy with lipid lowering agents].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles | 1997 |
[Effective cholesterol and triglyceride lowering with atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Pyrroles | 1996 |
Atorvastatin versus simvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 1997 |
[Prevention of cardiovascular diseases: Value of CSE inhibitors in the management of lipid metabolism disorders].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles | 1998 |
Atorvastatin (Lipitor).
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic | 1998 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
[Drug clinics. Drug of the month. Atorvastatin (Lipitor)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diet, Fat-Restricted; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Liver; Pyrroles; Receptors, LDL; Tablets; Triglycerides | 1998 |
[Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Pyrroles; Time Factors | 1998 |
Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 1999 |
Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.
Topics: Adult; Angiotensin Receptor Antagonists; Atorvastatin; Blood Pressure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Reactive Oxygen Species; Receptors, Angiotensin; Simvastatin | 1999 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Ischemia; Pyrroles; Recurrence | 1999 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Stents | 1999 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Platelet Aggregation Inhibitors; Pyrroles | 1999 |
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia.
Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles | 2000 |
The nature of the statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2000 |
Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia.
Topics: Ataxia; Atorvastatin; Autoantibodies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Ophthalmoplegia; Pyrroles; Receptors, Cholinergic; Visual Acuity | 2000 |
Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic | 2000 |
Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Resistance; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Male; Middle Aged; Pyrroles; Retreatment; Time Factors; Treatment Outcome; Triglycerides | 2000 |
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors | 2000 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |
Effect of atorvastatin 15 mg/week on serum lipids in patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles | 2001 |
[Meeting report. "MIRACL" study of "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering"].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Ischemia; Patient Selection; Pyrroles; Treatment Outcome | 2000 |
[Disturbances in cholesterol metabolism].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Triglycerides | 2001 |
F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet.
Topics: Adrenal Glands; Anilides; Animals; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Caseins; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Pyrroles; Rabbits; Sterol O-Acyltransferase | 2001 |
Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.
Topics: Acetylcholine; Animals; Anticholesteremic Agents; Atorvastatin; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hypercholesterolemia; Kidney; Male; Nitroprusside; Oxazoles; Phenylephrine; Platelet Aggregation Inhibitors; Pyrroles; Rabbits; Renal Circulation; Vasodilation | 2001 |
Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Coronary Disease; Exercise Test; Female; Heart Rate; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Time Factors | 2001 |
Global risk assessment in the presymptomatic patient.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Critical Pathways; Family Practice; Heptanoic Acids; Humans; Hypercholesterolemia; Life Style; Mass Screening; Pyrroles; Risk Assessment | 2001 |
Insulin resistance syndrome and type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Metabolic Syndrome; Pyrroles; Risk Factors; Survival Rate | 2001 |
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Topics: Animals; Aorta; Arteries; Arteriosclerosis; Atorvastatin; Carotid Arteries; Chemokine CCL2; Cholesterol; Coronary Vessels; Down-Regulation; Femoral Artery; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunohistochemistry; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pravastatin; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine | 2001 |
Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Arteries; Atorvastatin; Compliance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Severity of Illness Index; Treatment Outcome | 2001 |
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.
Topics: Acute Kidney Injury; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Delavirdine; Drug Interactions; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mixed Function Oxygenases; Pyrroles; Rhabdomyolysis | 2002 |
Increased superoxide anion production by platelets in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Arachidonic Acid; Atorvastatin; Blood Platelets; Cholesterol; Cholesterol, LDL; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Superoxides; Triglycerides | 2002 |
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve.
Topics: Alkaline Phosphatase; Animals; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Biomarkers; C-Reactive Protein; Calcinosis; Cell Division; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Heart Valve Diseases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Macrophages; Male; Microscopy, Immunoelectron; Osteoblasts; Osteopontin; Proliferating Cell Nuclear Antigen; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sialoglycoproteins | 2002 |
Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Israel; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome | 2002 |
Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2002 |